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Artificial Antigen Presenting Cells (aAPC) are synthetic platforms for T cell activation, 
made by coupling T cell activating proteins to cell-sized, spherical particles. While this 
size and shape are chosen to mimic endogenous APC and simplify manufacture, 
respectively, platforms based on alternative geometries and sizes could have significant 
advantages. I thus set out to develop nanoscale aAPC and ellipsoid aAPC, and to 
understand the relevant nanoscale structures governing T cell activation that may impact 
on APC design. 
 For example, T cells regulate binding sensitivity through nanoscale changes in lateral 
membrane organization, which may affect nano- but not micro-aAPC binding and 
function. Cells activated by a high dose of peptide lost ability to bind CD8-dependent but 
not CD8-independent MHC-peptide, a phenomenon attributed to loss of nanoscale co-
localization between CD8 and TCR. 
I next developed aAPC based on biocompatible iron-dextran paramagnetic particles 50-
100 nm in diameter induced antigen-specific T cell proliferation in vitro and enhanced 
tumor rejection in a subcutaneous mouse melanoma model. Nano-aAPC bound 2-fold 
more TCR on activated cells with highly clustered TCR compared to naive cells with less 
clustered TCR, leading to weaker stimulation of naive cells. To enhance naive T cell 
activation, a magnetic field was used to drive aggregation of paramagnetic nano-aAPC, 
resulting in a doubling of  the size of TCR clusters and increased  T cell expansion in 
vitro and after adoptive transfer in vivo.  
We coupled magnet-enhanced T cell activation to a magnetic column pre-enrichment 
strategy using nano-aAPC. Since nano-aAPC are functionalized with MHC-peptide that 
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can bind and activate TCR, iron-oxide cores to capture bound cells in a magnetic 
column, and co-stimulatory anti-CD28, they can enrich and expand cognate cells. 
Magnetic enrichment 1000-fold expansion in one week with the frequency of antigen-
specific cells increasing from <0.1% in naive precursors to 10-20% after just one 
stimulation. Enrichment also significantly enhanced proliferation in lymphopenic hosts 
after adoptive transfer by reducing competition for proliferative cytokines. Enrichment 
and expansion with nano-aAPC is a streamlined approach to generating tumor-specific T 
cells from naive precursors with minimal culture.  
Finally, I developed “stretched,” ellipsoid micro-aAPC that increased T cell 
proliferation 2-5 fold compared to equivalent doses of spherical aAPC. Ellipsoid aAPC 
made larger contact surfaces with T cells, better recapitulating endogenous interactions.
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1 State of the Art 
1.1 Mechanisms of T Cell Activation 
T cells face a seemingly insurmountable challenge: from a sea of irrelevant self-antigens, they 
must find and respond to a small number of pathogenic or dangerous antigens. However, peptide 
antigens from both self proteins and from pathogens are presented in the context of a Major 
Histocompatability Complex (MHC) protein, meaning that only a small portion of the peptide-
MHC ligand they recognize makes the difference between target and distraction. And the 
consequences of a mistake, an inappropriate response to self-antigen, is horror autotoxicus, as 
Paul Ehrlich described violent and destructive autoimmunity. 
As a result of this daunting task, a complex machinery has developed around the T cell receptor, 
assisting in and modulating the recognition of cognate (specific) antigen. Like the B cell 
receptor, the T cell receptor relies on accessory proteins to initiate downstream signaling. Unlike 
the BCR, however, all TCR interactions with cognate ligand take place during cell-cell 
interactions. The TCR is no antibody: its binding, signaling, and spatial organization only make 
sense within the context of a membrane. 
In this chapter, I will briefly review biophysical aspects of TCR signaling, with a particular 
emphasis on TCR behavior within the membrane. I will further focus the discussion on spatial 
organization, the patterns of receptor clustering and distribution that can modulate T cell 
responses. 
1.1.1 TCR-MHC Recognition: What Makes a ‘Cognate’ Antigen? 
A key property of the T cell is specificity: T cells will only activate and respond to one or a small 
number of peptides presented in the context of specific MHC alleles. This MHC-peptide 
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combination (pMHC) is the cognate antigen for a given T cell receptor, and underlies the ability 
of T cells to differentiate between healthy and pathologic tissue. Despite being absolutely critical 
to understanding T cell function, the question of why certain TCR-pMHC binding events can 
trigger T cell activation, whereas a vast majority cannot, is still poorly understood. In other 
words: what makes a certain MHC-peptide cognate for a certain TCR? 
This question can be addressed in two ways. The first approach is biophysical: viewing T cell 
activation as a “black-box,” can certain kinetic or equilibrium binding parameters predict 
successful TCR-MHC interactions? The second is mechanistic: how does a TCR transduce a 
binding event into a signal within the cell? Does the signal involve a comformational change in 
the protein, a mechanical stimulus, or a change in protein aggregation or clustering? These two 
approaches are complementary, and an understanding of each is required to appreciate the 
specificity of the TCR. A review of each approach follows. 
1.1.1.1 Biophysical Models of TCR Binding 
Even prior to a complete mechanistic understanding of T cell activation, biophysical approaches 
can shed significant light on TCR triggering by MHC. Such approaches begin by measuring 
kinetic and equilibrium binding parameters and attempting to identify which parameters are 
critical in determining antigen specificity. 
TCR-pMHC binding parameters have traditionally been measured by two techniques. The first is 
Surface Plasmon Resonance (SPR), in which soluble ligands flows across a receptor fixed to a 
gold substrate. A binding event leads to the SPR effect, allowing the on rates, off rates, and 
overall avidity of binding to be measured. The second approach involves soluble, fluorescently 
tagged MHC constructs such as dimers and tetramers, whose association to and disassociation 
from T cells can be monitored by flow cytometry or microscopy [1–3].  
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Both approaches have yielded the same conclusion: TCR avidity for cognate MHC is 
surprisingly weak, in the micromolar range, compared to nanomolar avidity for antibodies and 
their ligands. As will be discussed further, it is important to remember that in both approaches 
either pMHC, TCR, or both are removed from the context of an APC or T cell membrane, 
significantly altering binding behavior.  
Despite the somewhat artificial basis of these measurements, a large literature exists attempting 
to correlate biophysical parameters of TCR-pMHC binding with T cell response. The overall 
approach broadly follows three steps: 1) TCR-pMHC binding parameters are measured for a 
panel of TCR and antigens; 2) these antigens are classified as cognate agonists or non-cognate 
antagonists based on their ability to induce a functional response in T cells, such as downstream 
signaling, cytokine production, or proliferation; 3) binding parameters and T cell responses are 
plotted against each other to identify the parameter that best predicts response. 
The results of these studies have been frequently contradictory, and data have supported several 
models. Avidity models propose that the equilibrium disassociation constant is the critical 
parameter for activation[2,4–6], since equilibrium parameters determine the total number of TCR 
engaged during prolonged APC/T cell contact. In contrast, kinetic models propose that 
association or disassociation rates are the critical determinant[7–10].  
Kinetic models can be further subdivided into the nonexclusive categories serial triggering and 
kinetic proofreading. In the serial triggering model[11–13], disassociation rates cannot exceed a 
certain value, because a given pMHC must rapidly make serial contacts with multiple TCR to 
generate sufficient signal. In contrast, kinetic proofreading [7,14–16] suggests that disassociation 
rate cannot drop below a certain value because many sequential events are required for signaling 
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complex assembly, an idea supported mechanistically by the underlying complexity of the 
downstream T cell signaling complex. More recently, a “confinement time model” was proposed 
in which a rapid association rate could compensate for a rapid disassociation rate[16,17] by 
increasing rapid re-binding events. 
A number of explanations have been proposed for these conflicting results, including variations 
in the functional outcome measured, insufficiently broad panels of TCR-pMHC measurements, 
or correlation between parameters complicating attempts to differentiate them. More generally, 
these discrepancies have led researchers “back to the drawing board,” and motivated productive 
attempts to make more accurate and physiological measurements of TCR-MHC interactions. For 
example, binding parameters measured in situ using advanced imaging techniques show large 
increases in both association (100-fold) and disassociation (4-12 fold), ultimately resulting in 
increasing affinity[18].  
Other approaches have focused on measuring two rather than three-dimensional binding 
parameters. During T cell/APC interactions, receptors are confined to the two-dimensional axis 
of cell-cell contact, whereas measurements using soluble MHC involve a third degree of freedom 
during binding. Two dimensional measurements may be made by assessing interactions of TCR 
with an MHC-coated bead[19,20], and may lead to more accurate description of TCR-pMHC 
binding. 2D affinity analysis has resulted in the identification of a wider range of T cells reactive 
with given ligands covering a broad range of affinities [21,22]. 
Despite this progress, no single biophysical explanation exists for TCR specificity. It is 
becoming clear that measurements derived in vitro under artificial binding conditions are only 
the first step toward understanding why certain pMHC trigger activation and others do not. 
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Moving forward, it is important to remember that TCR recognize MHC in the context of a cell-
cell interaction, and that the actions and mechanisms of antigen recognition cannot be completely 
separated from the membrane. 
1.1.1.2 Possible Mechanisms of TCR Signal Transduction 
With the identification of the TCR protein in late 1982 and early 1983 by the Allison[23], 
Reinherz[24], and Kappler/Marrack[25] groups, and the subsequent cloning of the TCRβ chain 
by Hedrick and Davis in 1984[26], it became clear that TCR itself did not contain an extensive 
intracellular domain, and possessed no obvious mechanism for transmitting a binding event into 
a signal within the cell. Subsequent work shifted attention to the CD3 accessory protein, which 
was closely associated with TCR and contained Immunoreceptor Tyrosine-Based Activation 
Motifs (ITAMs) that were phosphorylated during T cell activation[27]. Thus, a mechanism was 
required to transduce an extracellular binding event between TCR and pMHC into an 
intracellular phosphorylation of ITAM residues on CD3.  
By analogy to other receptor systems, a change in protein conformation was proposed to mediate 
this outside-inside signaling. Flexibility observed after TCR-pMHC binding occurs primarily in 
the antigen-binding CDR3 portion of the TCR protein, suggesting that external TCR surface can 
adjust to “fit” its cognate ligand[28]. Furthermore, structural studies have shown that a 
conformational change occurs in the AB-loop of TCRα, which is near the CD3ε binding site[29]. 
Finally, it is known that after MHC binding, a C-terminal proline –rich sequence is exposed on 
CD3ε[30]. However, this motif appears to be involved in regulating TCR/CD3 expression, not 
downstream signaling[31].  
Thus, a complete picture of how MHC alters TCR and/or CD3 conformation, and whether this 
process is required for T cell activation, has not been described. Despite the growing body of 
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solved pMHC/TCR crystal structures, a ternary pMHC/TCR/CD3 crystal structure does not yet 
exist due to the immense technical challenges involved. Furthermore, conformational models 
have struggled to explain how a common conformational signal is transduced despite the wide 
variety of TCR sequences and structures, with different TCR clones yielding different structural 
features[28]. 
A common structural mechanism that is an alternative to conformational change involves the 
transmission of mechanical forces after MHC binding. This theory was advanced in part because 
the CD3γε heterodimer was found to be rigid rather than conformationally responsive[32]. 
Although several variants of the proposed model exist, a common theme includes a pulling 
action on TCR creating a “piston-like” movement of rigid CD3 that exposes activating ITAM 
residues. 
During T cell activation, fluctuations of the APC membrane can generate a pico- to fentonewton 
force on the T cell membrane[33]. These forces can also be triggered by a timed series of active 
pushing and pulling processes by the T cell[34]. Mechanical forces in this range induced by 
micromanipulation of TCR by pMHC or clonotypic antibodies can trigger downstream signaling 
responses in T cells [35,36], and mechanical signals between T cells and APC enhanced by shear 
flow triggered stronger T cell stimulation in vitro[37]. Thus, mechanical triggering is a 
compelling mechanism of activation. However, no studies to date have firmly defined a 
necessary role for mechanical force generation during T cell signaling, and it remains to be seen  
Thus, both conformational and mechanical models of triggering are intriguing but have not yet 
yielded conclusive evidence as the primary mechanism of TCR triggering. Other mechanisms 
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have been explored in parallel, including the influence of rearrangements in spatial organization 
of membrane receptors  
1.1.2 Spatial Organization During T cell Activation 
The idea that spatial organization of the TCR and accessory signaling proteins plays a critical 
role in T cell activation gained support with the discovery of the immune synapse[38], a micro-
scale cell-cell interaction structure formed by T cells and APC. During immune synapse 
formation, adhesion molecules such as LFA-1 migrate to the periphery of the T cell contact site, 
the peripheral Supramolecular Adhesion Cluster (pSMAC), whereas TCR, CD3, and a host of 
signaling proteins are found in the cSMAC. However, the discovery of the synapse was soon 
followed by studies that showed that synapse formation, which occurs minutes after T cell-APC 
contact, was preceded by strong TCR signaling, and was thus not the long-sought after 
mechanism of T cell activation[39]. Thus, today the immune synapse is appreciated as a structure 
that is a consequence of sustained T cell-APC interactions, and modulates T cell response, but is 
not absolutely required for TCR triggering. 
Regardless, the search was on for other structures and changes in the lateral organization of TCR 
that could explain the early activation events involved in T cell activation. This search was aided 
by several technical innovations, chief among them the use of model lipid bilayers coupled to 
Total Internal Reflection Microscopy (TIRF). Model bilayers provide a large, flat contact surface 
which can be functionalized with pMHC and adhesion ligands at the appropriate density[40], and 
TIRF provides a high-resolution, low-background image of the T cell-APC contact interface[41].   
These studies revealed that TCR clusters, 100’s of nm in diameter and containing 10’s to 100’s 
of TCR, were formed soon after contact with cognate MHC (reviewed in [42]). These clusters 
are enriched for signaling molecules such as Lck, Zap-70, Lat, and SLP76, suggesting they are 
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directly involved in T cell signaling. Microcluster formation precedes but is closely associated 
with synapse formation, as both involve a cortical F-actin flow that leads to inward migration of 
TCR. 
By what mechanism could spatial rearrangements during T cell activation lead to 
phosphorylation of downstream signaling proteins? A common element in spatial models is 
kinase concentration and phosphatase exclusion – phosphorylating proteins are concentrated in 
the region that contains their substrate, whereas dephosphorylating proteins are excluded, tipping 
the local balance towards phosphorylation and signaling. Consistent with this hypothesis, it was 
recently shown that close apposition between the T cell and APC membrane drove exclusion of 
proteins such as CD45, whereas the binding energy between TCR and pMHC was sufficient to 
keep these proteins within the contact area[43]. This mechanism was shown to be sufficient for T 
cell signaling in a reconstituted system. Furthermore, new high-resolution imaging techniques 
have shown nanoscale co-localization of TCR and downstream signaling proteins, which is 
enhanced after cognate pMHC binding[44]. 
1.1.2.1 Persistent Changes in TCR Organization Before and After T Cell Activation 
Spatial heterogeneity in membrane organization and TCR clustering can be detected even in the 
absence of activation by cognate antigen. Using immunoprecipitation and immunoblotting 
techniques, Fernandez-Miguel et al. demonstrated that the αβ T cell receptor can exist as a 
multivalent structure on naive T cells, composed of at least two TCR and a higher order CD3 
stoichiometry[45]. While immunoprecipitation is highly dependent on technical considerations 
such the detergent used during membrane lysis, disassociation with a milder reagent showed a 
similar effect[46]. TCR likely exist in several distinct monovalent and multivalent forms at 
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baseline, prior to antigen engagement[47]. During T cell activation, these TCR islands 
concatenate to form the large microclusters that are observed by TIRF imaging[44]. 
Following activation, TCR undergo a state-dependent, persistent increase in the extent of TCR 
clustering. Binding assays using dimeric MHC-Ig fusion proteins demonstrated that T cells 
activated four days previously showed enhanced binding of low concentrations of MHC, with a 
high degree of cooperativity[1,48]. Since this effect was not observed with monovalent MHC, 
the authors predicted a higher degree of clustering led to enhanced binding of MHC dimers. 
Persistent TCR clusters on activated cells was directly visualized using electron[49] and k-Space 
Image Correlation microscopy[50], with a distinct increase in clustering noted compared to naive 
cells. 
In general, receptor clustering prior to ligand engagement can be a mechanism of enhanced 
binding and increased sensitivity. For example, clustering of chemo-receptors on E coli. 
significantly lowers the threshold and enhances the dynamic range of chemotactic responses[51]. 
Preliminary evidence suggests that such clustering may be partially responsible for the high 
degree of T cell sensitivity to antigen; for example, only multivalent but not monovalent 
TCR/CD3 complexes were phosphorylated after stimulation with a low dose of antigen[46,52]. 
Enhanced clustering may also partially explain the increased sensitivity of previously activated T 
cells to antigen, acting in concert with changes in downstream signaling[53]. However, the 
mechanisms of persistent TCR clustering and how they relate to clustering observed during 
ligand engagement are still not understood. 
1.1.3 The Role of the Accessory Protein CD8 in Binding and Signaling 
While the TCR/CD3 complex is the primary molecule involve in T cell signaling, many 
accessory proteins influence binding and signaling. For example, two distinct classes of T cells 
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can be characterized by expression of either CD8 or CD4 co-receptor proteins in addition to 
TCR/CD3. These two sub-types, termed killer and helper T cells respectively, are functionally 
distinct and arise from positive selection by either MHC Class I ligands in the case of CD8, or 
MHC Class II ligands in the case of CD4, during thymic development. 
Co-receptors have two complementary but controversial roles during T cell activation (reviewed 
in [54]). It is known that both CD4 and CD8 have binding sites on their respective MHC ligands, 
and crystal structures have been described for the ternary pMHC-TCR-CD8/4 complex. 
However, the precise contribution of co-receptor binding to pMHC has been a matter of some 
debate. Co-receptors are cytoplasmically associated with the src-family tyrosine kinases Lck and 
Fyn, which are involved in early T cell signal transduction. The binding of co-receptor to MHC 
spatially localizes these kinases with the CD3 ITAMs they phosphorylate, which enhances but is 
not required for T cell activation[55].  
Secondly, co-receptor binding may stabilize binding between TCR with pMHC, but the 
contribution of this role may be context-dependent. Experiments have shown that the presence of 
CD4 does not significantly contribute to TCR-pMHC binding [18]. The affinity of CD8 for 
MHC Class I is weak, at approximately 50 μM in the mouse and 150 μM in the human[54], 10-
100 fold weaker than between TCR and MHC. Affinity is similarly low when measured using 
2D techniques [56]. A role for CD8 is further marginalized by evidence that pMHC binds TCR 
prior to engaging CD8 [57]. This has led some authors to argue that the co-receptor does not 
make a significant contribution by binding MHC, except insofar as it co-localizes Lck[58].   
Despite this, significant evidence exists that at least some TCR are dependent on the presence of 
CD8 to bind cognate soluble MHC[59,60], whereas others are “CD8-independent” [61,62]. 
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Micropippette assays have revealed that despite being of low affinity  and binding MHC in a 
second phase after TCR, the cumulative effect of CD8-MHC interactions can still be 
significant[20]. CD8 stabilization may thus be beneficial only for particularly weak pMHC 
ligands[63], and its presence can enhance T cell binding and activation in such cases[64]. 
Furthermore, a role for CD8 binding to MHC can vary with the activation state and may be lost 
as a mechanism of T cell suppression or activation [65–67]. Thus, in evaluating the binding 
contribution of CD8, it is important to consider both the affinity of TCR for MHC as well as the 
particular state of the relevant T cell. 
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1.2 Artificial Antigen Presenting Cells 
Artificial Antigen Presenting Cells (aAPC) are bioengineered platforms for T cell stimulation. 
Like endogenous APC, aAPC deliver a series of receptor and cytokine-mediated activating 
signals that trigger T cell signaling and activation. In turn, activated T cells mediate a therapeutic 
effect that takes advantage of three critical properties of adaptive immunotherapy: 1) T cell 
responses are specific, targeting specific antigens on diseased tissue while sparing the healthy 
host; 2) T cells responses are robust, undergoing up to 1,000-fold clonal expansion after 
activation; and 3) T cell responses have memory, maintaining therapeutic effect for many years 
after initial treatment.  
Thus, there is tremendous interest in developing flexible, reliable, and economical techniques for 
inducing T cell immunity. As we will discuss, aAPC possess a number of advantages over 
competing techniques in achieving these goals. 
aAPC have been built upon a wide variety of biocompatible platforms, including cell lines, 
liposomes, and biodegradable polymer particles, and coupled to a wide variety of proteins that 
deliver T cell activating signals. Building an optimal aAPC requires carefully selecting the 
platform and proteins that will lead to optimal T cell effector function in vivo and in vitro. In this 
chapter, I will review the basic principles of aAPC design, and review previous experience with 
platforms developed with various components. First, we will motivate the need for aAPC by 
comparing aAPC-based T cell stimulation techniques to comparable technologies. 
1.2.1 When and Why to Use APC 
aAPC are one of only several strategies for in vitro or in vivo T cell activation. In vitro, T cells 
can be expanded with culture and stimulation techniques that rely autologous APC, soluble 
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activating proteins and autologous feeder cells, or peptide-pulsed APC lines. In vivo, vaccination 
with DNA, peptide and adjuvant, or whole-cell vaccines can lead to antigen processing by host 
APC and direct T cell priming. While each of these approaches can be effective and is in 
therapeutic development, aAPC have several advantages that must be considered when choosing 
a T cell activation strategy.  
APC Dysfunction and Immune Suppression 
In vivo vaccination approaches for T cell expansion depend upon a functional APC compartment 
that can process antigen, recognize danger signals, and prime active immunity. APC dysfunction 
in several pathological states, and particularly cancer, motivates a desire to replace or 
supplement the endogenous APC compartment with fully functional aAPC.  
The peripheral blood of cervical carcinoma patients shows decreased numbers of CD11c+ and 
CD123+ DCs, correlated with increased levels of immunosuppressive cytokines IL-6 and TGF-β 
in serum[1]. Similarly, blood DCs from breast cancer patients undergo spontaneous apoptosis[2]. 
What DC remain are poorly functional, with DCs from lymph nodes and peripheral blood of 
cancer patients showing low stimulatory capacity ex vivo[3], and despite being associated with a 
mature phenotype, decreased production of immunostimulatory cytokines such as IL-12[4]. 
Within the tumor microenvironment, APC can go beyond simple dysfunction toward active 
immune suppression. Tumor-associated DCs upregulate a variety of genes associated with 
immunosuppression (IDO, ARG, TGF-β, and PD-L1) and tolerize T cells by a FOXO3-depndent 
mechanism [5,6]. Macrophages are polarized toward related wound-healing (M2) or 
immunosuppressive phenotypes characterized by fibrosis  and TGF-β production, respectively, 
rather than effective T cell priming and support[7]. Myeloid compartment differentiation is re-
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directed towards production of myeloid-derived suppressor cells (MDSC), which inhibit T cell 
function through a variety of overlapping mechanisms [8,9]. Thus, even if antigen is delivered to 
host APC by a vaccine platform, it may not lead to T cell activation, which may be a factor in 
poor results to vaccine based approaches for cancer immunotherapy[10]. 
Cost-And-Ease of Manufacture 
Biologic therapies that rely on in vitro culture of T cells with autologus APC or feeder cells are 
expensive and labor intensive processes. For cellular therapies for cancer, methods for expanding 
peripheral blood lymphocytes or tumor infiltrating lymphocytes are themselves a complex 
biologic that must be repeatedly assessed for safety and reliability, adding to complexity and 
expense. By way of example, an adoptive immunotherapy for cancer, sipuleucel-T (Provenge®), 
was recently approved by the FDA for treating prostate cancer and costs $93,000 per course of 
treatment[11]. The complicated culture process must be performed individually for each new 
patient, and the high price may limit its long term benefit. In contrast, aAPC can be produced for 
many patients in bulk and designed from easily manufactured, biocompatible platforms, creating 
an off-the-shelf reagent that has significantly reduced cost compared to cellular biologics. 
Choosing the Right Signals 
In designing an aAPC, the engineer must select the T cell stimulatory molecules that will be 
coupled to the platform and influence T cell development. This presents an opportunity to 
precisely control the signals received by T cells in a way that is not possible when relying on 
endogenous APC, which deliver innumerable, interacting, incompletely understood signals to a 
given cell. Since T cell behavior and effector phenotype are modulated at least in part by signals 
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received during initial activation, this could lead to the expansion of high quality T cells which 
are optimally designed for a specific application. 
What describes an “optimal” T cell? The characteristics required for effective therapy will 
obviously vary with pathological state, but can be broadly described in general. Optimal T cells 
have high functional avidity, meaning they mediate effector response in response to low doses of 
antigen[12,13]. They may have high binding avidity, meaning that the interaction between TCR 
and MHC, in contrast to many anti-cancer responses which are modulated by central tolerance to 
self antigen and are of low avidity [14]. They are polyfunctional, meaning that they can produce 
a large number of effector cytokines, a trait associated with control of chronic viral 
infections[15,16]. They are not exhausted and maintain proliferative capacity[17,18], as 
indicated by telomere length [19–21] and surface phenotype (high CD45RO, CCR7, IL-7R, 
CD27; low KLGR-1, PD-1, CTLA-4, TIM-3, LAG-3) [22]. 
The precise signals required to tune T cell quality in general, and particularly in the context of 
aAPC, are unknown. However, aAPC are a reductionist system, thus represent both a platform 
from which to study basic aspects of T cell stimulation and a mechanism for implementing that 
knowledge therpeutically. For example, virus-specific T cells generated by aAPC were more 
polyfunctional than those generated by autologous monocyte derived dendritic cells[23], which 
may be due the dose and density of antigen delivered [Yen Paper]. The lessons garnered from 
such studies may then be adapted to tune T cell development and craft an optimal response. 
1.2.2 Designing an aAPC: The Signal 1/2/3 Paradigm 
A general paradigm for the design of aAPC has been to mimic T cell activation by endogenous 
APC, and to select T cell activating signals that lead to optimal stimulation. As discussed in 
Chapter 1.1, and briefly described here, T cells require a series of carefully orchestrated 
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activation signals to trigger activation. In the healthy host, these are provided by endogenous 
APC such as macrophages, B cells, and dendritic cells. In aAPC design, these same signals are 
generated by coupling proteins expressed by these cells to an aAPC platform that trigger 
responses from receptors on the T cell membrane. 
Signal 1 
The first signal, Signal 1, is mediated by the interaction of TCR on the T cell with peptide 
presented on MHC peptide on the APC. Class I MHC preferentially interacts with T cell 
receptors are specific for one or several MHC-peptide combinations, and thus Signal 1 
determines specificity of the T cell response for a given epitope. MHC-binding to TCR triggers 
activation of the TCR-associated CD3 signaling complex through as-of-yet poorly understood 
mechanisms[24,25]. In aAPC design, Signal 1 can be provided by either MHC-peptide binding 
to TCR, or by engaging the CD3 complex directly with an anti-CD3 antibody.  
Soluble MHC proteins can be produced recombinantly and loaded with appropriate peptide for a 
variety of antigens of interest. Although Class I MHC have been more widely used and generated 
for a larger number of alleles, Class II MHC for stimulating CD4 T cell responses are also 
available. The aAPC engineer must select a combination of MHC allele and peptide presented by 
that allele that induces a T cell response against the antigen of interest; in humans, HLA-A201 
has been most frequently studied, based on its high frequency in the United States. In mice, Kb 
and Db alleles, as well as Ld, are frequently used based on their presence in the common 
laboratory strains C57BL6/J and Balb/c, respectively. Following stimulation, the yield and 
frequency of antigen-specific cells can be monitored using soluble, multimeric MHC reagents. 
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Alternatively, Signal 1 can be provided by an antibody against the CD3 signaling complex. A 
variety of activating CD3 antibodies are available, including the OTK31 clone in humans and 
145-2C11 in mice, but the mechanism by which antibody binding triggers downstream T cell 
activation is not yet understood. Importantly, activation via CD3 triggers non-specific expansion 
of all T cells, including regulatory T cells and cells reactive against irrelevant antigens; over 
time, this can result in preferential expansion of irrelevant cells and reduced activity against the 
target. Thus, for most applications, a source of T cells enriched for activity against the antigens 
of interest is required. In cancer immunotherapy, tumor infiltrating lymphocytes can provide 
such a source of anti-tumor activity[26], or antigen-specific cells can be purified from Peripheral 
Blood Mononuclear Cells or other polyclonal sources by HLA-tetramer-based enrichment[27]. 
Unfortunately, anti-CD3/anti-CD28 beads have shown the ability to expand and sustain CD4 
[28]but not CD8 T cell cultures [29,30] without additional feeder cell support, making them an 
appropriate choice only when CD4 cells are required, or the additional cost and labor associated 
with culturing autologous feeder cells can be tolerated. 
Signal 2 
Signal 2, the co-stimulatory signal, is a series of interactions between receptors on the APC and 
T cell surface that provide both activating and inhibitory signals. The prototypical interaction, 
between B7.1 on the APC and CD28 on the T cell surface, leads to optimal T cell expansion. If 
Signal 1 is engaged in the absence of Signal 2 in vitro, CD4+ T cells enter a state of anergy, in 
which T cell proliferation and effector function after re-stimulation are limited[31]. Ineffective 
Signal 2 stimulation can also lead to the development of suppressive, regulatory T cells, and the 
balance between anergy  and regulatory development is an area of active study. 
 22 
A wide variety of activating Signal 2 interactions exist, including the B7 family co-receptors 
B7.1 and B7.2,and their cognate APC ligand CD28; and the TNF family co-receptors OX-40, 
CD70, 4-1BB, which interact with OX40L, CD27, and 4-1BBL on the APC, respectively.  Co-
stimulatory signals can also be inhibitory to T cell expansion and effector function, such as the 
interaction of B7.1 and CTLA-4 or PD-1 with PD-L1 (B7.H1) or PD-L2[32].  
In aAPC design, Signal 2 can be provided by coupling one of the aforementioned APC receptors 
to the surface of an aAPC platform. In practice, activating antibodies against co-stimulatory T 
cell receptors, such as the anti-mouse CD28 antibody 37.51, have been shown to be an effective 
replacement for more expensive recombinant APC proteins[33]. While the downstream signaling 
mechanisms of each co-stimulatory receptor vary, engagement by certain “activating” antibody 
clones appears to be a commonly effective mechanism for triggering co-stimulatory receptor 
activation. 
Minimally, the addition of anti-CD28 antibody is required to design effective aAPC that induce 
robust T cell proliferation [34,35] and maintain the full complement of T cell effector 
functions[35,36]. Under certain conditions of extremely strong Signal 1 activation, robust 
expansion can be observed with Signal 1 alone[37], but the precise phenotypic characteristics of 
such T cells and their effectiveness in immunotherapy have not been described. On the other 
hand, many platforms instead rely on multiple co-stimulatory signals delivered 
simultaneously[38].  
The precise signals delivered by each Signal 2 are likely to differ, and thus the choice of Signal 2 
protein may be an important parameter in optimal aAPC design. For example, 4-1BBL may be 
more effective than anti-CD28 as an activating signal for CD8 T cell expansion[39,40], or even 
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synergize with simultaneously presented CD28[41]. The role of inhibitory signals has been 
explored to a lesser extent; the addition of a PD-L1 to aAPC does not appear to decrease T cell 
proliferation[42], but may have a role in shaping the subsequent response. 
Signal 3 
Signal 3 is a catch-all term for a variety of soluble signals released by APC that influence T cell 
activation and development. These include lymphotrophic cytokines such as IL-2, IL-7, and IL-
15; inflammatory signals such as TNF-α; and cytokines which modulate T cell development such 
as TGF-β, IL-12, IL-4, and IL-5. The precise effect of each of these signals is beyond the scope 
of this review, but the cytokine milieu released by APC before and during T cell activation is a 
critical determinant of T cell development after activation [43–45].  
During in vitro T cell stimulation by aAPC, the addition of exogenous IL-2 is required for robust 
T cell expansion[46–48]. Alternatively, proliferation can be supported by a variety of common 
gamma chain cytokines, such as IL-7, IL-15, and IL-21, which may have the further benefit of 
maintaining T cell replicative potential and inducing memory formation compared to IL-2 
[49,50]. These cytokines have been added to aAPC-stimulated cultures to generate cells more 
amenable to tumor immunotherapy[51]. IL-12 and Type 1 interferons added to culture can 
support proliferation at low to intermediate antigen doses, and the development of full effector 
function at any antigen dose [52–54]. 
There may be a further benefit to delivery of Signal 3 directly from aAPC, which could increase 
local cytokine concentration at the T cell-aAPC interface, spatially co-localize all 3 T cell 
stimulatory signals, and deliver cytokines to the appropriate site after in vivo administration. 
Thus far, application of Signal 3 in aAPC design has been limited by the capabilities of aAPC 
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platforms. While membrane proteins can be coupled to the surface of latex or iron-dextran 
microspheres, most platforms cannot mediate the controlled release of soluble T cell ligands. 
However, recent developments in design of aAPC based on biodegradable polymers, which can 
release encapsulated proteins in a spatially localized manner during hydrolytic degradation, have 
shown that IL-2 delivery from aAPC can significantly enhance T cell proliferation in vitro[55–
57]. This “paracrine” delivery was ten-fold more effective in inducing T cell expansion than the 
same overall dose of IL-2 in the culture media[56] 
1.2.3 Selecting a Platform 
aAPC are constructed by coupling T cell activating proteins described in the previous section to 
a suitable, biocompatible platform. While soluble MHC can induce some T cell activation[58–
60], fixing such MHC-antigen or anti-CD3 to a physical substrate, such as a latex bead, 
liposome, or microplate surface, significantly enhances the strength of T cell stimulation[59,61–
65] through mechanisms that may involve mechanical signals delivered by solid substrates [66–
68] or aggregation of TCR by physically constrained MHC [25,69]. The aAPC platform also 
spatially localizes multiple T cell activating signals, increasing the likelihood that a T cell will be 
exposed to both MHC and co-stimulatory signals simultaneously[70]. Finally, fixation to a nano- 
or microscale construct significantly alters antigen trafficking, internalization, degradation, and 
clearance[71] properties in vivo, which is discussed in greater detail below. 
Cell-based 
Initial aAPC design focused on creating APC-like cells without the need to culture autologous 
APC from each patient. These “cell-based” aAPC are thus based on readily cultured cell 
lines[72,73], particularly the K562 human erythromyeloid line[38,39,74–80] and the murine 
NIH/3T3 fibroblast line[81–83]. Importantly, K562 does not naturally express any T cell 
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activating proteins such as MHC or co-stimulatory proteins, allowing the investigator to select 
the precise signals delivered to T cells. These proteins of interest must then be stably expressed 
in the relevant line, for example by lentiviral gene transfer [80]. However, K562 cells do 
naturally express ICAM-1 and LFA-3, required to form an immune synapse, as well as negative 
co-stimulatory proteins PD-L1, PD-L2, and B7-H3.  
Unlike the synthetic bead-based platforms reviewed below, cell-based aAPC maintain features of 
a cell that may be relevant to T cell activation, such as antigen processing machinery and a fluid 
lipid membrane. The ability to process protein and present antigenic peptides on transfected 
MHC reduces the need to identify antigenic eptiopes a priori. Cell lines cannot of course be 
safely administered in vivo as a T cell vaccine, and are thus limited to in vitro applications. 
Liposomes 
Among the earliest cell-free platforms used for T cell activation were lipsomes, spherical 
vesicles with an aqueous interior generated by self-assembly of ampiphilic phospholipids and 
cholesterol. Liposomes have been used extensively as carriers [84] for water soluble drugs 
trapped in their aqueous core, and are sufficiently biocompatible to be administered in vivo. 
Liposome-based aAPC can be generated by detergent disruption of membranes from cells that 
express or are transduced to express the relevant T cell-activating signals[85,86], or by directly 
by mixing purified membrane proteins with ampiphilic lipids and surfactants at known 
ratios[63,64,87–90]. Exosomes derived from dendritic cells, which like liposomes are 
lipidbilayer structures that express MHC and other T cell activating proteins, have thus far been 
weakly immunogenic[91] but are being examined as an aAPC platform. 
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Like cells, liposomes have fluid lipid exteriors which allow the free movement of protein. Unlike 
cells, liposomes can be generated in sizes ranging from <100 nm to several microns in diameter; 
the importance of aAPC size as a design parameter will be reviewed below. Furthermore, 
liposomes can be used to deliver soluble Signal 3 molecules trapped within their core. 
Latex Beads 
Latex (polystyrene) beads were one of the first synthetic bead-based platforms used in aAPC 
design. They have been instrumental as a reductionist system for studying basic aspects of T cell 
biology[29,47,92–95], as well as translational platform for adoptive immunotherapy [96–99]. 
Latex-based aAPC are synthesized by chemically coupling soluble proteins to a functionalized 
polystyrene surface, or indirectly by attaching biotin-labeled T cell activating proteins to avidin-
coated particles.  
Polystyrene-based microparticle systems have predominantly used to expand T cells in vitro, as 
they have present serious biocompatibility concerns if co-infused with T cells or administered 
directly in vivo. Intravenously administered rigid particles greater than 3-5 μm in diameter lodge 
in small capillary beds, particularly in the lung[100–102], which could cause capillary infarction. 
This has motivated the development of particles which can be removed from or degrade during 
culture, as will be described in further sections. 
MHC presented on rigid bead-based platforms, or fixed on a cell surface by gluteraldehyde [37], 
may provide a stronger stimulatory signal than MHC presented on a cell membrane, and 
substrate rigidity  [66–68] is known to be a critical parameter for T cell activation. Alternatively, 
a hybrid lipid-latex particle can be synthesized by coating a silica or polystyrene microsphere 
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with plasma membrane vesicles[61,103–105], which combines the potential advantages of both a 
rigid substrate and a fluid membrane.  
Magnetic Particles 
Iron-oxide core, dextran coated nano- and microparticles have been extensively used for cell 
isolation and purification, with paramagnetic particles binding ligand-labeled cells of interest and 
trapping them in a magnetic field[106,107]. Although iron-dextran nanoparticles display 
excellent biocompatibility when co-infused with labeled cells [108–110], iron-dexran 
microparticles can lodge in capillary beds like their polystyrene counterparts. Unlike polystyrene 
particles, however, paramagnetic iron-dextran microparticles can be removed from T cell culture 
using a magnetic field, or degrade into iron and dextran metabolites after in vivo injection, 
providing a considerable advantage in biocompatibility. Furthermore, removal of paramagnetic 
beads and their co-stimulatory signals may actually enhanced T cell proliferation under certain 
circumstances[46].  
Iron-dextran micropraticles have been thus been extensively characterized as aAPC [34,111–
115]. They have been studied both as platforms for translational application of tumor 
antigens[34,114], and as a tool for the study of basic aspects of T cell antigen recogntition and 
development[23,116–118]. CD3/CD28 coupled iron-dextran are commercially available as CD4 
expansion platforms[119], have been used to support regulatory T cell expansion in a number of 
settings [78,120]. Their availability as clinical-grade reagants that can be removed prior to 




Like liposomes, microspheres assembled from biodegradable polymers were initially developed 
as vehicles for drug delivery[123,124]. Microparticles can be synthesized in a variety of sizes 
(100’s of nms to 10 micrometers in diameter) from a variety of polymers, such as poly (lactic 
acid) (PLL), poly (glycolic acid) (PGA), and their co-polymer, poly (lactic-co-glycolic acid). 
Over several hours to weeks, depending on their formulation, biodegradable polymer particles 
are hydrolyzed to non-toxic end products, releasing drugs encapsulated within them. 
Due to their excellent biocompatibility and degradation properties, biodegradable polymer 
particles are an excellent choice for aAPC platforms that will be administered in vivo[125]. 
Importantly, they can be designed to release soluble cytokine signals as they degrade, and are the 
most promising platforms for integrating these signals into aAPC design[126,127].  
1.2.4 Choosing a Therapeutic Approach 
The selection of T cell activating proteins and aAPC platform should be made in concert with the 
development of a therapeutic approach. There are two basic approaches to using aAPC: they can 
be used to generate T cell responses in vitro that are then adoptively transferred into the patient, 
or directly administered in vivo as a T cell vaccine. Both approaches have advantages and 
disadvantages, which will be reviewed below. 
Adoptive Immunotherapy 
Antigen-specific T cells generated in vitro and adoptively transferred into a patient can mediate 
profound immunotherapeutic effects. For example, adoptive transfer of large numbers tumor 
infiltrating lymphocytes (TILs) generated from melanoma cultures can mediate complete and 
durable regression of even large and metastatic tumors[26]. Adoptive transfer of CMV-specific 
lymphocytes has been studied as a means of limiting immunosuppression post-
transplant[33,128], and regulatory T cells have been transferred to control autoimmune 
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disease[129] and Graft-vs.-Host disease[78]. A critical step thus involves generating a large 
number of antigen-specific T cells in vitro, which can be performed using aAPC (reviewed 
in[130]). 
Adoptive immunotherapy possess several key advantages over direct in vivo injection and 
vaccination. By stimulating T cells in a constrained in vitro culture environment, the investigator 
can ignore otherwise challenging issues of aAPC biodistribution, clearance, and trafficking. 
Furthermore, adoptive immunotherapy at least temporarily separates the patient and their 
accompanying pathology from the therapeutic cells, allowing each to be conditioned and treated 
separately. For example, high intensity lymphodepletion with chemotherapy or radiation prior to 
adoptive transfer significantly enhances immunotherapy for metastatic melanoma [131–133] by 
at least two mechanisms[26,134]: depleting the immunosuppressive regulatory cells that inhibit 
productive anti-tumor responses, and it creating “space” in the lymphoid compartment that 
decreases competition for lymphotrophic cytokines and improves retention of transferred cells. 
This approach is made possible by the physical separation of the patient and their ex vivo 
cultured cells, which would otherwise be depleted as well. On the other hand, in vitro T cell 
culture is costly and labor-intensive compared to direct administration, and can be described as 
designing a “new drug” for each patient. 
The most direct method of generating antigen-specific T cells involves expanding polyclonal 
populations of CD8 or CD4-sorted lymphocytes, splenocytes, or PBMC with aAPC bearing the 
MHC-peptide of interest. This is a particularly useful approach if antigens specific to the cellular 
targets involved in disease have been described, and robust T cell responses can be generated 
against these antigens in most patients. The amount and frequency of antigen-specific cells that 
can be generated is highly dependent on aAPC platform, antigen choice, and culture conditions. 
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CD8+ T cells can be expected to expand approximately 10-50 fold after one week[40], and up to 
several hundred fold over 2-4 weeks[75,112]. The resulting antigen specificity of the culture 
depends on the precursor frequency of the cells of interest: naive CD8 precursor frequencies are 
estimated to be on the order of 10-800 per 10 million [135], but responses against common 
pathogens such as flu exist at considerably higher frequencies [116]. Thus, representative 
frequencies at one week can be as high as 5% after one week o stimulation[73] for tumor 
antigen, or up to 20% for CMV[136]. This increases significantly with repeated stimulation, . 
These numbers compare favorably with the numbers of T cells required for adoptive 
immunotherapy. For example, approximately 106 antigen specific T cells are required for the 
durable regression of established subcutaneous melanoma in mice[137], and approximately 1010 
are transferred for cancer immunotherapy during clinical trials[138], numbers which can be 
reliably generated by aAPC stimulation for many relevant antigens.  
Alternatively, one can simultaneously generate T cell populations against multiple antigens of 
interest with aAPC platforms conjugated to anti-CD3. This approach is particularly relevant if 
the investigator has access to a pool of T cells that already has the required activity; for example, 
T cells with activity against melanoma can be cultured from Tumor Infiltrating Lymphocytes. 
Unfortunately, TILs cannot be expanded from all melanoma patients, nor in most other 
cancers[139]. Furthermore, depending on the starting T cell population, CD3-based stimulation 
may preferentially expand T cells with irrelevant specificities, decreasing the antigen-specificity 
of the resulting culture[77]. 
To avoid this problem, or if a source of antigen-specific cells is unavailable, T cells against the 
antigens of interest can first be sorted with MHC multimers, then expanded polyclonally with 
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anti-CD3 aAPC [27,140–143]. This allows the generation of T cell populations from readily 
accessible compartments such as peripheral blood. 
Direct Vaccination 
Direct injection of aAPC as a T cell vaccine is simpler and cheaper than adoptive 
immunotherapy. However, several key challenges arise when designing an effective direct 
injection strategy. Chief among these are particle clearance and the trafficking properties of the 
selected aAPC platform. 
To activate T cells, aAPC must co-localize with T cells after administration, and must not be 
cleared prior to encountering these cells. The in vivo delivery and biodistribution of bead-based 
therapeutics is determined by particle size, shape, and surface charges, as well as interaction with 
host proteins  [102,144,145]. Particle size can be a critical determinant; for example, microscale 
particles have limited lymphatic drainage from their injection site when injected subcutaneously 
[146]. Furthermore, particles greater than 3-5 μm in diameter can embolize to small capillary 
beds in the lung when administered intravenously [100–102], and are preferentially cleared by 
and targeted to certain phagocytic subsets [147,148]. The trafficking and distribution properties 
of in vivo administered aAPC remains a critical and understudied aspect of aAPC design. Thus, it 
is not yet known what route of administration is most effective at priming T cell responses, or 
what percentage of administered aAPC make contact with relevant T cells prior to degradation 
and clearance. 
Despite this, several successful direct vaccination studies have been published using aAPC. The 
earliest reports involve 5 μm diameter silica microbeads injected intraperitoneally in tumor-
bearing mice[61]. Importantly, no antigen-specific responses or tumor activity could be detected 
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unless a cell-based tumor vaccine was co-administered along with aAPC, suggesting aAPC could 
only boost existing responses. Alternatively, such aAPC could synergize with administration of 
cyclophosphamide to reject established P815 mastocytoma and two fibrosarcoma models, 
although beads alone once again demonstrated minimal activity[103]. This platform was 
subsequently assessed in a Phase I trial of patients with disseminated melanoma[104], with 8/15 
patients developing antigen-specific cytolytic T cells, but only one partial tumor response.   
Other cell-free aAPC systems have been shown to be effective without additional modulation. 
Iron-dextran microparticles injected intravenously [34] can mediate regression of both 
subcutaneous melanoma and interavenous lung metastases. Similarly, latex particles 
administered both intravenously and subcutaneously generated robust antigen-specific T cell 
responses, and subcutaneously administered microparticles mediated B16 melanoma rejection 
[96]. Still, the paucity of published reports demonstrating the effectiveness of in vivo 
administration of aAPC suggests much remains to be discovered before this therapeutic approach 
is optimized. 
1.2.5 Advanced Considerations in aAPC Design 
The selection of T cell stimulating proteins and a therapeutic strategy are the minimal 
requirements for aAPC design. Advances in particle synthesis, however, are allowing greater 
control over aAPC design that may further improve T cell responses. These advances have 
developed in parallel with a better understanding of T cell activation by endogenous APC, and 
allow the investigator to both mimic and improve upon T cell-APC interactions. These 
“advanced” considerations are reviewed below: 
MHC Valency 
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The recognition of cognate MHC by TCR takes place in the context of a cell-cell interaction, 
with close apposition of membranes [24] constraining TCR-MHC binding kinetics to a two-
dimensional plane [149]. Soluble MHC monomers, separated from their natural context in the 
APC membrane, have surprisingly low, micromolar avidity for cognate TCR . This has prompted 
the development of multimeric MHC constructs such as dimers and tetramers, which enhance 
overall binding avidity [150–152]. Studies with multivalent MHC suggest that multivalent but 
not monovalent MHC fixed to a rigid surface can trigger T cell stimulation[153]. 
By analogy, while monomeric MHC coupled to aAPC microspheres can trigger T cell 
activation[61,94], multivalent MHC may induce stronger responses[62,112]. However, no 
comprehensive examination of multivalency has been performed. Furthermore, multivalent 
MHC constructs can have other biophysical disadvantages: commonly used MHC tetramers have 
been coupled aAPC [96,98,154], but their rigid tetrahedral geometry orients a fraction of MHC 
molecules toward the particle surface and away from the interacting T cell.  
Antigen Density 
A similar effect to MHC multivalency at a slightly larger scale may be mediated by MHC 
density. Antigen density on APC membranes is known to affect subsequent T cell response 
[155–158]. This principle may also apply to aAPC design, although antigen presented on aAPC 
is usually supraphysiologically dense compared to the small numbers (as few as 1-10)[159,160] 
of cognate MHC-peptides that trigger T cell activation. 
A density threshold of monomeric MHC is critical for T cell activation, and the addition of more 
beads at a lower density is not sufficient to overcome this effect[29,62]. However, the density of 
MHC may control the avidity if the resulting cultured T cells, with higher avidity resulting from 
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a lower MHC density  [161]. Thus, if high avidity T cell responses are required, investigators 
must titrate density to achieve T cell proliferation without sacrificing T cell quality. 
TCR and MHC Clustering 
The spatial organization of surface receptors plays a critical role in T cell binding to MHC and 
subsequent activation, with TCR organized in microclusters both prior to[162,163] and during T 
cell activation[164,165]. This is mirrored by clustering of MHC on the APC surface[166]. 
Receptor clustering is thought to enhance the sensitivity and dynamic range of binding and 
signaling events by encouraging cooperative binding of multivalent ligands and spatial co-
localization of signaling proteins[162,163,167]. 
There may thus be benefits to manufacturing aAPC with clustered protein signals. One study 
used αCD3, αCD28, and αLFA-1 monoclonal antibodies, pre-clustered on liposomes using 
neutravidin rafts, to efficiently activate MART-1 CD8 T cells[63], although the precise role of 
clustering in enhancing T cell responses could not be clearly defined. In a separate liposome-
based study, CD4 stimulation was significantly stronger from aAPC presenting clustered 
compared to unclustered MHC[168].  Further study will require synthesis of platforms other than 
liposomes with spatially controlled receptor patterning [169]. 
Particle Size, Contact Area, and Synapse Formation 
Studies on synthetic bead-based aAPC have largely focused on development of cell-sized, micro-
scale aAPC in order to better mimic T cells interaction with Antigen Presenting Cells. This 
choice is theoretically reinforced by microscale T cell-APC interactions observed during 
activation. For example, the immune synapse is a pattern of surface receptor reorganization 
several microns in diameter, with centrally located TCR and peripherally located adhesion 
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molecules. The synapse, while not absolutely required for activation, does modulate antigen 
search and recognition [170]. A related process, asymmetric cell division, is hypothesized to 
regulate memory development by providing a microscale geometrical cue that induces polarity 
during cell division [171]. 
While synthetic surfaces coupled to T cell stimulatory signal are a common platform for studying 
synapse formation[172], the ability of cell- or bead-based aAPC to induce synapse or ACD 
formation is not well-described. However, studies have suggested that a broad contact surface 
between T cells and aAPC is required, with only beads larger than 2 microns in diameter able to 
induce T cell proliferation [94,126].  Steenblock et al.[57] demonstrated that polymer-based 
nanoparticles were much less efficient than microbeads in inducing short-term functional 
responses, with no reported proliferation.  
If nanoscale aAPC were able to induce T cell activation, there would be significant advantages to 
using these smaller particles. Unlike microparticles, nanoparticles of approximately 50-100 nm 
diameter can be taken up by lymphatics and transported to the lymph nodes [84,146] thus 
gaining access to a larger pool of T cells. In addition, nanoscale delivery vehicles preferentially 
accumulate in tumors through enhanced permeability retention due to poorly formed tumor 
vasculature[173,174]. By delivering an immunostimulatory signal in situ, aAPC in the tumor 
microenvironment may address one of the most prominent hurdles in cancer immunotherapy, the 
immunosuppressive tumor microenvironment [175]. 
On the other hand, there are significant biophysical hurdles that must be addressed in designing a 
nanoscale aAPC system. For example, nanoparticles might be sensitive to enhanced TCR 
clustering, which is itself nanoscale, in a way that larger particles are not. In addition, there is a 
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high degree of local curvature on a nanoparticle compared to microparticle surface, which limits 
the interaction of neighboring ligands with the cell membrane. Furthermore, while Asymmetric 
Cell Division immune synapse formation are not absolutely required for T cell activation[176], it 
is not clear whether nanoscale interactions can recapitulate these microscale structures. 
Preliminary evidence suggests that 60-90 nm liposomes can induce a ‘capping’ of TCR on the T 
cell surface that approximates the immune synapse[88], but many questions remain unanswered, 
including whether fluid lipid membranes are required on the aAPC for synapse formation, 
whether the lack of accessory interactions such as LFA-1/ICAM influences synapse formation by 
aAPC, and the ultimate downstream consequences of T cell activation without strong synapse 
formation on T cell function. 
Particle Shape 
Similarly to particle size, particle shape may affects both the interaction between T cells and 
aAPC, as well as the in vivo trafficking of aAPC after injection. Unlike particle size, however, 
existing design considerations have not been guided by a desire to recapitulate endogenous APC-
T cell interactions.  
Most synthetic APC platforms are spherical, a shape which is easily synthesized using standard 
chemical synthesis procedures such as double-emulsion of PLGA[123]. However, non-spherical 
geometries are critical components of T cell-APC interactions. While spheres minimize surface 
area for a given diameter, T cell-APC interactions involve the formation of a large, stable contact 
area where a high density of MHC is presented to a closely apposed T cell membrane[170]. Even 
prior to T Cell stimulation, activated Dendritic Cells increase surface area for antigen 
presentation by forming their namesake dendrites, large folded ruffles of APC membrane 
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optimized for T Cell interactions in the lymph node[177]. Thus, there may be a benefit to 
increasing the potential area for T cell contact on the aAPC surface by designing aAPC with non-
spherical geometries, such as ellipsoids. Alternatively, platforms with enhanced surface areas 
such as carbon nanotubes may be relevant systems for studying the influence of surface area on 
T-cell-aAPC interactions. 
Particle geometry also influences uptake by the Reticuloendothelial System, with ellipsoid 
particles with a long characteristic axis displaying showing reduced phagocytosis[178–181]. 
Interestingly, receptor-mediated internalization of antibody coated non-spherical particles was 
significantly enhanced, suggesting the interaction of geometry and uptake may be pathway 
dependent[182]. In either case, it is important to remember that in vitro uptake studies may not 
recapitulate in vivo behavior, adsorption of serum proteins such as complement significantly alter 
trafficking and clearance characteristics of in vivo administered micro- and nanoparticles. 
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1.3 Adoptive Cell Transfer for Cancer Immunotherapy 
The transfer of large numbers of tumor-specific lymphocytes into cancer patients can mediate 
complete, durable regressions of metastatic tumors. The remarkable series of clinical trials 
demonstrating the effectiveness of adoptive immunotherapy has spurred large-scale interest in 
both the clinical and basic aspects of adoptive immunotherapy for cancer. 
From a theoretical standpoint, cancer immunotherapy using T cells has long been of interest. 
Adaptive immunity has numerous beneficial properties that make it amenable for cancer 
treatment: 1) T cell responses are specific, and can thus potentially distinguish between healthy 
and cancerous tissue; 2) T cells responses are robust, undergoing up to 1,000-fold clonal 
expansion after activation ; 3) T cell response can traffic to the site of antigen, suggesting a 
mechanism for eradication of distant metasteses; and 4) T cell responses have memory, 
maintaining therapeutic effect for many years after initial treatment. 
Despite this theoretical interest, cancer immunotherapy could not proceed until it was established 
that immunity could distinguish tumor from healthy tissue[1]. Unlike microbial pathogens, 
tumors are fundamentally “self,” and belief in immune recognition cancer has waxed and waned 
since the cancer immunosurveillance hypothesis was first proposed. The identification of human 
tumor associated antigens (TAA’s) [2] was the culmination of a renewed interest in tumor 
immunology spurred by tumor transplant models in the mouse[3], and provided definitive proof 
that specific anti-tumor responses could be generated under the right conditions. 
The next hurdle to be addressed was the identification of a readily accessible pool of tumor-
specific lymphocytes. Using modern techniques, T cells with anti-tumor cytotoxic activity can be 
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identified in tumor samples of up to 80% of melanoma patients[4] (but less frequently in other 
cancers). It is now clear that the T cell infiltration and inflammation are “hallmarks” of 
cancer[5]. Still, the immune surveillance hypothesis remains controversial, and whether Tumor 
Infilitrating Lymphocytes (TILs) are spectators to cell death and dysfunction or actively 
mediating rejection of human cancers is open to debate. Furthermore, the very co-existence of 
tumor-specific T cells and large tumors casts doubt on the effectiveness of these responses in 
cancer eradication. However, while the question of whether immunity does control cancer 
remains a matter of some debate, adoptive cell therapy has conclusively demonstrated that under 
the right therapeutic conditions, ACT can eradicate tumors.  
1.3.1 ACT Can Eradicate Tumors 
Adoptive cell therapy involves the isolation of T cells from a patient or compatible donor;  ex 
vivo expansion, manipulation, or enrichment of these cells; and subsequent re-infusion. While 
the mechanism of action was not initially understood, allogeneic stem cell transplantation 
(HSCT) for hematological malignancies represents the earliest adoptive transfer of T cells with 
tumoricidal activity in cancer patients[6]. Rather than simply replacing leukemic bone marrow 
with a healthy transplant, donor cells mediate a graft-vs.-tumor effect against allogeneic antigens 
present on leukemic cells[7], which reduces tumor burden and prevents recurrence[8]. 
Unfortunately, lack of specificity in the allogeneic responses makes it challenging to separate the 
graft effect on tumor from the graft effect on host. Thus, developments in HCST have paralleled 
ACT development in general, as outlined below.  
The earliest trials of ACT using lymphocytes isolated from cancer samples were conducted at the 
surgical branch of the NCI in 1988[9], following the demonstration in 1987 that TILs could be 
cultured in the lymphotrophic cytokine IL-2 and exhibited cytotoxic activity against cancer cells 
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in vitro[10]. Objective responses by RECIST criteria were observed in 11 of 20 patients with 
metastatic melanoma, and in 34% of patients of a larger follow-up report in 1994[11]. 
Unfortunately, only 5 of the 29 responses were complete, and the median duration of response in 
these early studies was only 4 months. 
A major breakthrough occurred with the addition of lymphodepletion prior to ACT. The benefits 
of total body irradiation and lymphodepleting chemotherapy were first illustrated in mouse 
models of B16 melanoma[12], demonstrating the value of pre-clinical animal models of ACT. 
As discussed in greater detail below, lymphodepletion enhances ACT by reducing competition 
for cytokines and eliminating the multiple layers of immunosuppression that stifle productive 
tumor responses. The addition of lymphodepletion to ACT increased response rates in Stage IV 
melanoma patients to 49%, 52%, and 72% with three sequential protocols of increasing intensity 
total body irradiation [13–15]. Complete responses were achieved in 20 of 93 patients treated, 
and 19 of these 20 responses have persisted for at least 5 years. Comparable results have now 
been achieved have now been achieved outside of the NCI, with 48% response (4 complete, 11 
partial) in a trial that utilized a lymphodepleting chemotherapy regimen but no TBI [16,17]. 
While these results represented a stunning breakthrough in melanoma treatment, the protocol 
could not be applied to patients that lacked readily cultured T cell responses, or to cancers other 
than melanoma in which TIL culture remained a challenge. While both breast and colon cancer, 
for example, do contain TILs, their antigen specificities are still incompletely defined, and a 
significant proportion of those lymphocytes have suppressive rather than anti-tumor 
activity[18,19].Several approaches have thus been developed to increase the proportion of 
patients and cancers which can be treated using ACT. 
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Tumor-specific T cell clones can be generated from repeated antigen-specific stimulation of 
patient-derived (autologous) or donor-derived (allogeneic) T cells in vitro[20].  For example, a 
recent pilot study explored the use of allogeneic CD8+ T cells with activity against the Wilms 
tumor antigen 1 (WT1) in leukemia patients who relapsed after HSCT[21]. Clones were 
generated by leukophoresis of HLA-matched donor cells and repeated stimulation with peptide-
pulsed, autologus Dendritic Cells over several months. This approach can be described as an 
attempt to uncouple the Graft-vs.-Tumor effect from the Graft-vs.-Host effect of hematopoietic 
cell transfer by generating T cells of a single antigen-specificity from donors. Adoptively 
transferred lymphocytes remained detectable in patient blood long-term, and transient responses 
were observed in 2/11 of these high relapse-risk patients, with stable disease observed in 3 
others. Similar approaches have been applied to CTL clones in melanoma[22,23] and ovarian 
cancer[24]. 
A potentially limitless source of T cells with almost any desired specificity can be derived from 
autologous lymphocytes genetically engineered to express the relevant TCR (reviewed in [25]). 
Tumor-reactive TCR must first be identified in T cells isolated from patients with naturally 
occurring anti-tumor activity, and can be engineered to increased affinity specificity by changes 
to complementarity-determining regions [26]. Antigen-specific TCR may also be derived from 
mice engineered to express human antigens[27]. Retroviral or lentiviral transfection is then used 
to transfer cDNA encoding the desired TCR specificity to T cells isolated from the patient[28]. A 
key theoretical concern with this approach is that engineered T cells contain both endogenous 
and engineered TCR (and thus dual specificity), which may lead to cross-reactivity after 
activation. TCR chains from native and engineered TCR could also pair to create novel TCR 
 55 
with new specificities. Despite this concern, side effects of genetically engineered T cell therapy 
have primarily been due to on-target effects of tumor antigen expressed on healthy tissue. 
In melanoma, genetically-engineered T cells have not been as successful as TIL-derived ACT 
[29], with only 2/18 patients showing partial response and sustained levels of circulating cells at 
one year.  A subsequent study of two additional TCR specificities showed objective response 
rates of 19-30%[27]. However, the use of genetic engineering has vastly expanded the range of 
potential cancers amenable to ACT therapy, including neuroblastoma[30], synovial cell 
sarcoma[31], and colorectal cancer[32], among others. However, the use of TCR derived from 
responses in other patients eliminates the contribution of central tolerance, increasing the risk of 
autoimmune toxicity[31]. Despite the comparatively weak responses and safety concerns, 
interest in this approach is high due to its ability to treat a variety of cancers and the potential to 
improve results by additional genetic modifications, as will be discussed later. 
While gene-modified T cells can be generated against many tumor antigens, TCR are still HLA-
restricted, meaning that new specificities must be described for each tumor antigen and HLA 
allele. The development of chimeric antigen receptors (CARs) provided a more universal 
approach to targeting tumor antigens that are expressed on the membrane of cancer cells. Now 
on their third generation, CARs are hybrid receptors formed by the fusion of an extracellular 
tumor-specific antibody fragments, CD3-derived ITAM signaling chain, and a co-stimulatory 
signaling domain [33]. CARs have been explored with moderate success against carbonic 
anhydrase in Renal Cell Carcinoma[34] and L1 Adhesion molecule (CD171) in 
neuroblastoma[35], among other antigens (reviewed in [25]). The most promising results have 
been achieved in hematologic malignancies [36,37], where CD19-targeted CARs can recapitulate 
the mechanism of rituximab therapy without the need for repeated antibody administration.  
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Two decades after the first trials demonstrated the feasibility of large-scale adoptive cell transfer, 
a series of approaches have been developed to generate antigen-specific T cells against cancer. 
Attention has turned toward making ACT more safer, more effective, and more reliable. In the 
sections that follow, I will attempt to synthesize knowledge derived from these trials to generate 
steps towards the design of optimal adoptive cellular therapy. 
1.3.2 Selection of Tumor Antigens 
A primary goal in the design of all cancer therapeutics is the selection of targets that are present 
on tumor but not healthy cells. In immunotherapy, this means identifying tumor-associated 
antigens (TAAs) which are expressed solely or preferentially on cancer cells. With the 
development of in vitro antigen-stimulated clones, TCR-engineering, and CARs as sources of 
antigen-specific T cells, the choice of antigen has become an explicit first step in the 
development of many ACT protocols. 
Tumor-Associated Antigens 
TAAs can be classified into four major groups[38]: 1) Antigens over-expressed in tumors: these 
antigens arise from non-mutated proteins which are present on healthy tissue, but are over-
expressed in cancer, often because they provide a growth advantage to the cell. Central tolerance 
mechanisms [39]ensure that T cell responses against these antigens are largely poorly 
immunogenic and low-affinity[40], as will be discussed in further detail below. Prototypical 
antigens include HER-2/Neu in breast and ovarian cancer, and RAGE-1 in renal cell carcinoma. 
2) Melanoma differentiation genes: antigens derived from differentiation proteins specific to the 
melanocyte lineage are overexpressed in melanoma and are recognized by TILs in many patients. 
While they are also found on healthy melanocytes, differentiation antigens are highly 
immunogenic and may explain the unique success of TIL therapy in this disease. Protoypical 
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antigens in this category include gp100/pmel117, Melan-A/MART-1, and TRP-2. 3) Antigens 
resulting from mutations: these so-called neo-epitopes arise from somatic mutations in cancer. 
Mutation patterns are unique to each patient [41,42] and may occur as ‘driver’ mutations central 
to oncogenesis, or passenger proteins accumulated during tumor progression [43]. Because they 
result in novel antigenic eptitopes that are not regulated by Central Tolerance, neo-antigens are 
more likely to generate high affinity T cell responses. 4) Cancer-germline antigens: many 
cancers share common expression of cancer-germline (aka cancer-testis) proteins that are only 
expressed on male germline cells, which reside in an immunoprivileged site and are thus less 
vulnerable to autoimmune T cell targeting. This expression appears to be due to a common de-
differentiation program associated with genome-wide demethylation. Prototypical antigens 
include the MAGE family genes and NY-ESO1.  
Databases of known tumor antigens classified by category are now widely available to guide 
selection [44]. An ideal target would have minimal off-target effects and expression on healthy 
tissue; would be widely shared by many patients in many cancers; would permit the generation 
of high avidity T cell responses against it; and would be critical to tumor progression, reducing 
the likelihood of loss of expression and immune escape. A comparison of these desired traits to 
the categories of tumor antigens above immediately suggests that no antigen will constitute a 
perfect target. However, numerous trials now exist whose results guide target selection, and they 
will be referenced throughout the remainder of this review. 
Off-Target Effects 
A key determinant of the success of ACT in melanoma is a well-tolerated and controlled side-
effect profile. The loss of skin pigmentation due to melanocyte destruction, vitiligo, is 
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disfiguring but not life-threatening, and was one of the first indicators of ACT activity[45]. The 
presence of melanocytes in the eye and ear can trigger mild uveitis and hearing loss that can be 
controlled by topical steroids. This permits the use of TILs and T cells specific for melanoma 
differentiation antigens, which are of high affinity but mediate autoimmune melanocyte 
destruction. 
Side effects of ACT in other cancer histologies similarly depend on expression of tumor antigen 
on healthy tissue. The use of CAR against CD19 in B cell leukemias leads to B cell aplasia and 
hypogammaglobulinema due to CD19 expression on B cells [37]. Tissue damage may also 
increase with higher affinity/sensitivity of the adoptively transferred cells, as described in greater 
detail below[46]. 
Unfortunately, off-target effects cannot always be predicted based on available pre-clinical 
knowledge; TCR targeting carcinoembryonic antigen was predicted to have limited toxicity in 
mouse models[47], but induced severe transient colitis in trials[32]. The use of TCR-engineering 
permits the use and re-use of defined TCR specificities, and the gradual development of well-
described safety profiles. This knowledge, however, comes at a price, and may only be 
discovered after significant toxicity has occurred; for example, the previously unrecognized 
expression of MAGE isoforms in the brain led to neuronal cell destruction using an anti-MAGE-
A3 TCR [31]. A high affinity anti-MAGE-A3 TCR also induced myocardial damage even 
without MAGE-A3 expression in the heart due to cross-reactivity [48]. As a means of limiting 
unexpected toxicities, TCR-engineered T cells can also be engineered to express a “kill-switch” 
that can be used to eliminate cells following transfer: these include sensitivity to gancyclovir 
through expression of HSV-TK[49], or rituximab by expression of CD20[50]. 
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Multiple Antigens and Immune Escape 
There is a theoretical concern that under selective pressure by T cells with a single antigen 
specificity, tumors could down-regulate antigen or MHC expression, as is known to occur during 
cancer development[51], as a mechanism of immune escape. In mouse models of B16 
melanoma, tumor recurrence is associated with loss of antigen expression [52,53], whereas 
adoptive transfer of T cells with multiple specificities can prevent this process and enhance 
treatment [54].  
In humans, TIL-derived ACT transfer remains the most clinically effective form of adoptive 
immunotherapy; this could be due to the transfer of polyclonal T cells against many antigens, but 
also to the inherent immunogenicity of cancers such as melanoma from which TILs can be 
cultured. Within TIL trials, the most successful results were achieved when patients had multiple 
persistent antigen-specific responses [55][56], which is again suggestive but may again be 
explained through numerous mechanisms. Furthermore, loss of MHC expression has been 
observed following immunotherapy[57]. Thus, there is reason to believe ACT would benefit 
from multiple simultaneous antigenic targets, but thus far no direct evidence from trials.  
CD4 T cells in ACT 
CD4 T cell “help” provided to CD8 and APC is important for formation of productive immune 
responses, and particularly memory[58]. Furthermore, CD4 T cells are master regulators of the 
balance between rejection and suppression in the tumor microenvironment [59], coordinating 
responses primarily through secretion of inflammatory and suppressive cytokines. While CD4 T 
cells can directly lyse tumors such as melanoma which express antigen presented in the context 
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of MHC Class II[60], most tumors do not [59], and ACT has thus focused on Class I-restricted 
antigens.  
Mouse models suggest that CD4 T cells are capable of enhancing the effect of adoptively 
transferred CD8 T cells and coordinating anti-tumor responses when adoptively transferred on 
their own[59]. In fact, CD4 cells can be more effective than CD8 cells under conditions of 
minimal manipulation and post-adoptive transfer support[61]. Helper cells can be skewed in 
vitro  to a number of subsets associated with unique patterns of cytokine production and immune 
cell recruitment, and which may have different levels of anti-tumor activity; in melanoma, a 
Th17 polarized subset was superior to unskewed (Th0) and Th1 polarized cells[62]. Finally, T 
cells that can directly recognize antigen presented on tumors and have the superior immune 
regulatory functions of CD4 cells can be generated by engineering of Class I restricted TCR into 
CD4 cells[63,64]. 
CD4 use in clinical trials of ACT has thus far been limited by a lack of well-established Class II 
restricted antigens and techniques for reliability generating CD4 cells. A case report described  a 
single patient with melanoma who received autologous CD4 cells engineered with an NY-ESO-1 
TCR mediated a durable clinical remission[65]. A small trial of4 ovarian cancer patients treated 
with MUC1 stimulated CD4 cells generated responses in 2/4 patients[66]. However, CD8 
enriched TIL are non-inferior to bulk TIL for melanoma treatment[67], and the efficacy of CD4 
ACT compared to CD8 ACT remains unclear. 
1.3.3 Parameters of T Cell Quality: Replicative Potential, Avidity, and Polyfunctionality 
Replicative Potential 
The effectiveness of ACT correlates with the number of TILs or antigen-specific T cells that are 
adoptively transferred in animal models [68,69] and some [17] (but not all [70]) clinical trials. 
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This common-sense observation, coupled with a belief that “more is better,” led early 
investigators to repeatedly stimulate T cells ex vivo to induce repeated rounds of T cell division. 
The generation of tumor-specific T cells from polyclonal precursors similarly required multiple 
rounds of stimulation over several weeks to months until high antigen-specific frequencies were 
achieved. 
Unfortunately, the production of high T cell quantity during in vitro culture often comes at the 
cost of T cell quality. In particular, repeated stimulation with high doses of antigen can drive T 
cells toward an effector phenotype that, while highly cytotoxic, is also terminally differentiated 
and has low replicative potential. T cell differentiation from naive to effector cell shares many 
features in common with stem cell differentiation, with cells classified as more ‘stem-like’ on the 
basis of surface phenotype (CD62Lhi, CD45RO, CCR7hi, IL-7Rhi, etc.), increased telomere 
length, and high overall replicative capacity (reviewed in [71]). Based on these characteristics, T 
cells can be described (from most stem-like to most-differentiated) as naive (Tn), central memory 
(Tcm), and effector memory (Tem). 
Initial trials of TIL-derived ACT following lymphodepletion showed that tumor response and 
persistence in the host were correlated with telomere length prior to transfer [72]. Based in part 
on these observations, investigators set out to determine whether less-differentiated subsets 
might confer better anti-tumor activity. In mouse and primate models, naive T cells T cells were 
more than effective than effector or memory populations[73,74], and central memory cells 
outperformed effector memory cells[75–77]. Tumor response thus correlated with inversely with 
differentiation status.      
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As a result, numerous methods have been developed to maintain T cell stemness and replicative 
capacity while also generating sufficient antigen-specific T cells. The introduction of genetically 
engineered TCR allows the manufacture of large numbers of antigen-specific cells without the 
need to repeatedly stimulate polyclonal T cells with antigen[25]. New protocols for the rapid 
expansion of TILs have been developed that minimize time in culture prior to adoptive 
transfer[78]. Pharmacological inhibition of the Wnt-signaling during T cell activation generates a 
subset termed “T memory stem cell” that maintains high replicative capacity even after repeated 
division[79]. As will be reviewed in further detail below, the use of T cell growth supporting 
cytokines other than IL-2 can also maintain a more plastic phenotype. Finally, it is not yet clear 
whether differentiation status is a “one-way” street, and even highly cultured, repeatedly 
stimulated T cells clones generate cells with a Tcm phenotype after adoptive transfer into a 
lymphodepleted host[23]. 
Avidity 
T cell avidity is a biophysical description of the strength of binding between TCR and its cognate 
MHC. It is most commonly measured by binding to soluble MHC constructs[80]. A related 
concept, functional avidity, describes the sensitivity of T cell responses to antigen, with T cells 
that secrete cytokine in response to low antigen doses described as “high functional avidity” 
cells. In general, higher avidity (aka structural avidity) and functional avidity are correlated with 
each other[81], and with stronger immune responses and better control of infection[82,83]. 
Similarly, the adoptive transfer of high avidity T cells in mouse models of cancer leads to more 
effective tumor rejection[84–86]. 
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The use of genetically engineered TCR in ACT allows the selection of selection of high avidity T 
cell responses from a single patient, and further avidity enhancement by modification to the 
transferred TCR sequence [26,87,88]. For T cell populations derived by clonal selection, avidity 
can be tested and selected prior to cloning[20,89]. In general, stimulation with low doses of 
antigen is associated with the selection of higher-avidity clones [90] as well as increased avidity 
of individual clones by TCR and CD8 dependent mechanisms[91,92]. 
In an attempt to improve low response rates in trials of melanoma therapy using cells engineered 
with specificity against MART-1, a higher avidity anti-MART1 TCR was isolated and 
transferred into PBMC[93]. Using this higher avidity TCR, objective response rates increased 
from 14 [29] to 31 percent [46]. However, the higher avidity TCR was associated with 
significantly more toxicity, including a cytokine spike and serious skin rashes 3-5 days after 
transfer. A similar pattern of enhanced efficacy and toxicity was also observed with a high 
avidity TCR against MAGE-A3[31]. These results have motivated basic studies to understand 
the relationship between avidity, autoimmunity, and anti-tumor effectiveness. A study of in vitro 
and in vivo against melanoma by seven gp100-specific TCR, antitumor activity and 
autoimmunity were correlated across a range of avidities[94]. Thus, caution should be exercised 
when using high avidity TCR until off-target effects are better understood.    
Polyfunctionality 
Polyfunctionality is the capacity of T cells to produce many effector cytokines and chemokines 
(TNF-α, IFN-γ, MIP-1β, IL-2, etc.) simultaneously during effector responses. High levels of 
polyfunctionality among antigen-specific T cells are a marker of effective vaccine responses[95], 
and have been observed to correlate with effective control of chronic viral infections such as 
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HIV[96]. Polyfunctionality has also been proposed as a quality parameter that may explain why 
TCR-engineered T cells can persist in the host but fail mediate tumor rejection, but its role in 
determining the outcome of ACT is still unclear. In a small study of 3 melanoma patients, the 
functional profile of CD8+ Mart-1 specific engineered T cells varied over time, but no clear 
correlation with tumor response could be established[97].  
Further study of polyfunctionality will depend on the generation of highly polyfunctional T cells 
with tumor-specificity. Enhanced polyfunctionality during in vitro culture can be generated by 
selecting optimal antigen dose [YEN PAPER], or administration of kinase inhibitors and TLR 
agonists[98]. Alternatively, polyfunctionality can be enhanced after adoptive transfer by certain 
vaccine/adjuvant strategies [99]. CTLA-4 checkpoint blockade has also been shown to enhance 
polyfunctionality of endogenous immune responses[100], suggesting a possibility to integrate 
ACT with checkpoint blockade for melanoma.  
1.3.4 The Importance of Lymphodepletion 
The development of ACT was motivated in part by poor results with cancer vaccines, inducing 
tumor regression in only 4% of patients treated in early trials[101]. Subsequent work has 
suggested that this failure was due in part due multiple layers of immunosuppression found 
within the tumor microenvironment[102–104], explaining how tumor-specific responses could 
be found in patients but fail to reject cancer. This suppression is mediated by tumor cell 
production of immunosuppressive proteins such as TGF-β and PD-L1[105,106], as well as the 
recruitment of immunosuppressive immune cells such as regulatory T cells and Myeloid Derived 
Suppressor Cells[102,107]. These mechanisms represent T cell-extrinsic pathways of immune 
dysfunction (as compared to T cell-intrinsic pathways discussed earlier), and may be the 
consequence of peripheral tolerance mechanisms that control autoimmunity. Modulation of the 
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immunosuppressive tumor microenvironment is both a key therapeutic target and a tremendous 
challenge[108], with recent advances such as checkpoint blockade [109–111] seen as a means for 
unlocking the potential of cancer vaccines.  
A significant comparative advantage of adoptive immunotherapy is that cultured T cells are 
physically separated from the suppressive cells in the patient, reducing the need to find targeted 
therapies that block immunosuppressive but not tumor-specific cells. Instead, highly non-specific 
therapies such as high intensity radiation or chemotherapy can be used to induce a transient 
lympho- and myeloablation that stimultaneously depletes both suppressive and active immune 
cells, which are then replaced by ACT. This process can be conceptualized as a “re-boot” of the 
immune system, where the dysfunctional, suppressed immune compartment is replaced by a 
highly active immune compartment generated ex vivo.   
Lymphodepletion also enhances engraftment of adoptively transferred cells by reducing 
competition for lymphotrophic cytokines [112,113]. It has long been appreciated that T cells 
adoptively transferred into a lymphopenic environment undergo a robust, non-antigen driven 
homeostatic expansion driven by increased availability of the γ-chain cytokines IL-7, IL-15, and 
IL-21, and in some cases low affinity interactions with MHC [12,114,115]. MHC and γ-chain 
cytokine regulate the size of the T cell compartment by permitting T cell division and persistence 
normal conditions, and become scarce when the compartment is expanded following adoptive 
transfer. Lymphodepletion enhances the availability of homeostatic signals by reducing 
competition from host cells; for example, circulating levels of IL-15 are not detectable in patients 
prior to lymphodepletion, but high levels are detected immediately afterward [70]. 
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Homeostatic expansion can greatly enhance T cell function in the context of adoptive 
immunotherapy; for example, transfer of LCMV-specific T cells into lymphodepeleted but not 
immunocompetent LCMV-infected mice eliminates virus in hosts[116]. In fact, the combination 
of regulatory cell depletion and homeostatic cell expansion is sufficient to induce anti-cancer 
activity in animal models, even without exogenous antigen-driven stimulation [117–119]. In 
clinical trials, less than 0.1% of adoptively transferred T cells persisted in the host at one week 
prior to the introduction of lymphodepletion[120], whereas patients could be identified to have 
multiple persistent TIL clonotypes 2-3 months following ACT after its introduction[55][56].  
Furthermore, TIL persistence, and particularly the persistence of a wide variety of transferred 
clones, was significantly correlated with effective response. 
Finally, it has been proposed that total body irradiation and chemotherapy can enhance host 
antigen presentation, triggering tissue damage that induces the production of inflammatory 
cytokines and upregulation of co-stimulatory molecules by professional APCs[121–123]. Of 
course, this is a double-edged sword, as professional APCs are significantly depleted five days 
after treatment[124,125]. Thus, the overall effect of conditioning on antigen presentation is time-
dependent and incompletely understood, and the loss of APC may limit the effectiveness of 
vaccines used to boost T cell function after ACT. 
1.3.5 Cytokine Support Following Adoptive Transfer 
The cytokine IL-2 has a prominent role in the history of immunotherapy; it was the discovery 
that IL-2 could support TIL expansion in vitro that permitted the first trials of ACT against 
melanoma [10], and IL-2 has long been used as monotherapy in the treatment of melanoma, 
decreasing the size of lesions but not increasing survival[126,127]. Thus, IL-2 was a natural 
choice as cytokine support agent in melanoma treatment, and its administration to patients after 
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ACT can increase T cell expansion after adoptive transfer in animal models[68] and clinical 
trials[128]. In this context, IL-2 adminstration serves a similar purpose as lymphodepletion, 
increasing the availability of lymphotrophic cytokines ( by increasing the available pool rather 
than reducing competition). 
In many ways, however, IL-2 is not the optimal agent for supporting T cell proliferation. High-
dose IL-2 can lead to severe flu-like symptoms and dose-limiting toxicities in patients[127]. It is 
also associated with activation induce cell death of T cells[129], and skews T cell proliferation 
away from long-live memory responses toward short lived effector responses[130,131]. 
A number of cytokines similarly function to support T cell expansion and even signal through 
common receptor components (CD132, the common gamma chain) as IL-2, including IL-7, IL-
15, and IL-21. These cytokines, however, also appear to support memory formation and 
enhanced proliferative capacity [130–134] in T cell culture compared to IL-2. When 
administered in vivo, IL-15 improved survival and anti-tumor activity of adoptively transferred 
cells[76]. In a head-to-head comparison in a mouse melanoma model, all gamma chain cytokines 
were found to be capable of supporting anti-tumor activity of adoptively transferred CD8 T 
cells[68]. Thus, due to IL-2 cytotoxicity and the efficacy of other gamma chain cytokines in 
supporting persistet  
1.3.6 Enhancing ACT Through Gene Engineering 
The use of gene-engineered TCR has increased the range of cancers that can be targeted using 
ACT. Simultaneously, it has opened the possibility of further modifications to T cell function 
through the genetic engineering of other T cell behaviors to address existing limitations of ACT 
(reviewed extensively in [25]). 
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For example, the trafficking of lymphocytes to large solid tumors appears to be a rate-limiting 
step in tumor eradication. Intravital imaging has suggested that individual lymphocytes may 
interact with a given tumor cell for several hours[135], suggesting that large numbers of antigen-
specific cells in the tumor are required. Numerous barriers exist to efficient trafficking, however, 
including low expression of trafficking ligands such as L-selectin on tumor 
microvasculature[136], and suppressive mechanisms mediated by cancer also appear to impair T 
cell penetration into tumor cores [137]. To improve trafficking, cells can be engineering with 
chemokine receptors such as CXCR2[138] or CCR4[139], which enhances therapeutic efficacy 
in mouse models.  
As an alternative to intravenous administration of supportive cytokines, T cells can be 
genetically modified to express IL-2, IL7, IL-15, or IL-21[140–143]. As described previously, 
cytokine support is required for efficient engraftment of transferred cells, and autocrine delivery 
may eliminate the need for systemic administration and, particularly in the case of IL-2, a 
reduction in systemic toxicity. 
1.3.7 The Path Forward 
While the therapeutic potential of ACT in cancer has been conclusively demonstrated, much 
remains to be discovered and optimized. Tumor-specific cells can be generated from TILs, 
repeated stimulation with antigen, or genetic engineering, with each appropriate carrying 
advantages and drawbacks. T Cell quality in addition to quantity is emerging as a critical 
parameter of immunotherapeutic success, and strategies to improve avidity, safety, functionality, 
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2 Modulation of MHC Binding By Lateral Association of 
TCR and Coreceptor1 
2.1 Introduction 
T cells face the extraordinary challenge of finding as few as 1-10 cognate peptides presented in 
the context of Major Histocompatibility Complex (MHC) (1, 2), masked by thousands of 
irrelevant but structurally similar peptide/MHC on the opposing membrane. In addition, they 
must respond to complex environmental stimuli which heighten or dampen the response. As a 
result, T cell regulate the lateral organization of surface receptors to achieve optimal ligand 
recognition and activate downstream signaling cascades after binding (3, 4).  
Antigen recognition by naïve T cells induces lateral reorganization of membrane proteins on 
several length scales (5). The co-receptor CD8, which binds an invariant region of the 
polymorphic MHC (6, 7), mediates the association of T Cell Receptor (TCR) with src-family 
tyrosine kinases to initiate downstream signaling (8). Robust activation subsequently induces the 
formation of TCR and adhesion structures, including “bulls-eye” shaped immune synapses (5, 9)  
and TCR microclusters 100’s of nm in diameter (10), which function to generate, sustain and 
terminate TCR signals (11, 12).  
TCR clusters can also be observed days after the initial antigen recognition event, long after the 
antigen has been cleared (13, 14). In activated T cells, TCR clustering has been reported to lead 
                                                 
1 This chapter is reproduced in part from “Perica, K., Bieler, J. G., Edidin, M. & Schneck, J. Modulation of MHC 
binding by lateral association of TCR and coreceptor. Biophysical journal 103, 1890–8 (2012)” with permission 
from the publisher. 
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to enhanced binding of soluble peptide-MHC (15). These studies stand in contrast with 
observations that activated T cells may also lose the ability to bind cognate soluble MHC (16–
20). Changes in the CD8 coreceptor (20) have been implicated in loss of binding, but the precise 
signals regulating binding behavior are poorly understood. Furthermore, the contradiction 
between observations of enhanced binding and complete loss of binding after activation has not 
been explained.   
Here, we resolve this contradiction and show that changes in nanoscale colocalization of TCR 
and CD8 determine changes in binding after antigen stimulation. Primary stimulation with a high 
dose but not low dose of antigen leads to a transient spatial segregation of TCR and CD8. This 
spatial segregation can impair CD8-dependent MHC binding antigen depending on antigen dose 
during primary stimulation. Thus, despite having identical TCR, activated T cells can have 
different MHC binding properties due to changes in membrane organization of TCR and CD8. 
2.2 Materials and Methods 
Mice and reagents: 
2C TCR Rag-/- transgenic mice were maintained as heterozygotes by breeding on a C57/BL6 
background. PMEL TCR/Thy1a Rag-/- transgenic mice were a gift from Nicholas Restifo 
(National Institutes of Health, Bethesda, MD) and maintained as homozygotes. Balb/C mice 
were purchased from Jackson Laboratories (Bar Harbor, ME).  All mice were maintained 
according to Johns Hopkins University’s Institutional Review Board.  Peptides SIY 
(SIYRYYGL), SIIN (SIINFEKL), QL9 (QLSPFPFDL), mCMV (YPHFMPTNL), GP100 
(KVPRNQDWL) and ASN (ASNENMETH) were purchased from Genscript (Piscataway, NJ). 
Fluorescently labeled monoclonal antibodies were purchased from BioLegend (San Diego, CA). 
MHC monomers were obtained from NIH Tetramer Facility (Bethesda, MD). 
 82 
Cells: 
Cells used were obtained from homogenized mouse spleens after depletion of RBC by hypotonic 
lysis.  For Mixed Lymphocyte Reaction, 10x106/ml 2C splenocytes were activated by co-culture 
with 18x106/ml irradiated Balb/C splenocytes as allogeneic stimulator cells for 4-7 days in 
complete RPMI media supplemented with T cell factor, a cytokine cocktail harvested from 
human plasma (21). For peptide activation, 10x106/ml 2C splenocytes were activated by 
incubation with cognate peptide at the indicated concentration in complete RPMI plus T cell 
factor.  
Preparation of MHC-Ig Dimers  
Soluble MHC-Ig dimers, Kb-Ig and Ld-Ig, were labeled fluorescently and loaded with peptide as 
described previously(22).  Unless otherwise indicated, Kb-SIY and Ld-QL9 refer to soluble 
MHC-Ig dimer reagent of the corresponding allele loaded with the indicated peptide. Labeling 
with Alexa-488 or Alexa-657 succimidyl ester (Molecular Probes, Eugene, OR) was performed 
at pH 7.4 and labeled protein was purified by dialysis with a 50 kDa filter. Protein concentration 
was determined after labeling by size exclusion High Performance Liquid Chromatography. The 
efficiency of fluorophore labeling was calculated by measuring absorbance at 280 and 
fluorophore emission wavelength for the labeled proteins. Typically, approximately 1 dye 
molecule was attached per MHC-Ig molecule.   
Alexa Kb-Ig molecules were loaded with peptide by stripping at alkaline condition (pH 11.5), 
and then refolded in the presence of 40 fold excess peptide. Ld-Ig molecules were stripped under 
mildly acidic conditions (pH 6.5) and refolded in the presence of 40 fold molar excess peptide 
and 2-fold molar excess of human 2-microglobulin(23). 
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MHC-Ig Dimer Binding Assay: 
MHC-Ig dimer binding assays were performed as previously described(24). Briefly, CD8+ T 
cells were incubated at 4 °C at a concentration of 107cells/ml in FACS wash buffer (PBS + 2% 
FCS + .05% sodium azide).  15 l aliquots of cells were mixed with varying concentrations of 
peptide loaded, fluorescently labeled MHC-Ig dimers for 60-90 min. Without any washing, cells 
were analyzed by flow cytometry on a BD Biosciences FACSCalibur flow cytometer and 
analyzed using FlowJo software (Treestar, Ashland, OR). The mean channel fluorescence (MCF) 
was a measure of the amount of MHC-Ig dimer bound on cells.  A non-cognate dimer (Kb-SIIN 
or Ld-MCMV) was used to account for non-specific binding which was subtracted from the total 
binding to yield specific MHC-Ig binding.  The specific binding was normalized to the plateau of 
the binding isotherm and plotted against the peptide MHC-Ig dimer concentration.  
Confocal Microscopy 
For confocal microscopy, T cells were stained with Alexa Fluor 488-labeled H57 anti-mouse 
TCR antibody and Alex Fluor 647-labeled 53.6.7 anti-mouse CD8α  at a 1:100 dilution for 30 
minutes on ice.  Samples were washed and fixed immediately with 2% paraformaldehyde. 
Images were acquired on a Zeiss LSM 510 META (Zeiss, Oberkochen, Germany) laser scanning 
confocal at 100x magnification at the Johns Hopkins School of Medicine Microscopy Facility.  
k-Space Image Correlation Spectroscopy 
kICS imaging and analysis were performed as described previously(25). T cells were labeled 
using biotinylated Ld-QL9 monomer (NIH Tetramer Facility, Atlanta, GA) at a concentration of 
2μg/2-5 x 106 T cells in 100μl PBS for 30 minutes on ice and then washed once with 2 ml PBS, 
followed by 10nM streptavidin coated Quantum Dots 655 (Life Technologies, Carlsbad CA) in 
 84 
100 μl PBS incubated for 30 minutes at 4o C. Labeled cells were then washed 2x with 2 ml PBS 
before imaging.  
Cells were imaged using a 3-I Marianas Live Cell Imaging Workstation equipped with dual 
Cascade II 512 EM cameras at the Johns Hopkins University Integrated Imaging Center. 150-300 
images were obtained at 300 ms intervals. 
Each image series was corrected for background intensity values using a top-hat transformation, 
segmented using the watershed transform, and filtered for immobile components. Degree of 
Aggregation was calculated by dividing mean image intensity by clusters of differentiation (CD), 
a function of the autocorrelation of fast fourier transformed (FFT) image series in k-space with a 
custom program written in MATLAB (Mathworks, Natick, MA) (26). 
Forster Resonance Energy Transfer 
TCR-CD8 FRET was assessed by flow cytometry (17). Approximately 106 T cells were 
incubated with a 1:100 dilution of unlabeled or PE-labeled 53.6.7 anti-mouse CD8α as donor and 
500 nM uncoupled or Alexa Fluor 647-coupled Ld-QL9 in FACS buffer at 4o C for 30 minutes. 
Samples were stained with labeled Ld-QL9 and anti-CD8 antibody (Eboth), labeled L
d-QL9 but 
unlabeled CD8 (EA647), unlabeled L
d-QL9 but labeled anti-CD8 (EPE), or both reagants unlabeled 
(Enone).  FRET emission was assessed by flow cytometry on a BD FacsCalibur without 
compensation, with FL-3 channel for Alexa Fluor emission without direct laser excitation. FRET 
efficiency was calculated in FRET units(17, 27) as follows: FRET unit = (E3both – E3none) – 
[(E3A647 – E3none) ∙  (E2both/E2A647)] – [(E3PE – E3None) ∙ (E1both/E1PE)] 
where E1 is the fluorescence detected at 580nm upon excitation at 488 nm, E2 is the 
fluorescence detected at 670 nm upon excitation at 630 nm, and E3 is the fluorescence detected 
at 670 nm upon excitation at 488 nm.  
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Intracellular Cytokine Staining 
Four or seven days after primary stimulation, T cell functional activity was assessed by re-
challenge with artificial Antigen Presenting Cells (aAPCs). aAPCs were fabricated as described 
previously(28) by chemical coupling of MHC Dimer and anti-CD28 antibody to Dynal Magnetic 
Microbeads (Life Technologies, Carlsbad, CA). 
200,000 T cells were incubated in complete RPMI with the indicated concentration of activator 
bead for 5 hours in a round bottom 96 well plate in the presence of 0.2 μl GolgiPlug (BD 
Biosciences, Mountain View, CA). Cells were washed and fixed using a BD Cytofix/Cytoperm 
kit (BD Biosciences) according to the manufacturer’s instructions, then stained with anti-IL-2 
Alexa Fluor 647 and anti-IFNγ PE (BioLegend). Cytokine staining was assessed by flow 
cytometry and frequency of cytokine functional cells was assessed by comparison with an 
unstimulated control in FlowJo (TreeStar). 
2.3 Results 
T Cells Stimulated with a High Dose of Peptide Transiently Lose MHC Binding 
To evaluate the effects of peptide dose during stimulation on subsequent MHC-Ig binding, 
splenocytes from a 2C T Cell Receptor transgenic mouse (specific for peptide SIY presented in 
the context of MHC allele Kb) were activated with increasing amounts of the cognate peptide. 
Overall T cell expansion was equivalent and robust (approximately 10-15 fold) at all antigen 
doses used. Specific binding was characterized 4 days after activation as the difference between 
binding of cognate (SIY) and noncognate (SIIN) peptide-loaded Kb-Ig. Samples were not washed 
after binding which allowed for quantitative assessment of specific binding, as described in 
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Materials and Methods. As shown in Figure 2.1a, T cells stimulated with a high dose (100 uM) 
of peptide showed no measurable specific binding 4 Days after activation, while cells stimulated 
with a 6-log fold lower dose of peptide (100 fM) did. By Day 7, both high dose (HD) and low 
dose (LD) activated cells specifically bound Kb-SIY. Loss of binding is not unique to the 2C 
system, as PMEL TCR Transgenic T cells, which are specific for the melanoma antigen GP100 
presented in Db-Ig, show a similar loss and recovery when stimulated with a high dose of antigen 
(Figure 2.1b).  
Loss of binding is not explained by changes in surface expression of TCR and CD8 co-receptor 
(Figure 2.2). Four days after activation, surface expression as measured by fluorescent antibody 
staining was similar for TCR (MFI of 539 FU compared to 522 FU for HD and LD cells, 
respectively), CD8α (455 FU and 600 FU), and CD8β (1071 FU and 1072 FU). Differences in 
the expression level of CD8α and CD8β, as described previously(29),(30), are prominent seven 
days after activation when binding has recovered and thus cannot account for loss of binding.  
Equilibrium Binding Assays Suggest a Defect in CD8 Coreceptor Colocalization With TCR 
To understand the role of TCR and CD8 in high-antigen dose induced loss of binding, we 
performed equilibrium binding experiments on HD, LD, and Mixed Lymphocyte Reaction 
(MLR, stimulated by allogeneic splenocytes) activated cells. On Day 4, HD cells bound lower 
amounts of Kb-SIY at all concentrations examined (Figure 2.3a). At high concentrations of Kb-
SIY (250 nM), high peptide dose activated cells displayed six-fold lower binding than low dose 
activated cells. 
Some TCR require CD8 engagement to specifically bind cognate MHC-peptide, while others are 
CD8-independent, and bind to MHC even in absence of CD8 or after CD8 blockade(31–33). The 
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2C TCR transgenic system has several cognate ligands, and the alloantigen Ld-QL9 
peptide/MHC has been characterized as a CD8-independent binding partner(31, 32). HD cells, 
which could not specifically bind Kb-SIY at any concentration, bound 1 μM Ld-QL9 as well as 
LD or MLR stimulated cells (Figure 2.3b). However, Kd for binding L
d-QL9 to HD cells was 
423 μM compared to 117 μM for LD cells.  Day 7 recovery from loss of binding was seen with 
both Kb-SIY and Ld-QL9 ligands with complete recovery of Kd and a decreased off-rate for L
d-
QL9 (Figure 2.4). 
To confirm differential CD8 sensitivity, we incubated 500 nM of MHC-Ig either alone or with 
20-fold molar excess of the CD8-blocking antibody CT-CD8a. As described previously (31, 32), 
CD8 blocking antibody CT-CD8a was able to completely inhibit all specific binding of Kb-SIY 
MHC-Ig for all three cell samples (Figure 2.3c). The relative CD8-independence of 2C for Ld-
QL9 was confirmed by the insensitivity of Ld-QL9 binding to Day 4 stimulated cells in the 
presence of CD8 blocking antibody (Figure 2.3d).  
Spatial Segregation of CD8 and TCR 
The ability of high dose activated cells to bind the CD8-independent Ld-QL9 but not CD8-
dependent Kb-SIY implicates the CD8 coreceptor in loss of binding. Since CD8-dependent 
binding was impaired but CD8 expression was unchanged, we examined the relative spatial 
organization of TCR and CD8. We hypothesized that four days after high dose peptide 
activation, TCR and CD8 may not be colocalized on the T cell membrane, and so CD8 could not 
assist in MHC binding. 
The clustering of TCR and CD8 was examined with k-Space Image Correlation Spectroscopy 
(kICS), an image analysis technique that extends the ICS approach to quantum dot labels(26). 
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kICS allows the measurement of Degree of Aggregation (DA), with large DAs indicating that the 
labeled receptor is highly clustered at scales of 100’s of nms (Figure 2.5a). DAs were 
normalized to naive cells and reported as fold-change from naive. HD cells had less clustered 
TCR than naive (0.57-fold naive). In contrast, LD (1.67) and MLR cells (2.20) had more 
clustered TCR (Figure 2.5b). For CD8, HD (2.19), LD (3.24), and MLR (2.90) cells were all 
more clustered than naive cells. This finding suggests that TCR and CD8 may be organized in 
different membrane subdomains on the surface of high dose activated T cells. By Day 7, both 
CD8 and TCR were more clustered on all activated samples compared to naive, such that the 
degree of TCR clustering correlated with Kb binding (Supplementary Figure 2). 
Confocal microscopy was used to measure differences in CD8 and TCR colocalization. HD cells 
showed a significantly lower degree of colocalization (Pearson’s Correlation coefficient 
0.45 ± 0.02) between TCR and CD8 than LD cells (0.61 ± 0.03) on Day 4 (Figure 2.6a). On 
Day 7, when the binding defect had recovered, both HD and LD cells exhibit large Pearson’s 
Correlation coefficients of  0.70 ± 0.02 and 0.74 ± 0.02, respectively.  
CD8 and TCR Are Not Colocalized at the Nanoscale on High Dose Activated Cells 
Since CD8 must be located within 10’s of nms to TCR to assist in MHC binding, we assessed the 
colocalization of TCR and CD8 at the nanoscale by Forster Resonance Energy Transfer (FRET). 
FRET is the non-radiative transfer of energy from a directly excited donor fluorophore to an 
acceptor fluorophore; this only occurs when they are within 10 nm of each other, hence FRET is 
a measure of nanoscale colocalization(34). HD and LD cells were labeled with fluorescently-
tagged Ld-QL9 and anti-CD8 antibody. FRET was observed as a relative increase in the 
fluorescence intensity of the acceptor fluorophore when MHC-Ig and CD8 were fluorescently 
labeled with the appropriate FRET pair. Approximately 97% of naive CD8 T cells showed 
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nanoscale colocalization of CD8 and TCR by FRET (Figure 2.6a). Similarly, a majority of LD 
and MLR activated cells displayed a FRET shift. However, only approximately 30% of HD cells 
displayed a FRET shift (Figure 2.6a), consistent with reduced CD8-TCR colocalization. The 
amount of nanoscale colocalization can be quantified in FRET units as a normalized shift in 
acceptor intensity(27).  As shown in Figure 2.6b, HD cells have a decreased FRET intensity of 
16 FRET units compared to LD (62 units) or naive (43 units) cells. Reduced FRET was not due 
to a decrease in CD8 or MHC-Ig binding in HD cells (Figure 2.7), since coreceptor expression is 
unchanged and CD8-indpendent Ld-QL9 does not display loss of binding.  
FRET intensity recovered for HD cells from Day 4 to Day 7 (Figure 2.6c), while FRET was 
consistently high when observed on LD and MLR cells throughout. FRET thus uniquely reveals 
the loss of nanoscale localization between TCR and CD8 on high dose activated cells. 
Production of Cytokine IFNy Correlates With CD8-Dependent Binding 
The functional consequences of changes in binding of cognate ligand were assayed by 
intracellular cytokine staining assay, which measures T cell production of cytokine in response to 
antigen. Four or seven days after activation, T cells were re-challenged with an artificial antigen 
presenting cell (aAPC) (28),  a bead-based T cell activation platform presenting MHC-Ig and a 
co-stimulatory signal (Figure 2.8).  
As seen in Figure 2.8a, T cells were capable of producing the cytokine IFNγ when stimulated 
with PMA and ionomycin, stimuli that bypass the TCR. Thus, any functional defects observed 
when T cells are stimulated via their TCR are not due to downstream defects in T cell signaling, 
but to signals received by the TCR itself. 
 90 
When T cells were re-stimulated with Kb-SIY aAPC four days after stimulation, less than 20% of 
HD cells produced IFNγ at all aAPC-cell ratios examined. In comparison, up to 55% of LD cells 
were responsive (Figure 2.8b). However, both cell populations were able to produce high levels 
of IFNγ in response to a Ld-QL9 presenting aAPC (Figure 2.8c). Functional response of HD cells 
to Ld-QL9 but not Kb-SIY correlates with observed binding on Day 4. Again, similarly to binding, 
HD cells recovered functionally by Day 7, when up to 42% of cells produced the cytokine in 
response to a Kb-SIY based aAPC (Figure 2.8d).   
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2.4 Discussion 
In this study, we show that T cells dynamically regulate the organization of their receptor for 
antigen in response to activation signals, with consequences for MHC binding and thus 
functional response. T cells activated by a high dose of antigen bound CD8-independent but not 
CD8-dependent MHC-Ig. This difference was associated with a loss of colocalization at the 
nanoscale as measured by FRET between TCR and CD8. Decreased FRET in HD cells may be 
due to either a true loss of colocalization independent of MHC-Ig binding, or to a loss in the 
ability of MHC-Ig to induce TCR/CD8 clustering (35, 36). We observe no differences in the 
ability of MHC to independently bind TCR or CD8. Therefore, decreased FRET represents either 
a loss of colocalization in the resting state or an inability for CD8 and TCR to colocalize once 
they bind MHC. As a result, T cells are unable to produce cytokines in response to antigen 
challenge by CD8-sensitive antigen. The effect is transient, with colocalization, binding, and 
function recovering over time. 
Thus, despite the presence of identical receptors, activated T cells derived from the same 
precursor may have different surface receptor organization and different antigen binding 
properties based on their history of antigen exposure. FRET and co-immunoprecipitation studies 
have shown TCR and CD8 are(37–39) and are not(27, 36, 40) colocalized at the nanoscale on 
resting T cells. We suggest that differences in antigen exposure and timing may be the source of 
conflicting results. Similarly, antigen exposure is likely responsible for conflicting reports of 
enhanced binding(15) or loss of binding(16–20) after activation. 
The mechanism underlying dynamic T cell membrane organization remains unclear. TCR and 
CD8 (41, 42) are known to preferentially segregate in lipid rafts during stimulation and interact 
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with the galectin-glycan lattice(43). Recently, Demotte et al.(16) demonstrated that exogenous 
galectin treatment could reverse a tumor-induced defect in TCR-CD8 colocalization and binding, 
adding to evidence that interaction of galectins with N-linked glycosylation sites on TCR 
controls sensitivity of T cell responses(44). Long-term control of membrane organization could 
thus involve changes in lipid rafts, surface receptor glycosylation, and both endogenous and 
exogenous secretion of receptor-binding galectins. However, great care needs to be taken to 
identify mechanisms that operate seconds and minutes after T cell activation, as well as those 
mechanisms that control more persistent membrane changes.  
Persistent TCR clustering and TCR-CD8 colocalization coexist with and may be mechanistically 
related to more transient changes that occur upon exposure to antigen. TCR on a resting naive T 
cell are organized in small nanoclusters(14, 45) which concatenate(10) when the T cell 
encounters antigen. These signaling microclusters are thought to represent early signaling 
platforms upon which downstream kinases and scaffolding proteins assemble and activate(46). 
With sustained, robust stimulation, signaling microclusters migrate to the center of the micro-
scale immune synapse, where they are degraded(11, 12). Many days after stimulation, T cells’ 
membranes retain memory of the previous activation event, with more highly clustered TCR than 
naive cells (13, 15, 25) and different levels of CD8 colocalization depending on the strength of 
initial stimulation. These membrane structures can potentially affect both binding of antigen and 
the activation of downstream signaling proteins. 
It is well established that in chronic viral infections and cancer sustained exposure to low-dose 
antigen induces dysfunctional T cell responses(47, 48). We demonstrate that an acute exposure 
to high dose antigen in vitro can induce transient functional and binding defects, although this 
finding must be confirmed at physiological antigen doses in vivo. Long term antigen dose driven 
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responses also include binding-independent functional defects (29),(30) and a tendency toward 
effector compared to memory phenotypes as a result of acute high dose stimulation(49). We thus 
suggest that antigen-induced loss of binding is an intrinsic T cell response to high dose antigen 
stimulation, and need not be associated with the tumor microenvironment(17). Membrane 
organization induced loss of binding may serve as a regulatory mechanism to avoid excessive 






Figure 2-1. Transient Loss of Binding Induced By Stimulation With High Dose Antigen  
(A) Specific Binding. Splenocytes from TCR transgenic mice bearing the 2C receptor were 
activated with high (100 ug/ml) or low (100 fg/ml) doses of cognate peptide. At Day 4, viability 
was greater than 70% for high and 90% for low dose stimulated cells, both of which had shown 
robust proliferation by Day 7 (10-15 fold). Specific binding was characterized at the indicated 
timepoints by comparing cognate (SIY loaded Kb, no fill) and noncognate (SIIN loaded Kb, gray 
fill) fluorescence intensity of 500 nM labeled MHC-Ig. While low dose stimulated T cells show a 
classic difference between cognate and non-cognate binding, high dose activated cells (top left) 
show no such difference on Day 4. Both high and low dose activated cells show specific binding 
on Day 7 (bottom row). 
(B) Loss of binding is also observed for high but not low dose activated PMEL TCR transgenic 
splenocytes (top left). PMEL splenocytes were activated with 10 ug/ml and 10 pg/ml for high 
and low doses, respectively, and stained with 500 nM of Db-gp100 (cognate) and Db-ASN 





Figure 2-2 Equivalent surface expression of MHC binding receptors on high and low dose 
activated cells measured with fluorescently labeled antibodies 
Four or seven days after activation, T cells were stained with anti-TCR (Clone H57), anti-CD8α, 
or anti-CD8β antibody. High dose (HD - solid line) and low dose (LD-dashed lined) activated T 
cells had equivalent receptor expression on Day 4, when loss of binding was observed. On Day 
7, when loss of binding was not present, LD cells had higher expression of CD8α and CD8β but 




Figure 2-3 Loss of Binding is Ligand Sensitive 
 (A) Kb equilibrium binding is decreased on high dose activated cells. Mixed Lymphocyte 
Reaction (MLR, black square), high dose (HD, black circle), and low dose (LD, white circle) 
activated splenocytes were bound to increasing doses of cognate Kb-SIY and noncognate Kb-
SIIN. Mean MFI was measured without washing and specific binding characterized as the 
difference between cognate and noncognate binding.  
(B) Ld equilibrium binding is equivalent for HD, LD, and MLR activated cells at a high 
concentration of Ld (500 nM), but HD cells had four-fold higher Kd. Binding was calculated as 
difference between cognate (Ld–QL9) and noncognate (Ld–mCMV) fluorescense. 
(C) Relative CD8 dependence of Kb and (D) independence of Ld binding to 2C T cells. Specific 
binding of 500 nM MHC-Ig was calculated as above with (filled) and without (white) 
simultaneous addition of CD8-blocking antibody CT-CD8a. 
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Figure 2-4. Kb Equilibrium binding recovers on Day 7  
(A) Binding was measured by titration of Kb-Ig seven days after activation for HD (black circle) 
and LD (white circle) cells. Specific binding was defined as the difference in mean fluorescence 
intensity between cognate and noncognate binding. As expected, Kb binding recovers in HD 
samples by Day 7, with similar maximal binding when incubated with high amounts (500 nM) of 
MHC-Ig (57.6 MFI for HD compared to 60.3 MFI for LD).  
(B) Ld equilibrium binding with cognate (Ld –QL9) and noncognate (Ld –mCMV) MHC-Ig on 
Day 7. As on Day 4, Ld is similar on Day 7 for HD and LD splenocytes on Day 7. 
(C) Dimer binding off-rate. Four or seven days after activation, 2*106 HD (squares) or LD 
(circle) activated cells were incubated with 250 nM cognate or noncognate Ld and allowed to 
reach equilibrium. At time 0, a 30-fold molar excess of TCR blocking 1B2 antibody was added 
to prevent Dimer rebinding. Fluorescence intensity was measured at indicated timepoints and 
specific binding was measured as cognate MFI minus noncognate MFI. Results are presented as 
fraction of maximal binding (binding at time 0), and data were fit to a one phase exponential 
decay curve. 
On Day 4, high dose activated cells had a rapid Dimer off-rate of 6.21 *10-4 sec-1, partially 
explaining their high disassociation constant. By Day 7, HD activated cells had partially 
recovered, with a slower decay constant of 4.90 *10-4 sec-1 compared to 2.08 *10-4 sec-1 for 




Figure 2-5. TCR and CD8 Colocalization and Clustering Characteristics at Optical Scales 
(A) k-Space Image Correlation Spectroscopy (kICS). On left, schematic of receptor clusters 
illustrates Degree of Aggregation (DA) is calculated as mean image intensity divided by discrete 
receptor clusters measured on the cell. For a given cell, a high DA indicates that the fluorescently 
labeled receptors are aggregated into a small number of discrete clusters, and a low DA indicates 
that receptors are diffusely distributed across the cell. On top right, representative epifluorescent 
images used for kICS analysis show an HD stimulated cell with 0.98 DA, compared to 2.60 DA 
for the LD stimulated cell on bottom right. 
(B) TCR but not CD8 are comparatively unclustered on HD cells. Four days after activation, HD, 
LD, and MLR activated splenocytes were assessed by kICS. DA for individual cells are 
represented in the dot plot, with median DA for the sample shown as a black bar. DA were 
normalized to the median DA for a sample of naive T cells, shown as a light gray dashed line. 
DA for TCR on HD cells was lower than naive and significantly different (p<0.05, black bars) 
from LD and MLR cells. 
(C) Representative confocal images of HD (top) and LD (bottom) activated cell for TCR (green), 
CD8 (red), and colocalized TCR/CD8 (white).   
(D) TCR/CD8 colocalization correlates with loss and recovery of binding. Degree of 
colocalization was calculated by Pearson’s Correlation Coefficient on at least 15 cells four and 
seven days after activation. HD cells had significantly less colocalization (p<0.05, star) on Day 4 
compared to LD cells. In contrast, both samples have relatively high colocalization on Day 7 





Figure 2-6 Reduced Nanoscale Colocalization of TCR and CD8 on High Dose Activated 
Cells Revealed by FRET. 
(A) Four days after activation, naive, HD, LD and MLR activated T cells were bound to 500 nM 
Ld-QL9 Dimer and anti-CD8 antibody at 4oC. Background fluorescence was assessed with 
unlabeled acceptor (MHC-Ig) and PE-labeled donor (CD8) (left column). FRET manifests as a 
shift in fluorescence intensity in the FRET Channel (acceptor emission with no acceptor laser 
excitation) when both MHC-Ig and CD8 are labeled with fluorophore (right column). HD cells 
show the smallest shift as represented by the percentage of cells found in FRET gate.  
(B) FRET units are a normalized measure of FRET shift (as described in Materials and Methods) 
for all samples. (B) FRET shift four days after activation. High dose activated cells show the 
lowest degree of FRET shift compared to naive, LD, or MLR. (C) Day 7 FRET units show 
recovery in high dose nanoscale colocalization which correlates with recovery in Kb binding.
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Figure 2-7. Day 7 DA Is Higher On All Samples Than on Naive Cells.  
Seven days after activation, HD and LD activated splenocytes were labeled with (A) cognate 
monomeric MHC-biotin or (B) anti-CD8 fab, then streptavidin-quantum dots. Membranes were 
imaged as an epifluorescent time series and DA was assessed by kICS. At least 9 cells were 
collected for each sample. DA for individual cells are represented in the dot plot, with median 
DA for the sample shown as a black bar. DAs were normalized to the median DA for a sample of 
naive T cells, shown as a light gray dashed line. CD8 DA was significantly higher (p<0.05, black 
bar) on LD compared to HD cells, but clustering of TCR and CD8 on both LD and HD cells was 
enhanced on Day 7 compared to naive cells. This is consistent with a recovery in binding 







Figure 2-8. Functional Responses Correlate with Binding Defects.  
(A) HD or LD cells are capable of producing the cytokine IFNγ when re-stimulated on Day 4 
(white) or Day 7 (shaded) after activation with PMA and ionomycin, which activate T cells 
downstream of the TCR. IFNγ production was measured by Intracellular Cytokine Staining 
(ICS) and quantified as percentage of cells producing cytokine. 
(B) T cells were re-stimulated with beads bearing Ld-QL9 or Kb-SIY dimer and CD28 
costimulatory antibody on Days 4 or 7 at the indicated T cell to bead ratios (x axis). No 
stimulation and noncognate beads (at a 10 bead to 1 cell ratio) were used as negative control. 
With Day 4 Kb stimulation, LD cells showed dose-dependent IFNγ production that was 
significantly lower in high dose cells (top left). However, both HD and LD cells stimulated with 
Ld containing beads on Day 4 (bottom left) were able to produce cytokine. The difference 
between HD and LD cells had partially recovered on Day 7 (top right). 
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3 Nanoscale Artificial Antigen Presenting Cells for T Cell 
Immunotherapy2 
3.1  Introduction  
The induction of specific cytotoxic T lymphocyte (CTL) responses is a powerful therapy for 
pathogens and tumors. Specific CTL populations expand several logs to produce robust 
responses and generate long-term memory that can prevent recurrence of disease[1]. CTL can be 
directly activated in vivo, as in some vaccines [2], or generated in vitro and adoptively 
transferred into a patient [3–5].    
We have previously developed a cell-sized T cell expansion platform by coupling proteins that 
deliver two necessary and sufficient T cell activation signals to 4.5 μm diameter (“microscale”) 
beads [6,7]. Signals present on APC that are required for T cell activation include signal 1, a 
cognate antigenic peptide presented in the context of major histocompatibility complex (MHC) 
that binds the TCR [8], and signal 2, a group of co-stimulatory receptors that modulate T cell 
response. In our system, signal 1 is delivered by a chimeric MHC-immunoglobulin dimer (MHC-
Ig) loaded with a specific peptide, and signal 2 is either B7.1 (the natural ligand for the T cell 
receptor CD28) or an activating antibody against CD28. Both proteins can be directly chemically 
coupled to the surface of microscale beads to create artificial antigen presenting cells (aAPC).  
                                                 
2 This chapter is reprinted in part from “Perica, K. et al. Nanoscale Artificial Antigen Presenting Cells for T Cell 
Immunotherapy. Nanomedicine : nanotechnology, biology, and medicine [Epub Ahead of Primt], (2013).”, with 
permission. 
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The in vivo delivery and biodistribution of bead-based therapeutics is determined primarily by 
particle size [9–11]. Microscale particles have limited lymphatic drainage from their injection 
site and are preferentially cleared by and targeted to certain phagocytic subsets[12–14]. 
Nanoparticle platforms have different trafficking properties which would open new 
immunotherapeutic delivery strategies, but the appropriateness of nanoparticles for T cell 
activation has been questioned.  
Studies have suggested that only beads larger than 2 microns in diameter are able to induce T 
cell proliferation [15,16]. As a result, nanoparticles have traditionally been developed for antigen 
or drug delivery [17,18], or to study biophysical aspects of TCR-MHC binding [19,20]. When T 
cell activation was examined directly, Steenblock et al.[21] demonstrated that polymer-based 
nanoparticles were much less efficient than microbeads in inducing short-term functional 
responses, with no reported proliferation. 
Here, we present nanoscale, particle-based T cell activation platforms based on either 
paramagnetic iron-oxide particles 50-100 nm in diameter or quantum dot nanocrystals 
approximately 30 nm in diameter. We show these platforms induce antigen specific T cell 
proliferation and functional responses from murine and human T cells in vitro. Finally we show 
that nano-aAPC can prime CTL to attenuate tumor growth in vivo in a mouse melanoma model.  
 108 
3.2  Materials and Methods 
Mice and reagents 
2C TCR transgenic mice were maintained as heterozygotes by breeding on a C57/BL6 
background. pMEL TCR/Thy1a Rag-/- transgenic mice were a gift from Nicholas Restifo 
(National Institutes of Health, Bethesda, MD) and maintained as homozygotes. C57BL/6j and 
Nu/J mice were purchased from Jackson Laboratories (Bar Harbor, ME).  All mice were 
maintained according to Johns Hopkins University’s Institutional Review Board.  Fluorescently 
labeled monoclonal antibodies were purchased from BioLegend (San Diego, CA).  
Preparation of MHC-Ig Dimers  
Soluble MHC-Ig dimers, Kb-Ig and Db-Ig, were prepared and loaded with peptide as 
described[50]. Briefly, Kb-Ig molecules were loaded with peptide by stripping at alkaline 
condition (pH 11.5), and then refolded in the presence of 50 fold excess peptide. Db-Ig molecules 
were stripped under mildly acidic conditions (pH 6.5) and refolded in the presence of 50 fold 
molar excess peptide and 2-fold molar excess of human 2-microglobulin. Human A2-Ig was 
passively loaded in the presence of excess M1 peptide [51]. Peptides SIY (SIYRYYGL, 
synthetic), SIIN (SIINFEKL, derived from ovalbumin protein), GP100 (KVPRNQDWL, from 
melanocyte GP100 protein) ASN (ASNENMETH, from influenza A nucleoprotein), and M1 
(GILGFVFTL, from influenza A M1 protein) were purchased from Genscript (Piscataway, NJ). 
Protein concentration was determined after labeling by size exclusion high performance liquid 
chromatography (HPLC).  
Nano-aAPC Synthesis  
Nanoscale iron-dextran aAPC were manufactured in one of two ways. 2 μM biotinylated MHC-
Ig dimer and an equimolar concentration of biotinylated anti-CD28 antibody were incubated with 
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100 μL of anti-biotin Miltenyi Microparticles (Miltenyi Biotec) for at least 1 hour with gentle 
agitation at 4oC. Unbound protein was washed using a MS magnetic enrichment column 
(Miltenyi Biotec). Particle concentration was measured by absorbance at 405 nm using a 
Beckman Coulter AD340 plate reader. Alternatively, MHC-Ig dimer and B7.1-Ig were directly 
chemically coupled to biodegradable particles (Miltenyi Biotec). Total protein content was 
assessed by Bradford assay. Unless otherwise stated, “iron-dextran aAPC” refers to particles 
directly chemically coupled to MHC and B7.1, rather than anti-biotin coupling.    
Nanoscale quantum dot aAPC were manufactured by incubating 5 μM biotinylated MHC-Ig 
dimer and an equimolar concentration of biotinylated anti-CD28 antibody with 100 μL of 1 μM 
streptavidin coated quantum dots (Life Technologies) for 2 hours at at 4oC. Quantum dots were 
washed and concentrated using a Sartorius Vivaspin membrane with a 300,000 molecular weight 
cutoff. Quantum dot concentration was measured by absorbance at 405 nm using a Beckman 
Coulter AD340 plate reader. 
Micro-aAPC Synthesis 
Micro-aAPCs were fabricated as described previously[7] by direct chemical coupling of protein 
to 4.5 μm Dynal Magnetic Microbeads (Life Technologies, Carlsbad, CA). For the initial 
coupling step, 25 μg anti-biotin antibody (Sigma, St. Louis, MO) was added to 100 million 
Microbeads in 0.1 M sodium borate buffer. After washing in a magnetic column, biotin labeled 
MHC-Ig and CD28 were added in equimolar amounts to form aAPC. 
In Vitro Cell Expansion 
For murine cell culture, cells were obtained from homogenized mouse spleens followed by  
hypotonic lysis of RBC. Cytotoxic lymphocytes were isolated using a CD8 no-touch isolation kit 
and magnetic enrichment column from Miltenyi Biotec (Cologne, Germany) and if necessary 
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labeled with carboxyfluorescein succinimidyl ester (CFSE) for 15 minutes at 37oC, then washed 
extensively. One million CD8+ T cells and particles at the indicated dosages were mixed and 
cultured in 96 well round bottom plates for 4-7 days in complete RPMI media supplemented 
with T cell factor (TF), a cytokine cocktail of conditioned media harvested from stimulated 
human PBMC [6].CFSE fluorescence was measured on Day 4 using a BD FacsCalibur flow 
cytometer and analyzed in FlowJo (TreeStar). CFSE is diluted with each round of T cell division, 
and division thus manifests as a one half-fold decrease in CFSE fluorescence. 
For human cell culture, PBMCs from healthy HLA*0201 positive donors were isolated by 
Ficoll-Paque PLUS gradient centrifugation following the manufacturer’s protocol (GE 
Healthcare). CD8+ T cells were further purified from fresh PBMC using the CD8+ T cell 
negative selection kit (Miltenyi Biotec). The purity of CD8+ T cells was higher than 95%, as 
determined by flow cytometry. Three million CD8+ T cells and particles at the indicated dosages 
were mixed and cultured in 96-well round bottom plates for up to 14 days in complete RPMI 
media supplemented with TF. On day 7 after stimulation, T cells were harvested, counted and 
replated at the same T cell:nano-aAPC density. Antigen specificity was determined using HLA-
M1-specific, A*0201 PE or APC tetramers (Beckman Coulter) according to manufacturer’s 
protocol. 
Near-Infrared Imaging 
Anti-biotin coated micro- and nano-particles were labeled with IRDye 680 RD or 800CW 
Protein labeling kits from LI-COR Biosciences (Lincoln, Nebraska). Beads were washed in a 
magnetic column and biotin labeled MHC-Ig and anti-CD28 were added to form aAPC. pMEL T 
cells were labeled with CellVue NIR 815 labeling kits from LI-COR Biosciences according 
manufacturer’s instructions. 
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Nu/J mice were injected with 2 ×105B16 melanoma cells on the right flank. Four days later, 5 
×105 micro-aAPC and a fluorescence intensity equivalent amount of nano-aAPC were injected 
into the tail vein, ipsilateral flank, or hindlimb, as indicated. T cells were injected into tail vein. 
Biodistribution of injected aAPC was visualized with LI-COR Pearl Impulse imaging system 
(Johns Hopkins Molecular Imaging Center, Baltimore, MD). Area of distribution was calculated 
using thresholding of the NIR channel in the ImageJ application (NIH, Bethesda, MD).  
Effect of Nano-aAPC on Subcutaneous Tumor Growth In Vivo  
For QD aAPC experiment, 2 ×106 naive CD8+ pMEL T cells were adoptively transferred into 8 
week old C57BL/6 male mice by tail vein injection, except for control mice which received no T 
cells or aAPC treatment. The same day, B16 melanoma cells (2 ×105) were injected 
subcutaneously into the right flank. The following day, 5 mice per group were treated with either 
20 μL cognate QD aAPC, 20 μL non-cognate QD aAPC, or 20 μL PBS. Mice were treated days 
3, 4, and 5 with 30,000 units intraperitoneal IL-2. Tumor growth was monitored at 2 day 
intervals, using digital calipers, until tumor size was ∼200 mm2 at which point animals were 
euthanized. 
For iron-dextran aAPC experiment, 2 ×106 naive CD8+ pMEL T cells were adoptively 
transferred as before. Four days later, mice in the treatment group received 25 μL cognate HD 
nano-aAPC either intravenously, iv or subcutaneously, sc, with eight mice per group. Three days 
later, aAPC were injected either sc or iv. B16 melanoma cells (2 ×105) were injected sc four days 
later, and a second injection of aAPC were given four days after tumor, either iv or sc on the 
ipsilateral flank. Tumor tracking and animal euthanasia proceeded as above. 
Tumor growth for each mouse was summarized as Area Under Curve calculated using 






Iron-Dextran Nano-aAPC Induce Antigen Specific T Cell Expansion 
Nanosized iron-oxide core, dextran coated particles produced by Miltenyi Biotec were selected 
as a nanoscale particle platform due to their extensive characterization and biocompatibility6. To 
produce nanoscale aAPC, soluble dimeric MHC-Ig loaded with an appropriate peptide (signal 1) 
and chimeric B7.1-Ig fusion protein (signal 2) were covalently coupled in a 1:1 ratio to the 
particle surface (Figure 3.1a). Alternatively, particles were manufactured by coupling 
biotinylated MHC-Ig and biotinylated anti-CD28 to an anti-biotin coated iron-dextran particle 
(Figure 3.1b).  
Iron-dextran aAPC were confirmed to be monodisperse with an average diameter of 50-100 nM 
in diameter using Nanoparticle Tracking Analysis (NTA, Figure 3.1c). Particles were suspended 
at a concentration of 8.3 nM (5×1012 particles/mL), and all subsequent volumes refer to particles 
at this concentration. By titrating the amount of protein present during the coupling reaction, we 
synthesized particles presenting a high density, HD  (65 μg protein/mL of particles), or low 
density, LD (16 μg protein/mL of particles), of protein as measured by Bradford Assay.  
To evaluate aAPC-induced T cell expansion, we utilized two TCR transgenic mouse models: 2C 
mice, whose T cells recognize the SIY peptide presented in the context of MHC Class I H2-Kb, 
and pMEL mice, whose T cells recognize a peptide derived from melanoma differentiation 
antigen GP100 presented in the context of MHC Class I H2-Db,. Four types of anti-biotin 
coupled iron-dextran particles were manufactured, presenting either Kb or Db loaded respectively 
with either the cognate peptide described above or a non-cognate peptide (SIIN for Kb, ASN for 
Db).  T cells were incubated with particles and proliferation was evaluated seven days later. 
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Particle based expansion was antigen-specific, as 2C cells only proliferated in the presence of 
Kb-SIY particles, and pMEL cells only proliferated in the presence of Db-GP100 particles 
(Figure 3.2A). Nano-aAPC mediated expansion is therefore antigen specific. Furthermore, both 
signal 1 and signal 2 were required for optimal expansion, and anti-biotin particles carrying 
either MHC-Ig or CD28 alone were not as effective at inducing robust T cell proliferation 
(Figure 3.2B). 
Soluble MHC-Ig and anti-CD28 are known to mediate weak T cell expansion in vitro [25,26]. To 
demonstrate that coupling of Signal 1 and 2 to solid support enhanced activation [27], nano-
aAPC mediated T cell expansion was compared to equivalent amounts soluble MHC-Ig and anti-
CD28. 10 ng of protein coupled to nano-aAPC induced greater T cell expansion than several 
orders of magnitude more soluble protein (Figure 3.3). Furthermore, soluble protein induced 
maximal expansion at an intermediate dose of 100 ng, whereas nano-aAPC mediated expansion 
was dose-dependent, reaching up to 30-fold expansion at a dose of 10 μg protein. 
Both the amount [28,29] and density [30,31] of antigen presented by APC influence downstream 
T cell behavior such as proliferation and cell death, and may thus be important parameters for 
aAPC stimulation. HD and LD particles were used to evaluate the effect of antigen density on T 
cell expansion and both sets of particles were titrated to evaluate the effect of antigen dose. 
Proliferation was characterized three days after stimulation by dilution of the vital dye 
carboxyfluorescein succinimidyl ester (CFSE). Seven days after stimulation, T cells were 
counted to characterize the overall balance between proliferation and death.  
Both HD and LD particles were able to induce pMEL T cell proliferation in a dose-dependent 
fashion (Figure 3.2C). As measured by CFSE dilution, HD particles induced proliferation in 
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79%, 98%, and 99% of cells for 1, 5, and 20 μLs of particles, respectively, per 1 million cells, 
while identical amounts of LD particles induced proliferation in 4%, 40%, and 93% of cells. By 
day 7, HD and LD particles had induced an overall expansion of T cells on the order of 5-30 
fold, with a minimum threshold of approximately 5 μL of LD particles and less than 0.5 μL of 
HD particles required to induce expansion (Figure 2D). Both CFSE proliferation and cell counts 
demonstrated that at any given quantity of particles, HD nano-aAPC induced greater expansion 
than LD. For example, at 5 μL of particles, HD particles induced 21-fold expansion, while LD 
particles induced only 7-fold expansion.  
To assess whether the increased amount of protein on HD particles fully accounted for the 
proliferation advantage, LD and HD particles were incubated with T cells at equal protein 
concentrations (that is, approximately 5-fold more LD particles at a given concentration of HD). 
Once aAPC were normalized for protein concentration, HD and LD particles induced similar 
expansion as measured by CFSE dilution on Day 3 (Figure 3.2E) or overall expansion on Day 7 
(Figure 3.2F). For example, 20 uL of LD particles or 3.5 uL of HD particles both induced 
proliferation in 94% of cells by Day 3, and approximately 17-fold expansion after 7 days of 
growth. Thus, at the antigen doses and densities evaluated, expansion was driven by total protein 
presented on aAPC, and not particle dose or protein density. 
Generating sufficient numbers of antigenic-specific T cells is a critical goal of immunotherapy. 
However, CTL can become anergic or even suppressive under certain stimulation conditions[32], 
so expanded lymphocytes must also be evaluated for their ability to produce critical effector 
cytokines, such as IFNγ, and to secrete cytotoxic granules, as indicated by surface expression of 
the degranulation marker CD107a. Seven days after particle-based stimulation, CTL were 
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harvested and re-challenged with peptide-pulsed splenocytes and assessed for functional 
response by intracellular cytokine assay (Figure 3.4).  
Functional responses were robust and equivalent for all three particle doses. CTL of all groups 
expressed high levels of CD107a, with up to 90% of cells degranulating and expressing high 
levels of IFNγ when re-challenged with peptide (Figure 3.4A-C). Thus, while particle to T cell 
ratio and protein quantity on particles influence the degree of CTL expansion, the resulting T 
cells displayed similar, strong effector responses regardless of particle dose. CTL phenotype was 
also assessed by expression of effector and memory surface markers CD44 and CD62L. After 
activation with either HD or LD nano-aAPC, naive CD44lo CD62Lhi T cells upregulated CD44, 
forming both CD62Lhi “Central Memory” (Tcm) phenotype and  CD62Llo “Effector Memory” 
(Tem) phenotypes (Figure S2D-E).  
We next compared nano-aAPC mediated T cell expansion to our micro-aAPC platform [7], 
which is based on 4.5 μm diameter iron-dextran beads. The total dose of protein was normalized 
between micro- and nano-aAPC. Micro- and nano-aAPC mediated robust, dose-dependent, and 
comparable levels of proliferation of pMEL T cells with acquisition of effector phenotype during 
three weeks of re-stimulation in vitro (Supplementary Figure 3.5). After one week, micro-
aAPC induced approximately 15-fold expansion, and nano-aAPC induced approximately 20-fold 
expansion at a high dose of aAPC. After three weeks, fold expansion of CTL as high as 650-fold 
expansion with nano-aAPC and 450-fold expansion with micro-aAPC was observed. Both sizes 
of aAPC induced upregulation of CD44 and downregulation of CD62L consistent with effector 
phenotypes. Total amounts of proliferation observed is consistent with previous studies [33] and 
illustrates that nano-aAPC induce robust proliferation comparable to micro-aAPC. 
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Quantum Dot Nano-aAPC 
To evaluate nano-aAPC based stimulation at an even smaller scale, and to demonstrate that 
nano-aAPC are not platform-exclusive, we obtained commercially available quantum dot core, 
avidin coated nanocrystals approximately 30 nm in diameter from Life Technologies. Biotin 
labeled dimeric Db-GP100 (signal 1) and anti-CD28 antibody (signal 2) were bound in a 1:1 
molar ratio to the nanocrystal surface to form a quantum dot nano-aAPC (QD-aAPC) (Figure 
3.6A). 
QD aAPC induced dose-dependent, antigen specific T cell expansion in vitro (Figure 3.6B). At 
the highest dose evaluated, T Cells expanded 14.6 fold after 7 days, while T cells stimulated with 
non-cognate control QD aAPC did not expand. 
Nano-aAPC Expansion of Endogenous Human T Cell Responses 
Antigen-specific precursor T cells exist as low-frequency, heterogeneous populations of 
peripheral blood mononuclear cells (PBMC). Thus, immunotherapy ultimately depends on the 
expansion of antigen-reactive CTL from a polyclonal pool of endogenous precursors. Antigen-
specific T cells in a polyclonal pool can be identified as cells that bind fluorescent MHC tetramer 
of the appropriate allele carrying the peptide of interest [34]. 
 
Anti-biotin iron-dextran aAPC were synthesized bearing the human HLA allele A2 loaded with 
the immunodominant T cell epitope derived from influenza protein M1 (signal 1) and anti-CD28 
(signal 2). PBMC were incubated with increasing doses of nano-aAPC and antigen-specific T 
cell expansion was assessed by tetramer staining after two consecutive stimulations. 
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Before stimulation, M1 specific precursor frequency in the peripheral blood was low, with 0.4% 
specific CD8+ PBMC (Figure 3.7A, top row). Incubation with nano-aAPC for one (middle row) 
or two (bottom row) weeks resulted in a dose-dependent increase in the percentage of antigen 
specific T cells. These data are summarized in Figure 3.7B. The highest dose (30 μL) of nano-
aAPC induced up to 44% of antigen specific T cells after one week or 80% after two weeks (left 
panel). This was associated with a dose-dependent increase in the total amount of antigen-
specific T cells (right panel), with up to 150-fold expansion after one week and 800-fold 
expansion after two weeks at the highest particle dose. Nano-aAPC thus induced large 
populations of antigen-specific T cells from small endogenous precursor populations.    
Enhanced Distribution of Nano- Compared to Micro-aAPC 
As discussed, nanoscale particles are expected to drain more efficiently via lymphatics than  
microscale particles[14,35], motivating our interest in developing a nanoscale aAPC. To assess 
biodistribution after subcutaneous injection, we injected near-infrared (NIR) labeled iron-dextran 
nano- and micro-aAPC into the right flanks of B16 melanoma bearing Nu/J (nude) mice.  
Twenty-four hours after subcutaneous injection, micro-aAPC remained largely confined to the 
injection site (Figure 3.8A, left). No significant drainage was observed up to 72 hours after 
injection. In contrast, nano-aAPC had spread diffusely across a larger area of the right flank, with 
most drainage occurring within the first 24 hours (Figure 3.8A, right). However, neither nano- 
nor micro-aAPC were observed to spread to the tumor itself. Distribution was quantified by 
measuring the area of particle distribution in the NIR channel above a certain fluorescence 
threshold. Twenty-four hours post-injection, nano-aAPC were visible in a 5-fold larger area than 
micro-aAPC (Figure 3.8B). 
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Enhanced drainage could lead to colocalization of antigen-specific T cells and nano-aAPC in 
lymph nodes. To simultaneously visualize T cell and aAPC biodistribution, we labeled pMEL T 
cells with a NIR membrane dye and injected them in the tail veins of Nu/J mice (Figure 5c). 
aAPC were labeled and injected subcutaneously as before. Forty-eight hours after injection, T 
cells were visible in axillary, inguinal, and cervical lymph nodes, as well as spleen. Nano-APC 
drained broadly from the injection site and a portion of particles were localized to the inguinal 
lymph nodes, where they could contact cognate T cells. Micro-aAPC, in contrast, were confined 
to the injection site, and not present at the same location as T cells.  
Nano-aAPC Inhibit Tumor Growth  In Vivo 
A mouse model of subcutaneous melanoma was chosen to demonstrate the functional efficacy of 
nanoscale aAPC for immunotherapy when injected directly in vivo. To evaluate QD-aAPC, naive 
TCR transgenic pMEL CTL were adoptively transferred into wild-type B6 mice, and mice were 
challenged the same day with B16 melanoma cells injected subcutaneously (sc) on the right flank 
(Figure 3.9A, top). The following day, mice were injected with either 20 μL of cognate QD 
aAPC or 20 μL of non-cognate QD aAPC or PBS as control.  One injection of QD aAPC 
significantly inhibited tumor growth (Figure 3.9A, bottom). After 16 days, mice treated with T 
cells and cognate QD aAPC had the smallest tumor burden, with an average tumor size of 22.1 
mm2 +/- (sd) 2.3, compared to 111.1 mm2 +/- 29.4 for T cell + noncognate aAPC treated mice, 
141.1 mm2 +/- 9.6 for T cells alone and 133.1 mm2 +/- 7.6 for untreated mice. Total tumor 
growth over the course of the experiment was summarized as area under the curve (AUC). Mice 
treated with cognate QD-aAPC had significantly less (p=0.028) overall tumor growth by AUC 
(33.1 mm2 +/- 7.8) than mice treated with control, non-cognate aAPC (373.6 mm2 +/- 227.0). 
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The route of particle administration is likely to affect bead trafficking, with subcutaneously 
deposited beads more likely to drain to local lymph nodes [36] and intravenously injected 
particles more likely to be filtered by the spleen. To test the impact of route of aAPC 
administration as well as the in vivo efficacy of iron-dextran aAPC, particles were injected either 
intravenously or subcutaneously three days after pMEL adoptive transfer. B16 Tumors were 
injected subcutaneously on right flank four days later, and a second injection of aAPC were 
given four days after tumor, either iv or sc on the ipsilateral flank. Thus, there were three 
treatment groups: mice receiving two iv bead injections, mice receiving one iv and one sc 
injection, and mice receiving two sc injections (Figure 6B, top). Control mice injected with non-
cognate aAPC received one iv and one sc injection.  
All three treatment groups had less tumor growth than mice injected with control bead (Figure 
3.9B, bottom). After 16 days, mice treated with one sc and one iv injection (sc/iv) showed the 
least tumor growth (48.0 mm2 +/- 31.16), followed by sc/sc treated (73.7 mm2 +/- 37.44), iv/iv 
treated (89.4 mm2 +/- 69.5), no treatment (88.4 mm2 +/- 17.8) and non-cognate treated (113 mm2 
+/- 39.4). Over the entire course of the experiment, sc/iv treated mice (AUC 52.6 mm2 +/- 29.7) 
and sc/sc mice (AUC 73.1 mm2 +/- 36.1) showed significantly less (p<0.02) tumor growth than 
control mice (AUC 162.7 mm2 +/- 77.6). Mice treated with two iv injections had less total tumor 
burden (AUC 103.0 +/- 86.1) than control, but did not reach the significance threshold (p = 
0.19). Thus, mice treated with at least one dose of nano-aAPC delivered subcutaneously had 
significantly less tumor than control. This was consistent with observations that sc injected nano-
aAPC drained from the injection site and were retained for several days after injection, whereas 
iv injected nano-aAPC were more likely to be rapidly cleared by renal excretion or filtered by the 
liver and spleen (Figure 3.10). 
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3.4 Discussion 
We have described two nanoscale T cell activation platforms, termed artificial antigen present 
cells (aAPCs), based on coupling signal 1, peptide-MHC, and signal 2, B7.1-Ig or anti-CD28, to 
iron-dextran nanoparticles and quantum dot nanocrystals. Nano-aAPC induced T cell expansion 
from both TCR transgenic mouse splenocytes and human, polyclonal peripheral blood T cells, 
generating CTL with a robust effector phenotype that inhibited tumor growth in vivo. Both 30 
nm quantum nanocrystals and 50-100 nm iron oxide nanoparticles were effective aAPC 
platforms, indicating that bead based aAPC can be explored at a range of nano-scales.  
Previous work suggested that nanoparticles were incapable of providing the robust activating 
signals necessary for T cell proliferation [15,16,21]. This is the first description of a nanoscale 
particle-based T cell stimulation platform that can effectively induce antigen-specific T cell 
proliferation in vitro and anti-tumor activity in vivo. Our success may be due in part to our use of 
MHC-Ig dimers, whose flexible hinge region and nanoscale MHC dimerization may provide 
more optimal TCR/MHC interactions than MHC monomer [15,37].  
Microscale, cell-sized bead platforms were initially chosen as aAPC to mimic structures that 
form between T cells-APC conjugates during activation [38]. For example, the immune synapse 
is a pattern of surface receptor reorganization several microns in diameter, with centrally located 
TCR and peripherally located adhesion molecules. The synapse, while not absolutely required 
for activation, does modulate antigen search and recognition [39]. A related process, asymmetric 
cell division, is hypothesized to regulate memory development by providing a microscale 
scaffold that induces polarity during cell division [40]. It has not been shown that aAPC of any 
size can recapitulate these structures, which seem to at least partly depend on coordinated 
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rearrangement of both the APC and T cell membrane. Furthermore, it is particularly unlikely that 
nano-aAPC will drive the formation of structures that seem to depend on microscale cell-cell 
interactions. The nature of T cell activation by nano-aAPC may thus have important 
consequences for T cell function and memory development. 
Nanoscale structures, such as clusters of TCR form on the T cell membrane even prior to 
formation of microscale structures [41,42],  are also thought to be important regulators of T cell 
responses. However, even on the nanoscale level, the mechanism of TCR triggering by nano-
aAPC is not clear. aAPC activate T cells through specific receptor-ligand binding at the cell-bead 
interface. Such interactions are not well defined when one of the participants is nanoscale [43].  
The geometry of the nanobead, such as high local curvature at the interface, may preclude 
multiple productive receptor-ligand interactions. Alternatively, nanoscale platforms may 
preferentially interact with nano-clustered receptors such as the TCR [44,45]. Nanoscale bead-
cell interaction platforms thus represent not just a novel approach to immunotherapy, but a tool 
for studying the delivery of biological signals at the cell membrane [19]. 
Nano-aAPC are better suited than micro-aAPC for in vivo administration and thus, allow the 
exploration of new particle-based immunotherapy strategies. Two potential sites where aAPC 
might be most effective are the lymph node, where naive and memory T cells reside and the 
tumor itself. Nanoparticles of approximately 50-100 nm diameter can be taken up by lymphatics 
and transported to the lymph nodes [14,36] thus gaining access to a larger pool of T cells. Nano-
aAPC were more efficiently distributed from the injection site than micro-aAPC, were found to 
co-localize with antigen-specific T cells in inguinal lymph nodes, and inhibited tumor growth 
when injected subcutaneously. This suggests drainage of nano-aAPC to lymph nodes is a 
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potential mechanism for optimal in vivo T cell activation, and the possibility of further tuning 
size [46] and particle surface properties[36] to enhance lymph node trafficking.  
In addition, nanoscale delivery vehicles preferentially accumulate in tumors through enhanced 
permeability retention due to poorly formed tumor vasculature[47,48]. In this study, nano-aAPC 
delivered subcutaneously were not observed to drain into the tumor environment directly, 
whereas future work will focus on delivery strategies that lead to intratumoral aAPC 
accumulation. By delivering an immunostimulatory signal in situ, aAPC in the tumor 
microenvironment may address one of the most prominent hurdles in cancer immunotherapy, the 
immunosuppressive tumor microenvironment [49]. Although our work demonstrates that nano-
aAPC can induce anti-tumor effector T cells from naive populations in vivo, it does not explore 
the capability of nano-aAPC to mediate rejection of established tumors in highly 
immunosuppressive microenvironments. Thus, whether a local stimulatory signal can overcome 
multiple layers of tumor immunosuppresion, or whether aAPC based stimulation can synergize 
with immunomodulatory therapies like checkpoint blockade, remains unknown. The enhanced 
drainage properties of nano-aAPC compared to micro-aAPC provides a system for examining the 
optimal distribution of aAPC for tumor rejection, and allows the exploration of new in vivo 





Figure 3-1 Synthesis and Characterization of Iron-Dextran Nano-aAPC .  
Nano-aAPC were synthesized in one of two ways: (A) Direct chemical coupling of soluble 
MHC-Ig dimer (signal 1) and B7.1-Ig (signal 2) in a 1:1 molar ratio to the surface of a 
paramagnetic iron-oxide, dextran-coated particle. (B) Binding of biotinylated MHC-Ig dimer 
(signal 1) and biotinylated anti-CD28 (signal 2) in a 1:1 molar ratio to anti-biotin coated 
particles. 
(C) Nanoparticle tracking analysis confirms that nano-aAPC are a monodisperse mixture of 




Figure 3-2. Nano aAPC Induced Proliferation is Antigen-Specific and Dose-Dependent 
(A) Antigen specific nano-aAPC induce proliferation. T cells were counted seven days after 
stimulation with anti-biotin coated nano-aAPC to calculate fold expansion from day 0. TCR 
transgenic 2C (grey) and pMEL (white) T cells proliferated only when incubated with 
nanoparticles bearing cognate MHC/peptide (22-fold and 16-fold, respectively), and not in the 
presence of nnaoparticles bearing either non-cognate peptide or non-cognate MHC (<3-fold). 
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(B) Addition of both signal 1 and signal 2 leads to optimal T cell expansion. At a dose of 10 μL 
particles per 1*106 T cells, only anti-biotin particles bearing both MHC-Ig and anti-CD28 
induced robust T cell expansion. 
Proliferation of CD8+ CTL induced by Low Density, LD (16 μg protein/mL particles),  and High 
Density, HD (65 μg protein/mL), particles. Results are representative of three experiments. 
(C) Equivalent doses of HD and LD particles were used to stimulate pMEL T cells. Proliferation 
was measured by dilution of CFSE three days after stimulation. Decreased fluorescence indicates 
increased proliferation. Equivalent volumes of HD particles induce greater proliferation than LD 
particles, with 0.5 uL LD particles inducing almost no expansion.  
(D) Fold expansion on day 7 of samples of dose equivalent samples shows a similar pattern. 
Proliferation is dose-dependent and 2-4 fold greater for HD particles compared to an equivalent 
dose of LD particles (21-fold compared to 7-fold at 5 μL).  
(E) Day 3 CFSE dilution of CD8+ CTL induced by LD and HD particles at equivalent protein 
concentrations, with approximately 5.5-fold more LD than HD at a given dose. When particle 
doses are normalized to equivalent protein concentrations, particles induce similar amounts of 
CFSE dilution.  
(F) Fold expansion on day 7 of samples demonstrates equivalent expansion for HD and LD 
particles at an equivalent protein dose (17-fold at 3.5 μL of HD and 20 μL of LD). A threshold of 




Figure 3-3. Coupling of MHC-Ig and anti-CD28 to Nanoparticles Enhances T Cell 
Stimulation.  
HD nano-aAPC, at 65 μg of total protein/ml, were incubated at titrated doses with 1x106 isolated 
CD8+ T cells. Equivalent doses of equimolar MHC-Ig and anti-CD28 antibody were compared 
in parallel. Fold expansion was assessed with cell counts seven days after activation. Data are 
representative of three experiments. 
(A) Nano-aAPC bearing 10 μg of total protein (Db-GP100 + CD28) were able to induce greater-
fold T cell proliferation (15x) than any dose of soluble protein. Nano-aAPC mediated expansion 
increased in a dose-dependent manner, reaching up to 32-fold expansion, whereas soluble protein 
mediated expansion peaked at 13 fold for 100 ng, then decreased for increasing protein 
concentration.  
(B) Cell viability was assessed by exclusion of Trypan Blue dye. Greater than 90% viability was 
observed for all nano-aAPC doses that induced T cell stimulation. In contrast, soluble peptide 





Figure 3-4. T Cell Functional Characterization 
(A-C) Intracellular Cytokine Staining. (A) CD8+ T Cells were expanded using HD and LD 
particles. Particle doses were chosen to induce either roughly equivalent expansion by HD and 
LD particles (3.5 uL and 20 uL, respectively) or more robust expansion (HD 20 uL). (B & C) 
Samples were re-stimulated on day 7 and assessed for effector function by intracellular cytokine 
staining assay. 20 uL HD sample (black circles), 3.5 uL HD sample (black filled square), and 20 
uL LD samples (unfilled square) all induced robust, equivalent, and dose-dependent (B) 
degranulation measured by CD107a and (C) IFNγ production.  
(B). Functional responses were robust and equivalent for all three particle doses. CTL of all 
groups expressed high levels of CD107a, with up to 90% of cells degranulating when re-
challenged with a high dose of peptide (C)Similarly, all three groups displayed high levels of 
IFNγ responsiveness.  
(D) Representative FACS plot shows three populations seven days after nano-aAPC stimulation. 
T cells were stained with anti-CD44 and anti-CD62L to characterize effector phenotype. (E) T 
cells were stimulated with 2, 10 and 50 μL of LD or HD iron-oxide nano-aAPC and 
characterized seven days later. Bar plots show percentage of naive (unfilled), Tcm (grey fill), and 
Tem (black fill) cells generated after stimulation. Lower doses of particles generated a higher 
proportion of CD62Llo CD44hi Tem cells, with 2 uL of LD and 2 uL of HD generating 51% and 




Figure 3-5. Micro- vs. Nano-aAPC Mediated T Cell Prolieration 
Proliferation induced by micro- and nano-aAPC with repeated re-stimulation in culture. aAPC 
doses were normalized to total dose of protein (MHC-Ig and anti-CD28). 
(A) Seven days after stimulation, proliferation was assessed by cell count and reported as fold 
expansion from Day 0. Data are representative of four experiments. Both micro- and nano-aAPC 
induce dose-dependent T cell expansion, with a maximal expansion of 13-fold for nano-aAPC 
and 19-fold for micro-aAPC at the highest dose examined here. Over two subsequent weeks of 
re-stimulation (on Days 7 and 14), T cell proliferation continued in a dose-dependent fashion. An 
optimal dose of 195 nanograms induced the most robust overall expansion with both platforms, 
reaching 644-fold expansion with nano-aAPC and 446-fold expansion with micro-aAPC after 21 
days. 
(B) Effector phenotype induced micro- and nano-aAPC during in vitro culture. After repeated 
stimulation with aAPC, nearly all T cells acquire a CD62Llo CD44hi effector phenotype. 
Representative FACS plots are shown for aAPC stimulation with the optimal dose of protein 
(195 ng).  
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Figure 3-6. Synthesis and Characterization of Quantum Dot Nano-aAPC  
(A) Quantum Dot (Qdot) Nano-aAPC were constructed by avidin-biotin mediated coupling of 
soluble MHC-Ig dimer (signal 1) and anti-CD28 antibody (signal 2) in a 1:1 ratio to the surface 
of a polymer-coated quantum dot particle. 
(B) Qdot Nano-aAPC expansion in whole CD8+ T cells. Fold expansion on Day 7 is dose 
dependent and antigen-specific. Non cognate particles did not induce any expansion, whereas the 
highest dose of cognate QD aAPC (Db-GP100) induced approximately 15 fold expansion of 




Figure 3-7. Antigen-specific Human T Cell Expansion From Endogenous Precursors 
(A) CD8+ T cells were isolated from PBMC by magnetic enrichment and incubated with 
increasing doses of iron-dextran nano-aAPC bearing A2-Ig complexes loaded with antigen 
derived from the immunodominant epitope of the influenza M1 protein, and assessed for antigen-
specificity by tetramer staining before stimulation (PBMC, top row) and after one (middle row) 
or two (bottom row) weeks of stimulation. Numbers in top left represent percentage of CD8+ 
cells that were tetramer positive (gated).The size of the M1 specific population increases with 
repeated rounds of stimulation (top to bottom) and increasing dose of nano-aAPC (left to right), 
from 0.36% of CD8+ PBMC to 77.7% at the highest dose. Plots are representative of results 
from three separate experiments, summarized in panel B. (B) Percentage of CD8+ PBMC 
binding HLA-A2 M1 tetramers increases with repeated stimulation and increasing dose of nano-
aAPC (left panel). The total number of tetramer positive cells (right panel) similarly increases 
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Figure 3-8Enhanced Drainage of Nano- Compared to Micro-aAPC.  
(A) Visualization of drainage of near infrared labeled micro-aAPC (left) compared to nano-
aAPC (right) after subcutaneous injection on right flank. Right flank views are shown for 
representative mice (3 mice/group) at the indicated timepoints after injection. Legend at right 
relates color in image to arbitrary fluorescence units. Micro-aAPC are confined largely to 
injection site, whereas local drainage of Nano-aAPC is more pronounced. (B) Biodistribution is 
quantified as area of visible drainage at indicated timepoints. Nano-aAPC have five-fold greater 
area of drainage than micro-aAPC at equivalent timepoints. (C) Simultaneous NIR images of 
biodistribution for pMEL T cells (green) and aAPC (red). Forty-eight hours after intravenous 
injection, T cells are visible in axillary lymph nodes, spleen, inguinal lymph nodes (white 
arrows, left to right) and cervical lymph nodes (not pictured). Right flank view (top row) shows 
nano-aAPC which were injected in right hindlimb 48 hrs. earlier reach inguinal lymph node, 
whereas micro-aAPC do not. This is even more pronounced after dissection (bottom row); aAPC 
signal is stronger and can be seen in the area of the inguinal lymph node (white arrow) for nano- 
but not micro-aAPC. Images are representative of three mice.  
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Figure 3-9. Nano-aAPC Inhibit Tumor Growth In Vivo 
(A) QD aAPC. B16 Tumors were injected subcutaneously on day 0, with injection of naive 
pMEL T cells on the same day. One day later, QD aAPC were injected intravenously (iv). IL-2 
was administered on days 3, 4, and 5. Tumor size was measured as surface area (mm2) on 
indicated days, with area under the curve (AUC) shown at right. Mice treated with pMEL T cells 
and cognate QD aAPC (black bars) had less tumor growth compared to no treatment (white), T 
cells alone (light grey), and T cells + noncognate QD aAPC (checkered) (4 mice per group). 
Significance was characterized over entire experiment by AUC (p<0.001 by ANOVA with 
Tukey’s Post-Test, * indicates significant difference from no treatment group).  
(B) Iron-Dextran aAPC. Naive pMEL T cells were injected intravenously on day -7. One day 
later, iron-dextran aAPC were injected either iv or subcutaneously (sc) on the right flank. B16 
tumors were injected sc on right flank on day 0. Mice in treatment arms were given an additional 
injection on day 4 post tumor injection either iv or sc, to form four treatment groups: noncognate 
aAPC iv (day -6) then sc (day 4) (checkered), cognate aAPC iv then iv (light grey), cognate 
aAPC iv then sc (dark grey), and cognate aAPC sc then sc (black). Mice treated with pMEL T 
cells and cognate Iron-Dextran aAPC iv/sc or sc/sc (filled squares) had less tumor growth 
compared to noncognate aAPC (7 mice per group, p<0.02 by ANOVA with Tukey’s Post-Test, * 





Figure 3-10. Biodistribution of Nano-aAPC After Intravenous (iv) and Subcutaneous (sc) 
Injection. 
Nu/J mice were injected with 2 ×105 B16 melanoma cells on the right flank. Four days later, 25 
μL of 8.3 nM nano-aAPC were injected either iv tail vein, or sc into the ipsilateral flank several 
cm from tumor. Images are representative of three mice per group. 
(A) Eight hours after injection, distribution of iv nano-aAPC is consistent with filtration by liver 
and spleen, as well as significant renal excretion. 48 hours later, nano-aAPC are only visible in 
liver and spleen, and intensity is significantly decreased, likely due to clearance. (B) In contrast, 
sc nano-aAPC are visible with high intensity 8 and 48 hours after injection, forming a depot on 
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4 Magnetic Field-Induced T Cell Receptor Clustering By 
Nanoparticles Enhances T Cell Activation and Stimulates 
Anti-Tumor Activity In Vivo  
4.1  Introduction 
 Nanoparticles functionalized with surface ligands are frequently used for targeted delivery of 
drugs, proteins, and genes to cells bearing specific receptors[1,2]. Since receptor binding can 
trigger downstream signaling in the target cell, nanoparticle engagement of membrane receptors 
can also be used to directly induce biological responses.  
We have previously described nanoscale artificial Antigen Presenting Cells (nano-aAPC), 50-
100 nm in diameter, as the first nanoparticles shown to initiate antigen-specific T cell activation 
by presenting peptide in the context of Major Histocompatability Complex (MHC) to cognate T 
cell receptors (TCR)[3]. While TCR-MHC interactions have been extensively studied for MHC 
presented on cells[4] and cell-sized, MHC-coated particles[5–8], receptor-ligand interactions at 
the cell-nanoparticle interface are not well understood and are likely to have unique 
properties[9]. For example, T cell activation induces a state of persistently enhanced nanoscale 
TCR clustering[10–13] and nanoparticles might be sensitive to this clustering in a way that larger 
particles are not.  
Furthermore, nanoparticle interactions with TCR clusters could be exploited to control or 
enhance receptor triggering. T cell activation is mediated by aggregation of signaling 
proteins[14], with ‘signaling microclusters’, 100’s of nms across, initially forming at the 
periphery of the T cell-APC contact site and migrating inward[15]. We hypothesized that an 
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external magnetic field could drive aggregation of paramagnetic nano-aAPC bound to TCR, 
resulting in aggregation of TCR clusters and enhanced activation of naïve T cells. 
Magnetic bead clustering has been used to study effects of mechanical stress[16] and receptor 
clustering[17,18] in a variety of systems. Magnetic fields can exert appropriately strong forces 
on paramagnetic particles, but are otherwise biologically inert, making them a powerful tool to 
control particle behavior[19,20]. In our approach, T cells bound to paramagnetic nano-aAPC are 
activated in the presence of an externally applied magnetic field. Nano-aAPC are thus 
themselves magnetized, and will be attracted to both the field source and to nearby nanoparticles 
in the field[17,20], inducing bead and thus TCR aggregation to boost aAPC-mediated activation.  
We show that nano-aAPC bound more TCR on and induced greater activation of previously 
activated compared to naive T cells. Application of an external magnetic field induced aAPC 
aggregation on naive cells, enhancing T cells proliferation in vitro and following adoptive 
transfer in vivo. In a melanoma adoptive immunotherapy model, T cells activated by nano-aAPC 
in a magnetic field mediated greater tumor rejection than T cells activated by nano-aAPC alone. 
4.2  Methods 
Mice and reagents 
2C TCR transgenic mice were maintained as heterozygotes by breeding on a C57/BL6 
background. Pmel TCR/Thy1a Rag-/- transgenic mice were a gift from Nicholas Restifo 
(National Institutes of Health, Bethesda, MD) and maintained as homozygotes. C57BL/6j mice 
were purchased from Jackson Laboratories (Bar Harbor, ME). All mice were maintained 
according to Johns Hopkins University’s Institutional Review Board. Fluorescently labeled 
monoclonal antibodies were purchased from BioLegend (San Diego, CA).  
 142 
 
Preparation of MHC-Ig Dimers and Nano-aAPC  
Soluble MHC-Ig dimers, Kb-Ig and Db-Ig, were prepared and loaded with peptides as 
described[5],see supplementary methods. Nano-aAPC were manufactured by direct conjugation 
of MHC-Ig dimer and anti-CD28 antibody (37.51; BioLegend) to MACS Microbeads (Miltenyi 
Biotec) as described[3]. Protein bound to nanoparticles was measured by fluorescence as 
described in supplementary methods. 
In Vitro Cell Expansion 
Cells were obtained from homogenized mouse spleens and lymph nodes followed by hypotonic 
lysis of RBC. Cytotoxic lymphocytes were isolated using a CD8 no-touch isolation kit and 
magnetic enrichment column from Miltenyi Biotec (Cologne, Germany). CD44-biotin antibody 
was added to primary cocktail to isolate CD44lo, naive cells. Where applicable, cells were 
labeled with carboxyfluorescein succinimidyl ester (CFSE) for 15 minutes at 37oC, then washed 
extensively.  
CD8+ T cells and nano-aAPC, at the indicated dosages, were mixed and cultured in 24 well flat-
bottom or 96 well round bottom plates for 4-7 days in complete RPMI media supplemented with 
T cell factor (TF), a cytokine enriched cocktail of conditioned media harvested from stimulated 
human PBMC [21]. Where indicated, culture plates were fixed between two Neodynium N52 
disk magnets between ¼ and ¾ inches in length (K&J Magnetics, Jamison, PA). CFSE 
fluorescence was measured at indicated timepoints using a BD FacsCalibur flow cytometer and 
analyzed in FlowJo (TreeStar). Fold expansion was assessed by cell counts seven days after 
stimulation. Expansion of endogenous antigen-specific cells was assessed by staining with 400 
nM fluorescently labeled MHC-Ig dimer seven days after activation.  
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Particle Binding Assays 
For equilibrium particle binding assays, CD8+ T cells were incubated at 4°C at a concentration of 
107cells/ml in FACS wash buffer (PBS + 2% FCS + .05% sodium azide). 30 l aliquots of cells 
were mixed with varying concentrations of nanoparticles bearing fluorescently labeled MHC-Ig 
dimer for 60-90 min. After washing, cell-bound fluorescence was measured by flow cytometer 
and MCF (mean channel fluorescence) was calculated using FlowJo. 
For particle off-rate binding assays, cells and a saturating dose of nanoparticle or soluble MHC-
Ig dimer were bound to steady-state as described above. MCF was measured at Time 0, followed 
by the addition of excess clonotypic 1B2 blocking antibody to prevent re-binding. MCF was 
measured at the indicated timepoints, and effective off-rate was calculated for exponential decay 
in GraphPad Prism (La Jolla, CA). Cell-particle contacts were estimated as described in Table 2. 
Microscopy 
T cells were bound to nano-aAPC for 60 minutes at 4oC. Cells were subsequently transferred to a 
96-well plate at 37oC in the presence or absence of a magnetic field generated by Neodymium 
N52 disk magnets. After 30 minutes, cells were washed and stained at 4oC with Alexa488 anti-
LFA1, monoclonal PE anti-mouse IgG1, and Alexa 647 anti-CD3ε. Samples were washed and 
fixed immediately with 2% paraformaldehyde. Images were acquired on a Zeiss LSM 510 
META (Zeiss, Oberkochen, Germany) laser scanning confocal at 100x magnification at the 
Johns Hopkins School of Medicine Microscopy Facility. CD3ε cluster size was determined using 
a particle-detection algorithm written in ImageJ (National Institutes of Health) using the built-in 
Particle Analyzer. 
Effect of Nano-aAPC on In Vivo T cell Expansion and Inhibition of Subcutaneous Tumor Growth   
CD44lo, CD8+ cells were isolated from pmel spleen and lymph nodes using a magnetic 
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enrichment column and activated for 24 hours in the presence or absence of a magnetic field as 
described above. 1 ×106 Thy1.1+ pmel cells were adoptively transferred into B6 Thy1.2+ wild 
type hosts (n = 6 mice per group). Mice were treated both the day of and the day after adoptive 
transfer with 30,000 units intraperitoneal IL-2. Seven and twenty-days after adoptive transfer, 
three mice per group were sacrificed and lymphocytes were isolated from peripheral blood, 
spleen, and inguinal, cervical, and axillary lymph nodes, and then stained with anti-Thy1.1 
antibody.  
Tumor rejection experiments were performed as above, except 3x105 B16 melanoma cells were 
injected subcutaneously ten days prior to T cell adoptive transfer.  Transient lymphopenia was 
induced by sublethal irradiation (500 cGy) one day before adoptive transfer with a MSD Nordion 
Gammacell dual Cs137 source (Johns Hopkins Molecular Imaging Center) as irradiation induced 
lymphopenia is thought to remove immunosuppressive host cells and reduce competition for 
lymphotrophic cytokines[22], and significantly enhances the effect of immunotherapy for 
melanoma in clinical trials[23]. Tumor growth was monitored at 2 day intervals using digital 
calipers, until tumor size was ∼150 mm2, at which point animals were euthanized. 
Preparation of MHC-Ig Dimers  
Soluble MHC-Ig dimers, Kb-Ig and Db-Ig, were prepared and loaded with peptide as described 
[2]. Briefly, Kb-Ig molecules were loaded with peptide by stripping at alkaline condition (pH 
11.5), and then refolded in the presence of 50 fold excess peptide. Db-Ig molecules were stripped 
under mildly acidic conditions (pH 6.5) and refolded in the presence of 50 fold molar excess 
peptide and 2-fold molar excess of human 2-microglobulin [3]. Peptides SIY (SIYRYYGL, 
synthetic), SIIN (SIINFEKL, derived from ovalbumin protein), GP100 (KVPRNQDWL, from 
melanocyte GP100 protein) and ASN (ASNENMETH, from influenza A nucleoprotein) were 
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purchased from Genscript (Piscataway, NJ). Protein concentration was determined after labeling 
by size exclusion high performance liquid chromatography (HPLC). 
Micro-aAPC Synthesis 
Micro-aAPCs were fabricated as described previously[4] by direct chemical coupling of protein 
to 4.5 μm Dynal Magnetic Microbeads (Life Technologies, Carlsbad, CA). For the initial 
coupling step, 25 μg anti-biotin antibody (Sigma, St. Louis, MO) was added to 100 million 
microbeads in 0.1 M sodium borate buffer. After washing in a magnetic column, biotin labeled 
MHC-Ig and CD28 were added in equimolar amounts to form aAPC. 
Nanoparticle Tracking Analysis 
A Nanosight LM10 equipped with a sensitive CCD camera was used for characterizing the size 
distribution of nano-aAPC by NTA. 50 μL of diluted nanoparticle solution was loaded into the 
sample chamber, which was connected to a 405 nm laser source. A 60 s movie containing the 
Brownian motion tracking of the scattering centroids (particles) was recorded using NTA 
software (Version 2.0). The movie was processed using the manufacturer recommended auto 
settings with manual adjustment of the gain, blur and brightness as recommended. The 
nanoparticle solution was diluted in phosphate buffered saline to adjust the sample concentration 
to 5×1012 particles mL−1. 
4.3 Results 
Nano-aAPC Preferentially Stimulate Activated T Cells 
T cell stimulation requires two activating signals delivered by endogenous APC: signal 1, a 
cognate antigenic peptide presented in the context of MHC that binds the TCR, and signal 2, one 
of a number of co-stimulatory receptors that modulate T cell responses[24]. Nano-aAPC are 
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synthesized by coupling chimeric MHC-Ig dimer (signal 1) and anti-CD28 antibody (signal 2) to 
50-100 nm paramagnetic iron-dextran nanoparticles (Figure 4.1A), which were selected as a 
nanoscale particle platform due to their extensive characterization and biocompatibility[25]. 
Protein coupling to particles was characterized by labeling with a fluorescent antibody against 
the protein of interest (Figure 4.2). Nano-aAPC present 13 ± 3 MHC-Ig dimers and 12 ± 5 anti-
CD28 antibodies per particle, for a protein density of 96 ± 10 and 92 ± 12 protein/ μm2, 
respectively (Table 5.1).  
To compare stimulation of naive versus activated T cells, we used CD44 depleted naive CD8+ 
splenocytes isolated from either pmel TCR or 2C TCR transgenic mice as a source of 
homogenous naïve T cells with defined antigenic specificities (Figure 4.3A). Activated cells 
were generated by stimulating CD8+ splenocytes for seven days with soluble peptide, GP100 for 
pmel T cells and SIY for 2C T cells.  
Three days after stimulation with a low dose of nano-aAPC,  8 ng total MHC-Ig, naive pmel T 
cells had not proliferated as measured by CFSE (Figure 4.1B - left), a vital dye that is diluted 
with each cell division. At the same dose, however, activated cells proliferated robustly (Figure 
4.1B – right). Nano-aAPC titration showed that naive cells had a higher threshold for nano-
aAPC-induced proliferation (8-10 ng of total MHC-Ig) than activated cells (less than 1.5 ng of 
total MHC-Ig) (Figure 4.1C).  
As control for aAPC size, we assessed T cell proliferation induced by cell-sized, 4.5 μm diameter 
iron-dextran micro-aAPCs. Micro-aAPC induced naive T cell proliferation at lower doses (1.5-8 
ng MHC-Ig) than nano-aAPC as measured by CFSE dilution on day 3 (Figure 4.3B), with 
approximately 10-20 fold expansion on day 7 (Figure 4.3C).  
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Thus, while activated cells respond equivalently to nano- and micro-aAPC, naive cells have a 
higher threshold for nano-aAPC based stimulation. This difference was not driven by differences 
in protein density between micro- and nano-aAPCs, as micro-aAPCs with higher density (HD) 
and lower density (LD) than nanoparticles based aAPC induced identical proliferation when 
normalized for total MHC-Ig (Figure 4.3D-E). Since response was sensitive to particle size, we 
hypothesized that the difference in responses was due to differences in nanoparticle interactions 
with TCR nanoclusters on naive versus activated cells.  
Nano-aAPC Bind More TCR on Activated Than Naive Cells 
To examine nanoparticle binding to TCR, we synthesized nanoparticles bearing MHC-Ig alone, 
thus removing the binding contribution of anti-CD28. Binding experiments were performed on 
naive and activated T cells, which bound nanoparticles bearing cognate MHC-Ig specifically and 
with low background (Figure 4.4A).  
Nanoparticles were bound to naive and activated cells to equilibrium, followed by the addition of 
the anti-clonotypic 1B2 blocking antibody to prevent re-binding. Nanoparticles showed faster 
disassociation from naive cells (half life of 531 seconds ± 149) than activated cells (984 s ± 221) 
(Figure 4.1D, Table 5.2). 
Disassociation rates can be used to estimate the number of contacts between cells and 
multivalent ligands, with more contacts leading to slower disassociation[26]. Nanoparticle 
disassociation from cells was modeled as an exponential stochastic process, with disassociation 
of soluble MHC-Ig dimer used to derive parameters and validate the approach (see Table 5.2 for 
details). The off-rate of a single TCR-MHC contact was measured for soluble MHC-Ig dimer 
binding to naive cells (Figure 4.4C), which is effectively monovalent[10]. As expected, MHC-Ig 
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dimers disassociated more slowly from activated cells, leading to 1.7 estimated contacts (Figure 
4.1E), consistent with previous reports[10,26].  
Nanoparticle disassociation from naive cells was significantly slower than free MHC-Ig  (Figure 
4.4C), and 2-fold slower from activated cells than naive. Nano-aAPC thus made an estimated 6.8 
contacts with naive cells, compared to approximately double (12.6) on activated cells (Figure 
4.1E, Table 5.2). These numbers represent 11% and 22% of MHC-Ig dimers, respectively, 
attached to the surface of nano-aAPC.  
Increased TCR-MHC contacts per particle could lead to fewer available TCR, inhibiting binding 
and limiting the total amount of nanoparticles that bind to an individual cluster. Consistent with 
this prediction, activated cells bound two-fold fewer nanoparticles at equilibrium than naive cells 
across a wide range of particle concentrations (Figure 4.1F). This difference was not due to T 
cell receptor expression, which was equivalent on naive and activated T cells (Figure 4.3B).    
Together the two-fold increase in total nano-aAPC bound and two-fold decrease of the TCR-
MHC contacts engaged by naive cells suggest the binding model shown schematically in Figure 
4.1G. Naive cells bind more nano-aAPC utilizing fewer MHC contacts due to the small scale of 
TCR clusters prior to cell-nanoparticle contact. Activated cells, in contrast, bind fewer 
nanoparticles because each particle makes contact with more TCR.   
Magnetic Fields Drive Aggregation of aAPC and TCR/CD3  
Based on the hypothesis that nano-aAPC bound to small scale TCR clusters, we took advantage 
of nanoparticle binding to T cells to control TCR cluster aggregation, and thus T cell activation. 
An exogenous magnetic field was used to drive aggregation of paramagnetic nano-aAPC bound 
to naive cells. Nano-aAPC were bound to naive T cells at 4oC, then cultured at 37 oC between 
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two neodymium disk magnets generating a maximum field strength of 0.2 T. We predicted that, 
in an external magnetic field, paramagnetic iron-dextran aAPC would be magnetically polarized 
and attracted to each other[18], driving aggregation of TCR (Figure 4.5A). 
Cluster formation was assessed by confocal microscopy. After one hour of binding at 4oC, we 
either stained and fixed cells immediately (Time 0), or transferred cells to a 37 oC incubator for 
30 minutes in the absence or presence of a magnetic field. Cells were then stained with 
antibodies against LFA-1 (green), an adhesion molecule used as a control; CD3ε (magenta), a 
signaling component associated with TCR; and MHC-Ig (red), to visualize the nano-aAPC. 
Finally, cells were fixed and imaged. 
Prior to incubation at 37oC, aAPC and CD3ε were distributed in a punctate pattern on the 
membrane, with small clusters diffusely distributed across the cell surface (Time 0, Figure 4.5B 
top left). LFA-1 was uniformly distributed across the cell. The LFA-1 and CD3ε staining 
patterns were identical to those at Time 0 after thirty minutes of incubation with non-cognate Kb-
SIINF particles (Non-Cognate, Figure 4.5B top right). In the absence of a magnetic field, 
incubation with cognate nano-aAPC did not drastically alter the distribution of either LFA-1, 
aAPC, or CD3ε (No Magnet, Figure 4.5B bottom left). However, after 30 minutes in a magnetic 
field, large aggregates of nano-aAPC formed on the membrane (Magnet, Figure 4.5B bottom 
right). These clusters of nano-aAPC co-localized with similarly sized clusters of CD3ε. The 
control molecule LFA-1 maintained a diffuse pattern across the membrane, indicating that CD3ε 
aggregation was due to its association with aAPC. 
To characterize the size and number of aggregates induced by aAPC, a particle-identification 
program was developed in ImageJ. The program was able to identify both diffuse, punctuate 
 150 
clusters from Time 0 cells (Figure 4.5C left), and larger aggregates induced by magnetic fields 
(Figure 4.5C right). 
Incubation in a magnetic field significantly increased TCR aggregation, beyond that seen after 
incubation with nano-aAPC alone, and led to larger CD3 complex aggregates on cells. Mean 
cluster area prior to incubation at 37oC was 0.30 ± 0.03 μm2, and this did not change after 
incubation with non-cognate nano-aAPC (Figure 4.5D). aAPC alone increased cluster size to a 
mean of 0.52 ± 0.06 μm2 (p<0.001). Clustering was further enhanced in a magnetic field to a 
mean size of 0.73 ± 0.11 μm2 (p<0.001 compared to No Magnet). The mean number of clusters 
per cell decreased from 6.5 ± 0.6 at Time 0 to 3.0 ± 0.2 with a magnetic field (Figure 4.5E). 
Nano-aAPC disassociation rate after culture in a magnetic field did not increase (Figure 4.4D), 
suggesting aggregate formation was not associated with an increase in TCR/MHC contacts, but 
rather aggregation of TCR nanoclusters bound to aAPC. In summary, aAPC aggregation induced 
by a magnetic field led to a 2-fold increase in TCR/CD3 aggregate size and a 2-fold decrease in 
the number of aggregates per cell. 
Activation in a Magnetic Field Enhances Proliferation of Naïve T cells  
To assess whether activation of T cells by aAPC was enhanced by culture in a magnetic field, 
CFSE-labeled pmel T cells were incubated with increasing doses of Db-GP100 nano-aAPC and 
cultured with or without an external magnetic field. Naïve T cells proliferated in a magnetic field 
at doses of nano-aAPC that induced minimal proliferation otherwise (Figure 4.6A). After 
incubation with nano-aAPC bearing 5 ng MHC-Ig, 29% of cells in culture had proliferated, 
compared to 89% of cells in a magnetic field. Proliferation at day 7 was up to 4 fold greater 
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compared to no magnet controls (Figure 4.6B). Culture in a magnetic field without aAPC did 
not lead to T cell proliferation (data not shown). 
The duration and strength of magnetic field stimulation required for optimal expansion were 
assessed by the addition and removal of neodymium magnets of varying size. One to three hours 
in a magnetic field (Figure 3C-3D) and a field strength of 0.2 T or more (Figure 4.6E-5.6F; 
Figure 4.7) drove 10-fold T cell expansion after one week.   
Magnetic field enhanced aAPC stimulation also enhanced expansion of antigen-specific T cells 
from endogenous, polyclonal T cell populations. We synthesized nano-aAPC bearing the Kb-Ig  
dimer loaded with the Trp2 peptide, which is specific for the Trp2 melanoma antigen. CD8+ 
splenocytes from wild type B6 mice were cultured with a limiting dose of aAPC and, after seven 
days, antigen-specific T cells were analyzed . Nano-aAPC alone, at this dose, did not induce 
expansion of antigen-specific T cells, as determined by comparing cognate Kb-Trp2 binding  to  
non-cognate Kb-SIINF binding (Figure 3G and Figure 4.8). When incubated with T cells in a 
magnetic field, however, aAPC generated approximately 3.4% antigen specific T cells after a 
single week (Figure 4.6G). This resulted in approximately 36,000 Trp-2 specific cells generated 
from a pool of 10x106 precursor cells (Figure 4.6H). With CD8 precursor frequencies estimated 
to be on the order of 10-800 per 10 million[27], this suggests 450 to 3,600-fold expansion in 
culture, comparable to the 1000-fold precursor expansion seen with viral infection in vivo[28].  
Magnetic Field Enhanced T cell Activation for Adoptive Immunotherapy 
The potential for enhancing stimulation of antigen-specific cells led us to study magnetic field 
enhanced aAPC stimulation prior to adoptive transfer in vivo. Thy 1.1+ pmel T cells were 
activated in vitro with aAPC in the presence or absence of a magnetic field and adoptively 
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transferred into wild type, Thy1.2+ recipient mice (see schematic Figure 4.9A). Seven or 
twenty-one days after adoptive transfer, mice were sacrificed and assessed for adoptively 
transferred, Thy1.1+ cells. 
Magnetic field enhanced nano-aAPC stimulation resulted in robust expansion of the transferred 
T cell population. On day 7, 3.1% of T cells in the spleen were Thy1.1+ for T cells stimulated in 
a magnetic field, compared with 0.6% for cells stimulated with aAPC but no magnetic field, and 
0.2% for untreated T cells alone that were not stimulated prior to adoptive transfer (p<0.01, 
Figure 4.9B-C). The largest percentage of cells was observed in the spleen on day 7 (Figure 
4.9C). The total Thy1.1+ cells in all organs examined reached approximately 1×106 for the 
magnetic field enhanced group (Figure 4.9D) on day 7, compared to less than 2×105 for the no 
magnet group. This 5-fold enhancement was roughly consistent with the enhancement seen in 
vitro. While fewer cells were seen on day 21, T cells activated by aAPC in a magnetic field 
established a detectable population in lymph nodes (0.15%), compared to 0.04% from T cells 
activated by aAPC alone and 0.01% from cells that were not stimulated at all (p<0.05, Figure 
4.9B-D).  
The functional consequences of magnetic field enhanced T cell stimulation were studied by 
treatment of B16 melanoma, a poorly immunogenic tumor with a high threshold for immune 
rejection[29]. Pmel T cells were adoptively transferred into mice bearing established 
subcutaneous B16 tumors ten days after tumor injection (Figure 4.9E) and transient 
lymphopenia was induced by sublethal irradiation (500 cGy) of mice one day before adoptive 
transfer as per standard approaches to adoptive immunotherapy[22,23]. 
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Tumor-specific T cells activated by aAPC in a magnetic field strongly inhibited tumor growth 
compared to no treatment controls, T cells alone and T cells stimulated by aAPC without a 
magnetic field (p<0.0001 treatment effect by two-way ANOVA, Figure 4.9F). At day 18, mice 
treated with magnetic field enhanced T cells had 8 to 10-fold smaller tumors than untreated or no 
magnet T cell treated mice. Similarly, magnetic field enhanced T cells significantly improved 
host survival, with 6/8 mice surviving and 4/8 having no detectable tumor at Day 28 post 
injection (p<0.001, Mantel-Cox, Figure 4.9F).  
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4.4 Discussion 
Receptor triggering by nanoparticles depends on poorly understood interactions at the 
membrane-nanoparticle interface[9], with unique features not present in other systems. We 
demonstrate that nanoparticles but not cell-sized particles are sensitive to TCR clustering 
controlled by the T cell activation state. Based on this hypothesis,  we show that an applied 
magnetic field leads to aggregation of TCR clusters, and in turn enhanced T cell proliferation in  
vitro and in vivo. Thus, nanoscale T cell activation platforms can be used to sense and 
manipulate the spatial organization of the T cell membrane.  
Particle size considerations also include the high degree of local curvature on a nanoparticle 
compared to microparticle surface, which limits the interaction of neighboring ligands with the 
cell membrane. Furthermore, cell-sized platforms may mimic the stable contact surface and 
directional cues observed during cell-cell contact, as seen during asymmetric cell division[30,31] 
or immune synapse formation[32]. In contrast to micron-sized interactions, many nanoparticles 
can engage a single cell, providing multi-directional spatial cues with no single contact surface. 
These features motivate the design of approaches like magnetic clustering, which both 
compensate for the weaknesses and exploit the unique strengths of nanoscale particles. 
Despite the challenges of designing nanoparticle platforms, their biocompatibility makes them a 
preferred platform for adoptive immunotherapy, as they are less likely than larger particles to 
induce tissue infarction or inflammation when co-injected intravenously with T cells[33]. Iron-
dextran nanoparticles are available in GMP-grade formulations, and cell isolation using magnetic 
enrichment followed by infusion is already a staple of cellular therapy[34,35]. The magnetic 
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fields generated for cell isolation are stronger than those used in this study, and magnet induced 
receptor aggregation could thus be incorporated into already-existing immunotherapy protocols. 
The use of nano-aAPC with an applied magnetic field allowed us to activate naive T cell 
populations, which were otherwise poorly responsive to stimulation. Naive T cells have been 
shown to be more effective than more differentiated subtypes for cancer immunotherapy[36–38], 
with higher proliferative capacity and greater ability to generate strong, long-term T cell 
responses. However, naive precursors are rare, at approximately 1 in 105 CD8+ cells[39], and 
there exists a need for methods that can rapidly generate large numbers of antigen specific cells 
without repeated stimulation, which exhausts proliferative capacity[40]. Thus, nano-aAPC could 
potentially be coupled to magnetic enrichment protocols to increase the yield of antigen-specific 




Figure 4.1: Nano-aAPC Binding to Naive and Activated Cells 
(A) Schematic of nano-aAPC synthesis by coupling MHC-Ig dimers and co-stimulatory anti-
CD28 to iron-dextran nanoparticles. (B) Proliferation of naive (left) and activated (right) pmel T 
cells measured by CFSE dilution 3 days after stimulation with nano-aAPC presenting 8 ng of 
Db-GP100 to 106 T cells. Unstimulated controls are shown in grey. (C) Naive (red) and activated 
(blue) cells were counted to measure fold expansion seven days after stimulation with titrated 
doses of nano-aAPC. Nano-aAPC presenting 8 ng or less of MHC-Ig induced minimal 
proliferation in naive cells (*, p < 0.01) compared to activated T cells. (D) Disassociation of 
Alexa-647, Kb-SIY labeled nanoparticles; time 0 represents addition of 1B2 blocking antibody 
to prevent re-binding. Data representative of three experiments, see Supplementary Table 1. (E) 
Mean TCR-MHC contacts made between Kb-SIY dimers (MHC-Ig) and Kb-SIY nanoparticles 
(Particle) with naive (red) and activated (blue) cells as estimated from disassociation data (see 
Supplementary Table 1). (F) Equilibrium binding of increasing doses of nano-aAPC (measured 
by total MHC-Ig presented) to naive (red) and activated (blue) cells. (G) A binding model that 
explains increased equilibrium binding and increased particle off-rate observed with naive cells. 
Naive cells bind more beads with fewer contacts per bead than activated cells.  
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 Figure 4.2. Characterization of Protein Bound to Nano- and Micro-aAPC By Fluorescence. 
(A) Mean fluorescence intensity (MFI) of antibody bound to nanoparticles and controls. Nano-
aAPC and Micro-aAPC (cell-sized) particles were incubated with excess of monoclonal anti-
mouse IgG1 (for MHC-Ig) and anti- antibody conjugated with PE for 30 minutes, and washed on 
a magnetic column. Fluorescent antibody bound to particles was detectable above background 
samples, including micro- and nano- particles not stained with anti-IgG1 (No Ab) and particles 
which were not coupled to protein and stained with anti-IgG1 (Blank). Protein concentration in 
solution was determined by comparison to an IgG1-PE standard curve. Fluorescence is shown 
for anti-IgG1 and is representative of three experiments. HD – High Density. LD – Low Density. 
(B) Particles in solution do not interfere with antibody fluorescence. Soluble anti-IgG1 PE 
antibody was titrated and measured for fluorescence. Similar fluorescence emission was 
observed when soluble antibody was measured in the presence of blank micro- and nano-
particles. (C) Washing in magnetic column was sufficient to remove free antibody. After three 
washes (Fraction 3), fluorescence is not detectable above background. Fluorescence of 0.63 
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ug/ml free antibody is provided for comparison. (D) Nanoparticle concentration was 
characterized by iron absorbance at 405 nm. Particle concentrations were determined by 
Nanoparticle Tracking Analysis. Titrations of nanoparticles were measured for absorbance and a 

























0.1 29 ± 6 214 ± 12 -- -- 
Micro HD 4.5 49,900 ± 
2800 
196 ± 11 27,200 ± 
4600 
107 ± 18 
Micro LD 4.5 15,300 ± 
1000 
60 ± 11 14,400 ± 
4500 
56 ± 17 
 
The amount and density of MHC-Ig and anti-CD28 on the surface of micro- (cell-sized) and 
nano-aAPC. Protein was quantified as described in Supplementary Figure 1, and particle 
concentration determined by counts (micro-aAPC) or Nanoparticle Tracking Analysis (nano-
aAPC). High (HD) and low (LD) density particles were synthesized by varying amount of 




Figure 4.3. pMEL T cell Proliferation Induced by Micro-aAPC 
(A) CD8+ pMEL splenocytes include a population of memory-phenotype, CD44 positive cells 
(representative percentage shown as percentage of CD8, left). CD44lo naive cells were isolated 
by a no-touch negative selection enrichment with anti-CD44 antibody in a magnetic enrichment 
column. (B) Proliferation of Naive CD44lo (left) and activated (right) cells by CFSE dilution 
stimulated three days with micro-aAPC (dark red and blue lines) and nano-aAPC (light red and 
blue lines) or unstimulated (grey lines). Micro- and nano-aAPC were used at doses presenting 
equivalent total amount of MHC-Ig (8 ng). Nano-aAPC data are re-produced from Figure 1. (C) 
Proliferation of naive (red) and active (blue) cells seven days after stimulation with indicated 
doses of micro-aAPC. (D) Effect of MHC-Ig density on micro-aAPC induced stimulation. High 
density (HD, blue) and low density (LD, red) micro-aAPC were normalized for total MHC-Ig (4-
16 ng). See Supplementary Table 1 for density. Proliferation assessed by CFSE dilution three 
days after activation. (E) Fold expansion of samples shown in D seven days after activation, 




Figure 4.4. Additional Binding Figures 
(A) Kb-SIY only  nanoparticles binding to cognate 2C T cells. Binding to activated cells, seven 
days after peptide activation (activated, blue, MFI 89) as compared to naive, CD44lo isolated 2C 
T cells (naive, red, MFI 179) and control non-cognate CD44lo pmel T cells (non-specific 
binding, grey, MFI 21). Binding is characterized as mean fluorescence intensity of Alexa 647 
labeled particles bound to cells. (B) Surface TCR expression of naive (MFI 137) and activated 
(MFI 128) cells measured with fluorescent anti-TCRβ. (C) Disassociation of Kb-SIY MHC-Ig 
dimers from activated (dark blue) and naive (dark red) cells. Disassociation of nano-aAPC from 
activated (light blue) and naive (light red) cells are reproduced from Figure 1 for comparison. 
(D) Disassociation curves of nano-aAPC bound to naive CD44low cells before (red) and after 








Naive 8.9 ×10-3 78 1 
Activated 5.2 ×10-3 112 1.7 
Nanoparticle Naive  (2.0 ± 0.5) × 10-3 531 ± 149 6.8 
Activated (0.9 ± 0.2) × 10-3 984 ± 221** 12.6 
 
AOff-rates experiments were performed by incubating naive or activated 2C TCR transgenic T 
cells with APC-labeled MHC-Ig or APC-labeled nanoparticles bearing Kb-SIY alone. After 
incubation for one hour at 4oC, cells were washed, a Time 0 fluorescence measurement was 
taken, and 1B2, an anti-clonotypic antibody, was added to prevent re-binding. Fluorescence 
measurements were then repeated at 2-10 minute intervals. Off-rates were calculated from a one-
dimensional exponential fit in GraphPad Prism. 
BHalf-lives were derived from off-rates in column A. Particles bound to activated cells had a 
significantly longer half-life (p<0.02 by paired t-test, where measurements were paired by 
experiment) than particles bound to naive cells. Three experiments were performed for each 
condition. 
CUnbinding of individual MHC-Ig on either dimer or particle can be stochastically modeled as a 
Poisson (aka memoryless or exponential) Process. For a Poisson Process with rate constant r, the 
departure time of the nth event is characterized by a gamma distribution with shape parameter n 






𝑒−𝑟𝑡, 0 ≤ 𝑡 < ∞ 
The mean of this distribution 𝐸[𝑡] =  𝑛 𝑟⁄ . If MHC-Ig dimer is assumed to make one contact with 
a naive T cell [1], then r can be estimated from the off-rate of MHC-Ig on naive cells (8.9×10-3). 
Thus, for any given condition, 𝐸[𝑡] is derived from the half-life of MHC-Ig dimer or particle on 
naive or active cells (𝑡1
2⁄
), and r is assumed constant. The number of TCR-MHC contacts is 







The true number of contacts is likely to be higher than this estimate, as MHC-Ig are likely to 




Figure 4.5. Clustering of aAPC and CD3ε Induced by a Magnetic Field 
(A) Schematic of magnet-induced clustering. We hypothesized that an external magnetic field 
generated by neodymium disc magnets (left) would induce aggregation of receptors bound to 
polarized paramagnetic beads (right). (B) After nano-aAPC binding (Time 0), cells were 
incubated for thirty minutes in the presence or absence of a magnetic field. Cells were 
subsequently stained with antibodies against LFA-1 (green), MHC-Ig on nano-aAPC (red), and 
CD3ε (magenta) and fixed prior to confocal imaging. Representative images are shown for cells 
prior to incubation (Time 0, top left), cells incubated with non-cognate particles (Non-Cognate, 
top right), cells incubated with cognate nano-aAPC (No Magnet, bottom left), and cells 
incubated with cognate nano-aAPC in a magnetic field (Magnet, bottom right). (C) Aggregate 
detection shown for representative images from Time 0 group (two on left) and Magnet group 
(two on right). White outlines represent borders of CD3 clusters (magenta) identified by 
algorithm. (D) Average cluster area identified with cluster detection algorithm (15 cells/group). 
The No Magnet group had significantly larger clusters than Time 0 (*, mean difference 0.22 
μm2), and the Magnet group had significantly larger clusters than both Time 0 (**, mean 
difference 0.46 μm2, p < 0.0001 by ANOVA with Tukey post-test ) and No Magnet (**, mean 
difference 0.24 μm2). (E) Cells in No Magnet group had fewer clusters per cell than Time 0 (*, 
mean difference 5.8 clusters) and Magnet group cells had fewer clusters per cell than No Magnet 
(**, mean difference 1.9 clusters, p < 0.001 by ANOVA with Tukey post-test).  
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Figure 4.6: Magnet-enhanced Nano-aAPC Stimulation Leads to Robust T cell Proliferation 
In Vitro. 
(A) Pmel T cell proliferation assessed by CFSE dilution three days after stimulation with doses 
of nano-aAPC presenting a total of 2, 5, and 10 ngs of MHC-Ig in the presence (red) or absence 
(black) of a 0.2 T external magnetic field. (B) Fold expansion of samples described in A assessed 
by cell counts seven days after stimulation. (C) Pmel T cells incubated with 5 ng MHC-Ig dose 
of nano-aAPC and 0.2 T magnetic field for 0-24 hours. Proliferation assessed by CFSE dilution 
at day 3. (D) Fold expansion of samples from C seven days after stimulation. (*, p<0.001 by 
ANOVA with Tukey post-test) (E) Pmel T cells incubated with 5 ng MHC-Ig dose of nano-
aAPC and magnetic fields of increasing maximal strength (0.15-0.225 T) generated by 
neodymium magnets of increasing thickness for twenty-four hours. (F) Proliferation of samples 
from E seven days after stimulation (* greater than no magnet, ** greater than 0.15 T magnet, 
p<0.001 by ANOVA with Tukey post-test). (G) Antigen-specific expansion of endogenous 
CD8+ lymphocytes from wild type mice after stimulation with Kb-Trp2 nano-aAPC in the 
presence or absence of a 0.2 T magnetic field for twenty-four hours. (H) Quantity of Kb-Trp2 
antigen specific cells generated by nano-aAPC stimulation in presence (red) or absence (white) 




Figure 4.7: Magnetic Field Strength Generated in Culture By Neodynium Disk Magnets 
Density plots of field strength in culture as estimated by finite element analysis with FEMM 
(Finite Element Method Magnetics) software. Disk magnets (magenta) ¾”, ½”, and ¼” in 




Figure 4.8. Non-cognate MHC Binding After Nano-aAPC Stimulation. 
Non-cognate (Kb-SIINF) staining of wild-type CD8+ lymphocytes after stimulation with Kb-
Trp2 nano-aAPC in the presence or absence of a 0.2 T magnetic field for twenty-four hours. 




Figure 4.9: Magnet-Enhanced T Cell Expansion In Vivo and Increased Efficacy of 
Adoptive Immunotherapy 
(A) Schematic of adoptive immunotherapy model. CD44lo, CD8+ T cells from Thy1.1+ pmel 
TCR transgenic mice were stimulated in vitro for 24 hours in the presence or absence of nano-
aAPC (5 ng total MHC-Ig) and magnetic field prior to being adoptively transferred into wild 
type, Thy1.2+ B6 recipient mice (6 mice per group). Mice received recombinant IL-2 ip on days 
1 and 2. Seven and twenty-one days after adoptive transfer, recipient mice were sacrificed (3 per 
timepoint) and cells from peripheral blood, inguinal lymph nodes, and spleen were stained for 
CD8 and Thy1.1 to quantify expansion of transferred cells. (B) Representative FACS plots from 
day 7 spleens and day 21 lymph nodes are shown, with frequencies of Thy1.1 cells reported as 
percentage of CD8+ cells. (C) Frequencies of Thy1.1+ cells were significantly higher in mice 
given T cells stimulated with nano-aAPC in a magnetic field (red) compared to nano-aAPC with 
no magnet (grey) and no stimulation (white)  (p<0.001 for treatment effect by two-way ANOVA 
for day 7 and 21). (D) Total Thy1.1+ cells in all organs combined on Day 7 and Day 21. Five-
fold more cells were observed in the nano-aAPC + Magnet group than nano-aAPC alone group 
on day 7 (p < 0.05 by student’s t-test), but did not reach significance on Day 21 (p = 0.15). (E) 
Schematic of treatment of established tumors with magnetic field enhanced adoptive 
immunotherapy. B16 melanoma tumors were injected subcutaneously into B6 mice, and mice 
were treated with partially myeloablative total body irradiation on day 9. 5×10 5 CD44lo, CD8+ 
pmel T cells stimulated for 24 hours with either nano-aAPC (5 ng total MHC-Ig) in a magnetic 
field (red) or nano-aAPC with no magnet (black) were transferred on Day 10. T cell alone (grey) 
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and untreated (unfilled) groups were used as control (8 mice per group). Mice received 
recombinant IL-2 ip on days 10 and 11. (F) Treatment with magnet-enhanced nano-aAPC 
activated T cells led to attenuated tumor growth compared to no magnet and control groups 
(p<0.0001 for treatment effect by two-way ANOVA). Arrow indicates timepoint of adoptive 
transfer (day 10). Mice were censored if dead or tumors were greater than 150 mm2. Treatment 
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5 Streamlined Enrichment and Expansion Using Nano-
aAPC for Adoptive Immunotherapy 
5.1 Introduction 
The adoptive transfer of large numbers of tumor-specific T cells can mediate rejection of 
otherwise treatment resistant cancers[1,2]. Antigen-specific cells can be isolated and expanded 
from tumor specimens, or generated by repeated in vitro stimulation with antigen followed by T 
cell cloning [3,4].  The addition of high intensity lymphodepletion with chemotherapy or 
radiation prior to T cell transfer has significantly enhanced therapeutic efficacy [1,5,6] by 
depleting immunosuppressive regulatory cells and decreasing competition for 
lymphoproliferative signals such as common gamma chain cytokines [2,7]. 
Decreased competition for cytokines in a lymphopenic environment triggers a burst of antigen-
independent proliferation termed “homeostatic expansion.” In an adoptive immunotherapy 
setting, this competition can come from either reconstituting host T cells, or irrelevant T cells 
that are adoptively transferred simultaneously with the antigen-specific cells of interest. For 
example, the co-transfer of 10-50 million bystander T cells into a sublethally irradiated host 
significantly attenuates homeostatic expansion of both CD4+ and CD8+ T cells in a dose-
dependent manner [8–10]. This motivates a desire to transfer highly pure populations of antigen-
specific T cells.  
Unfortunately, the repeated stimulation and 4-6 weeks of in vitro culture necessary to generate T 
cell cultures of high antigen-specific number and frequency also exhaust T cell proliferative 
capacity[11]. Exhaustion manifests as a terminally differentiated effector phenotype with 
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telomere shortening, characteristics associated with treatment failure in clinical trials[6,12]. In 
contrast, naive or “stem-like” T cells which proliferate robustly in the host are more potent 
mediators of tumor regression[11,13,14]. 
Lengthy culture also increases the cost and labor of adoptive immunotherapy, which limits 
applicability outside the research setting. Furthermore, existing T cell culture techniques rely on 
endogenous APC or feeder cells, which are themselves a complex biologic that must be 
generated for each individual patient[15]. The dendritic-cell based vaccine Provenge, the first 
FDA-approved immunotherapy for prostate cancer, costs approximately $93,000/patient[16].  
Thus, optimal T cell populations would be derived from naive cells, have a high frequency of 
antigen-specific cells, would not require use of endogenous APC, and have not gone through 
repeated stimulations and prolonged culture. We hypothesized that this could be accomplished 
by enrichment of tumor-specific cells prior to activation with a synthetic bead-based platform. 
To streamline and simplify this procedure, we developed a nanoscale artificial Antigen 
Presenting Cell platform (nano-aAPC) capable of inducing antigen-specific T cell expansion in 
vitro and in vivo [17]. Nano-aAPC are functionalized with MHC-peptide that can bind and 
activate TCR, iron-oxide cores to capture bound cells in a magnetic column, and co-stimulatory 
anti-CD28, thus enriching and expanding cognate cells simultaneously. We show that this 
process, termed enrichment and expansion, can generate large numbers of high-frequency T cells 
from naive precursors. Furthermore, we explore T cell expansion after adoptive transfer and the 
ability of generated T cells to mediate tumor rejection. 
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5.2 Materials and Methods 
Mice and reagents 
2C TCR transgenic mice were maintained as heterozygotes by breeding on a C57/BL6 
background. pMEL TCR/Thy1a Rag-/- transgenic mice were a gift from Nicholas Restifo 
(National Institutes of Health, Bethesda, MD) and maintained as homozygotes. C57BL/6j and 
Nu/J mice were purchased from Jackson Laboratories (Bar Harbor, ME).  All mice were 
maintained according to Johns Hopkins University’s Institutional Review Board.  Fluorescently 
labeled monoclonal antibodies were purchased from BioLegend (San Diego, CA).  
Preparation of MHC-Ig Dimers  
Soluble MHC-Ig dimers, Kb-Ig and Db-Ig, were prepared and loaded with peptide as 
described[50]. Briefly, Kb-Ig molecules were loaded with peptide by stripping at alkaline 
condition (pH 11.5), and then refolded in the presence of 50 fold excess peptide. Db-Ig molecules 
were stripped under mildly acidic conditions (pH 6.5) and refolded in the presence of 50 fold 
molar excess peptide and 2-fold molar excess of human 2-microglobulin. Human A2-Ig was 
passively loaded in the presence of excess M1 peptide [51]. Peptides SIIN (SIINFEKL, derived 
from ovalbumin protein),  and GP100 (KVPRNQDWL, from melanocyte GP100 protein) were 
purchased from Genscript (Piscataway, NJ). Protein concentration was determined after labeling 
by size exclusion high performance liquid chromatography (HPLC).  
Nano-aAPC Synthesis  
Nanoscale iron-dextran aAPC were made by direct chemical coupling of MHC-Ig dimer and 
B7.1-Ig to biodegradable particles (Miltenyi Biotec). Micro-aAPC Synthesis 
Micro-aAPCs were fabricated as described previously[7] by direct chemical coupling of protein 
to 4.5 μm Dynal Magnetic Microbeads (Life Technologies, Carlsbad, CA). For the initial 
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coupling step, 25 μg anti-biotin antibody (Sigma, St. Louis, MO) was added to 100 million 
Microbeads in 0.1 M sodium borate buffer. After washing in a magnetic column, biotin labeled 
MHC-Ig and CD28 were added in equimolar amounts to form aAPC. 
Enrichment and Expansion  
For murine cell culture, cells were obtained from homogenized mouse spleens followed by  
hypotonic lysis of RBC. Cytotoxic lymphocytes were isolated using a CD8 no-touch isolation kit 
and magnetic enrichment column from Miltenyi Biotec (Cologne, Germany) and if necessary 
labeled with carboxyfluorescein succinimidyl ester (CFSE) for 15 minutes at 37oC, then washed 
extensively. Ten million CD8+ T cells and 20 μL of nano-aAPC bearing the antigen of interest 
were incubated in 300 μL of B media for one hour at 4oC. The resulting mixture was passed over 
a Miltenyi MACS MS column and the positive fraction eluted in media and directly cultured 
without washing. Media was based on RPMI media supplemented with T cell factor (TF), a 
cytokine cocktail of conditioned media harvested from stimulated human PBMC [6]. Frequency 
of antigen-specific cells was characterized seven days later by staining with cognate Pentamer 
(ProImmune) or MHC-Ig dimer. 
Effect of Nano-aAPC on In Vivo T cell Expansion and Inhibition of Subcutaneous Tumor Growth   
Thy1.1+ pmel or WT T cells were adoptively transferred into B6 Thy1.2+ wild type hosts. Mice 
were treated both the day of and the day after adoptive transfer with 30,000 units intraperitoneal 
IL-2. Seven days adoptive transfer, three mice per group were sacrificed and lymphocytes were 
isolated from peripheral blood, spleen, and inguinal, cervical, and axillary lymph nodes, and 
tumor, then stained with anti-Thy1.1 antibody.  
Tumor rejection experiments were performed as above, except 3x105 B16 melanoma cells were 
injected subcutaneously ten days prior to T cell adoptive transfer.  Transient lymphopenia was 
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induced by sublethal irradiation (500 cGy) one day before adoptive transfer with a MSD Nordion 
Gammacell dual Cs137 source (Johns Hopkins Molecular Imaging Center). Tumor growth was 
monitored at 2 day intervals using digital calipers, until tumor size was ∼150 mm2, at which 





Enrichment of Antigen-Specific Cells 
Enrichment and expansion are performed by incubating polyclonal CD8+ lymphocytes with 
nano-aAPC, passing the cell-particle mixture through a magnetic column, and eluting then 
culturing the magnet-bound fraction (Figure 5.1a). To assess efficacy of enrichment, a known 
number of Thy1.1+ pmel TCR transgenic T cells specific for Db-GP100 melanoma antigen were 
incubated at a 1:1000 ratio with Thy1.2+ CD8 T cells from B6 mice. The frequency of antigen-
specific cells increased more than 10-fold from 0.09% to 1.17% after enrichment with the 
highest dose of Db-GP100 nano-aAPC assessed (Figure 5.1b). Titration of nano-aAPC  of 
particles incubated with T cells increased the enrichment frequency and resulted in recovery of 
up 95% of pmel cells added to culture (Figure 5.1c).  
Enrichment of wild-type Db-GP100 cells from polyclonal CD8 splenocytes was assessed by 
staining with soluble MHC pentamer. Frequency of Db-GP100 cells was below detectable 
frequencies prior to enrichment, but increased to 0.30% afterward. The frequency of non-specific 
Kb-Trp2 cells did not increase (Figure 5.1d).  
Although micro-aAPC made from a 4.5 μm diameter iron-dextran particles mediated antigen-
specific T cell expansion, T cells formed frequently formed conjugates with non-cognate micro-
aAPC, resulting in little to no enrichment of antigen-specific cells (Figure 5.2). In contrast, 
nano-aAPC bound T cells with high specificity and low background; thus, nano-aAPC are a 
uniquely effective reagent for antigen-specific enrichment.  
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Expansion of Antigen-Specific Cells Following Enrichment 
We next sought to characterize antigen-specific T cell expansion after enrichment. Magnet-
bound fractions of enriched cells and nano-aAPC were eluted and cultured in vitro (positive 
fraction). To explore the effect of enrichment on proliferation, the enrichment procedure was 
“undone” in a control sample by collecting the negative fraction and adding it back to the 
positive fraction (Figure 5.3a). Seven days after enrichment with a Kb-Trp2 nano-aAPC, 17.6% 
of cells expanded from the positive fraction were Kb-Trp2 specific, compared to 1.46% of cells 
from the negative+positive, not enriched group (Figure 5.3b). Although the negative+positive 
sample contained more cells total, the enrichment procedure resulted in a 2-3 fold increase in 
total antigen-specific cells (Figure 5.3c). By analogy to enhanced expansion seen with 
lymphodepletion in vivo, we suggest this may be due to reduced competition for lymphotropic 
cytokines. 
After one week, 1.5x105 Trp2-specific cells were generated from 107 polyclonal CD8 T cells. 
Precursor frequencies for CD8 responses to foreign antigen range from 10-100/107[18], and may 
be even lower for the melanoma self-antigen Trp2; thus, a lower end estimate of Trp2-specific 
proliferation is between 1000 fold, comparable to proliferation after viral infection in vivo.   
Enrichment and expansion similarly yielded large numbers and high purity of cells specific for 
melanoma antigen Db-GP100, model antigen Kb-SIIN, and mammary carcinoma antigen Ld-A5 
(Figures 5.3d, 5.3e). Precursor frequencies for Db-GP100 have been estimated at 10 in 10 
million [19], indicating up to 5,000 fold proliferation, and 20-350 in 10 million for Kb-
SIINF[20], indicating up to 6,000 fold expansion.  
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Under selective pressure by the immune system, tumors down-regulate antigen or MHC 
expression, as is known to occur during cancer development[21], as a mechanism of immune 
escape. In mouse models of B16 melanoma, tumor recurrence is associated with loss of antigen 
expression [22,23], whereas adoptive transfer of T cells with multiple specificities can prevent 
this process and enhance treatment [24]. A streamlined procedure for generating T cells against 
three separate antigens was developed by enriching and expanding cells with a combined batch 
of Db-GP100, Kb-SIINF, and Kb-TRP2 bearing nano-aAPC. All three antigens generated robust 
responses when cultured simultaneously (Figure 5.3F). Although frequencies for each antigen 
generated during “triple-expansion” were lower than those observed when cultured individually, 
the total frequency of tumor-specific cells in the population was increased, and the number of 
antigen-specific cells generated was the same (Figure 5.3G).Thus, the effect of simultaneous 
culture of three antigens was additive. 
Magnet-Induced Clustering of nano-aAPC 
The robust expansion induced by nano-aAPC may be due in part to the effect of the magnetic 
field used during enrichment. We have previously shown that nano-aAPC bound to T cells in a 
magnetic field aggregate on the cell surface, inducing CD3 clustering, strong T cell activation 
and increased proliferation (Chapter 4). We thus visualized clustering of CD3ε and aAPC 
before and after passage through a magnetic enrichment column (Figure 5.4). CD3ε clusters 
increased in area from 0.43 ± 0.03 μm2 to 1.22 ± 0.34 μm2 during passage. Notably, cells spend 
only 5-10 minutes in a magnetic column at room temperature; incubating the cells for 30 minutes 
at 37oC did not lead to further increases in cluster size. Magnetic fields generated by the MACS 
enrichment magnet are quite strong, at approximately 1 T, which may explain why clustering 
was relatively rapid.  
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Future work to validate the effect of magnetic fields on enhancing proliferation will compare the 
Positive and Positive+Negative fractions of magnetic enrichment to cells which have not passed 
through a magnetic column.   
Nano-aAPC Induced Expansion of Co-Infused T cells 
The ultimate goal of enrichment and expansion is to generate an antigen-specific T cell 
population that can be re-infused for cancer immunotherapy. At Day 7, T cell cultures can be re-
enriched to further increase the frequency of antigen-specific cells. Re-enrichment increased 
antigen-specific frequency 4-fold, generated a 40% Trp2-specific population (Figure 5.5). 90% 
of antigen-specific cells were recovered after re-enrichment. Furthermore, nano-aAPC were 
retained in the positive fraction of the magnetic column and may be co-administered with T cells. 
Thus, re-enrichmet after one week of culture generates a combined product of nano-aAPC cell 
and 40% tumor specific for in vivo administration.  
The capacity of nano-aAPC to further expand T cells after co-administration in vivo was verified 
using pmel T cells as a model. The administration of one million pmel T cells with cognate nano-
aAPC led to 4% antigen specificity in peripheral blood 3 days after administration, although 
frequencies rapidly decreased thereafter (Figure 5.6A). T cells co-administered with nano-aAPC 
alone resulted in approximately 1% antigen-specificity. Furthermore, only T cells co-
administered with cognate nano-aAPC inhibited growth of B16 lung metastases administered 
three days previously, indicating nano-aAPC activation induced effector function (Figure 5.6B).  
As discussed, lymphodepletion prior to adoptive transfer improves retention of adoptively 
transferred cells by removing competition for proliferative cytokines. This phenomenon has been 
ascribed to antigen-independent homeostatic expansion. However, to demonstrate that decreased 
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competition can also enhance nano-aAPC-induced, antigen-driven expansion, we developed a 
pmel model where irrelevant cells in the host were removed by lymphodepletion, and the 
frequency of irrelevant bystander cells was varied in the donor cells. 105 pmel cells were co-
administered with either 106 or 107 bystander B6 cells to mimic the effects of nano-aAPC 
enrichment. Cells were transferred into either untreated animals or animals lymphodepleted the 
previous day with 500 cGy gamma radiation. Furthermore, all populations received nano-aAPC 
to drive antigen-specific expansion after transfer. 
Both lymphodepletion and decreasing bystander cells enhanced expansion. Frequency of pmel 
cells was approximately 5-fold higher in spleen and lymph nodes seven days after transfer 
(Figure 5.6C) with 106 bystanders compared to 107. Both sets of lymphodepleted animals had 
significantly higher frequencies of pmel cells (10-50 fold) than immunocompetent animals.  
As expected, increased numbers of total CD8+ lymphocytes were recovered from 
immunocompetent animals (21.4 million ± 1.7) compared to lymphodepleted animals (5.7 
million ± 1.2) (p<0.001 by t-test). Furthermore, lymphodepleted animals that received 107 
bystanders had slightly larger numbers of lymphocytes than those that received 106 bystanders 
(6.8 million ± 1.3 vs. 4.9 million ± 0.81, not significant). Nevertheless, the total numbers of 
antigen-specific cells generated was greater with lymphodepletion and decreased bystander 
animals by 16- and 4-fold, respectively (Figure 5.6D). 
Ogoing experiments seek to determine the relative contributions of homeostatic and antigen-
driven proliferation, as well as the effect of the enrichment and expansion protocol on expansion 
of endogenous antigen-specific cells. 
Tumor Rejection By Adoptive Transfer of Enriched+Expanded Cells 
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The inhibition of established B16 melanoma by adoptive transfer requires on the order of 105 
tumor-specific transgenic pmel cells[25]. Comparable numbers are achieved by 
Enrichment+Expansion from 10 million CTL WT naive precursors after one week in culture. 
Thus, we treated animals bearing 8 day established B16 melanoma with lymphocytes expanded 
for 5 days with Kb-Trp2 and Db-GP100 nanoparticles simultaneously. Mice were irradiated with 
gamma irradiation one day prior to adoptive transfer. 
Enrichment+Expansion treated animals had significantly less tumor growth than untreated or 
non-cognate (Kb-SIINF) treated animals (Figure 5.7). 2/8 treated animals completely eliminated 
tumor 30 days after treatment, whereas all animals in control groups were euthanized. This 
established than Enrichment+Expansion can generate sufficient cells to treat established 
melanoma after just one week. 
Ongoing experiments compare tumor rejection from Enriched (Positive) and Not Enriched 
(Positive+Negative) and No Magnet activated T cells. 
Immediate Reinfusion Without In Vitro Culture Is Not Sufficient For Tumor Rejection 
An even more streamlined approach to adoptive immunotherapy would involve the immediate 
re-infusion of enriched lymphocytes on Day 0 into hosts, since nano-aAPC can induce T cell 
expansion when co-injected with T cells. However, since CTL precursors exist on the order of 
10-100 per mouse, there may not be sufficient tumor-specific cells adoptively transferred using 
this strategy. 
10 million Thy1.1+ donor lymphocytes were enriched and immediately co-infused with Kb-Trp2 
nano-aAPC into irradiated, WT Thy1.2+ tumor-bearing mice. Seven days later, mice were 
sacrificed and the frequency of Thy1.1+, Kb-Trp2 binding T cells was assessed in the spleen and 
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tumor (Figure 5.8A). Although large numbers of adoptively transferred Thy1.1+ cells were 
detectable, no animal had greater than 0.11% Trp2-specific CTL in spleen; this animal is shown 
in Figure 5A. Most animals (4/6) had no detectable Trp2+ cells. Despite inducing robust 
expansion of co-injected pmel T cells (Figure 5.6), nano-aAPC did not induce robust antigen-
specific expansion.  
Furthermore, Enriched and immediately re-infused lymphocytes could not inhibit established 
B16 melanoma. Fourteen days after tumor injection, treated and untreated animals had similar 
subcutaneous tumor size (Figure 5.8B). 
To verify the need for the threshold of tumor-specific cell number required to inhibit melanoma 
growth in our hands,  we assessed inhibition of established B16 melanoma using increasing 
numbers of pmel T cells. 105 but not 104 or 103 pmel CTL co-infused with nano-aAPC 
significantly inhibited tumor growth (Figure 5C), validating the requirement to generate 
sufficient numbers of cells prior to transfer. T cells at all three doses could not inhibit tumor 
growth without co-infusion of nano-aAPC. 
5.4 Conclusions 
Adoptive cell transfer can mediate sustained, complete tumor rejection in melanoma. However, 
the expansion of ACT beyond the research setting requires the development of less expensive, 
streamlined approaches to generating tumor-specific T cells. aAPC are an off-the-shelf platform 
for simplifying T cell culture by eliminating the need to simultaneously culture autologous 
dendritic or feeder cells, which are themselves a complex biologic that must be assessed for 
safety and reliability. 
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Several sources of tumor-specific cells exist for adoptive immunotherapy. Tumor-infiltrating 
lymphocytes have been highly effective in trials, but cannot be cultured from all patients or most 
cancers. Polyclonal cell populations can be genetically engineered to express anti-cancer TCR; 
however, these TCR are derived from high-avidity responses in model patients or even 
humanized mouse responses. Thus, they have not undergone Central Tolerance mechanisms and 
can mediate destructive off- and on-target toxicity[26,27].  Cells derived from naive precursors 
have been described as the most effective immunotherapy subset, and autologous lymphocytes 
are likely to have a better safety profile than engineered TCR, but the process of generating 
tumor-specific T cells requires extensive culture that exhausts proliferative capacity and 
increases cost. 
We propose to uncouple this trade-off using enrichment prior to expansion, quickly generating a 
autologous T-cell/nano-aAPC product of large number and purity for infusion into cancer 
patients. While antigen-specific T cells can be enriched using MHC tetramers after T cell 
expansion [28,29], our platform simplifies this process by coupling enrichment and expansion in 
a single reagent. Furthermore, cross-linking of TCR by multimeric MHC in the absence of co-
stimulation can induce T cell apoptosis or anergy [30]. Thus, the use of a single platform for both 
T cell enrichment and activation has significant advantages over existing approaches. 
Furthermore, our approach attempts to generate maximal expansion after adoptive transfer by 
removing irrelevant cells. We show here for the first time that removal of bystander cells and 
lymphodepletion also improve antigen-specific (and not only homeostatic) expansion, 
presumably by reducing competition for proliferative cytokines. While antigen-specific 
expansion in the host could also potentially be enhanced by vaccination, professional APCs are 
significantly depleted as a result of lymphodepleting treatments [31,32]. Thus an artificial APC 
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Figure 5.1. Nano-aAPC Mediated Enrichment of Antigen-Specific T Cells 
A) Schematic of magnetic enrichment and expansion. Antigen-specific CD8+ T cells bound to 
aAPC are retained in a magnetic column in the “enrichment” step. Enriched cells are then 
activated by aAPC and proliferate in the “expansion” step. B) Nano-aAPC mediate antigen-
specific enrichment of cognate, Thy1.1+ pmel cells from a pool of thousand-fold more 
polyclonal, Thy1.2+ B6 splenocytes. C) Summary antigen-specific cell frequency and percent 
cells recovered after pMEL enrichment performed as in C with increasing amounts of nano-
aAPC. D) Enrichment of endogenous Db-GP100 splenocytes by nano-aAPC (top). Frequency of 




Figure 5.2. Micro-aAPC Are Not Effective For Antigen-Specific Enrichment 
A) Binding of Micro- (top) and Nano- (bottom) aAPC to cognate pMEL (red) or non-cognate 2C 
(blue) CD8+ T cells, characterized by fluorescent labeling of bound beads. No bead (grey) 
background is shown as control. B) Micro-aAPC do not enrich cognate cells. Thy1.1+ pmel cells 
were incubated at a 1:1000 ratio with polyclonal, Thy1.2+ B6 splenocytes, and enrichment was 
attempted using Db-GP100 microparticles. Frequency of Thy1.1+ cells did not significantly 
increase after enrichment. C) Summary antigen-specific cell frequency and percent of cells 
recovered, performed as in C with increasing amounts of micro-aAPC. D) Both micro-aAPC and 
nano-aAPC induce dose-dependent expansion of pmel cells. Particle amounts were normalized to 
total amount of MHC-Ig presented by particles as described in Chapter 4.     
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Figure 5.3. Expansion of Antigen-Specific T cells After Enrichment. 
A) Schematic of cell fractions used to assess expansion of cells after enrichment. Bead-bound 
antigen-specific T cells are bound to a magnetic column (positive fraction), whereas unbound 
cells pass through (negative fraction). The negative fraction can be added back to the positive 
fraction to un-do the effect of enrichment. B) Increased frequency of antigen-specific cells 
generated after seven days of culture by Kb-Trp2 nano-aAPC as a result of enrichment. Negative 
(left), positive (middle), and negative added back to positive (right) fractions were eluted and 
cultured for seven days, then stained with cognate Kb-Trp2 (top) and control Kb-SIINF (bottom) 
dimer. C) 10-15 fold increase in frequency of Kb-Trp2 cells (*, p<0.001 by t-test) and 2-3 fold 
increase in total Kb-Trp2 cells (p<0.05) when cells are enriched. D) Representative FACS plots 
(3 experiments each) of Db-GP100, Kb-SIINF, and Ld-A5 dimer expansion seven days after 
enrichment with cognate nano-aAPC. E) Summary of percent antigen-specific cells (left) and 
total antigen specific cells (right) after enrichment and activation with indicated nano-aAPC. F) 
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Three antigens (Db-GP100, Kb-SIINF, Kb-Trp2) enriched and expanded simultaneously. 
Representative FACS plots of antigen-specificity for each antigen from the same T cell culture. 
G) Comparison of antigen-specificity (left) and total antigen-specific cells (right) generated for 





Figure 5.4: Re-Enrichment on Day 7 
(A) A T cell culture enriched and expanded using Kb-Trp2 nano-aAPC seven days previously 
was harvested and re-enriched. Antigen-specific T cell frequency increased from 10% to 
approximately 40%.  
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Figure 5.5: CD3 Aggregation Induced By Magnetic Enrichment Column 
(A) Representative images of cells stained for LFA-1 (green), MHC-Ig on nano-aAPC (red), and 
CD3ε (magenta) before (top) and after (bottom) passage through a magnetic enrichment column 
(B) Average cluster area identified with cluster detection algorithm (20 cells/group). The Magnet 
and 30 Minutes in Magnet groups had significantly larger clusters than No Mag (p < 0.01 by 
ANOVA with Tukey post-test). The Magnet and 30 Minutes in Magnet groups also had 




Figure 5.6: Expansion After Adoptive Transfer 
(A) Expansion of one million Thy1.1+ pmel T cells after co-administration with cognate Db-
GP100 nano-aAPC (pink) was significantly greater than after co-admistration with non-cognate 
Kb-SIIN nano-aAPC, as measured by frequency in blood. (B) Cognate nano-aAPC stimulated 
pmel cells led to decreased numbers of melanoma metastases in animals given B16 iv three days 
prior to treatment. Animals treated with non-cogante aAPC + T cells, cognate aAPC had 
significantly larger numbers of metastases per lung. (C) Effect of depletion and decreased 
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bystander competition on expansion after adoptive transfer. B6 mice were untreated or 
lymphodepleted with 500 cGy gamma radiation one prior to adoptive transfer of pmel T cells. 
The effect of enrichment was modeled by the co-administration of either 106 or 107 irrelevant B6 
cells. Both lymodepletion and administration of fewer bystander cells increased the frequency 






Figure 5.7: Treatment of Established Melanoma With Enriched and Expanded CTL 
A) Cognate Kb-Trp2 and Db-GP100 Enriched+Expanded lymphocytes cultured for 5 days prior 
to adoptive transfer inhibited melanoma growth (p<0.01 by two-way ANOVA, 8 mice/group, 
red). Mice were injected with subcutaneous melanoma eight days prior and irradiated with 500 
cGy gamma irradiation one day prior.  Non-cognate Enriched+Expanded lymphocytes (black) 
did not inhibit tumor growth (compraed to untreated, gray). (B) Survival of animals from A; 
animals were euthanized when tumors reach greater than 150 mm2. 2/8 mice showed complete 
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rejection of tumors in the Kb-Trp2 and Db-GP100 treated group, which had significantly longer 
survival compared to non-cognate and untreated groups (p<0.01 by Mantel-Cox). 
 
Figure 5.8. Immediate Reinfusion of Day 0 Cells in Tumor Treatment  
A) FACS plots characterizing specificity of adoptively transferred Thy1.1 positive enriched and 
expanded cells. Cells from spleen (top right) and tumor (bottom right) were gated for CD8 
lymphocytes (left); antigen specificity was assessed by Kb-Trp2 pentamer and Thy1.1 antibody 
staining. The highest frequency measured, 0.11%, is shown. (B) Treatment of eight day 
established melanoma in mice irradiated one day prior with 500,000 Enriched, Kb-Trp2 nano-
aAPC co-infused cells. Tumor sizes at day 14 are shown. Controls include reconstituted 
Positive+Negative fractions (not enriched), unstimulated T cells, and untreated animals (5 
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animals/group). C) Subcutaneous B16 melanoma tumors treated with 105 ,  104, or 103 pMEL 
cells +/- nano-aAPC. Co-transfer of 105 or 103 pMEL cells with aAPC inhibited tumor growth 
compared to T cells alone (*, p < 0.05 by two-way ANOVA), whereas 104 cells with aAPC was 
not significant compared to 104 cells alone, but was significantly less than no treatment (**, 
p<0.05 by two-way ANOVA).  
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6 Particle Shape Dependence of CD8+ T cell Activation by 
Artificial Antigen Presenting Cells3 
6.1 Introduction 
 Geometry and spatial organization are critical components in many biological systems. 
The cytoskeleton, its organization, and the physical cues that it can transmit, result in dramatic 
                                                 
3 This chapter is reproduced in part from [add citation] with permission from the publisher, written in collaboration 
with Joel Sunshine and Jordan Green. 
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effects on cell fate[1]. This is seen within the immune system in a variety of ways including 
during the interaction of a T cell with an antigen presenting cell (APC), which is a critical 
determinant of T cell fate and effector function. With activation, APC such as dendritic cells 
have major changes in their cell morphology resulting in significant increases in their overall cell 
surface area facilitating interaction with naïve T cells to direct T cell fate. Once an initial contact 
has been made by a T cell and an APC or some other target cell, T cell activation is further 
modulated by the formation of the immune synapse, a large surface area of close membrane 
apposition between the DC and T cell membrane, with concomitant cytoskeletal rearrangement 
and clustering of surface proteins[2-6]. Materials science approaches have helped to elucidate 
how the spatial organization and clustering of ligands that make up this synapse are important[7]. 
Thus, taking into account the geometry and spatial organization at cell-cell interfaces is 
important in studying biological responses. 
Reductionist systems have facilitated the study of effective immune responses.  One such 
system is the acellular artificial antigen presenting cell (aAPC).  aAPCs have been made by 
coupling proteins required for T cell activation to particles.  Minimally, T cell activation requires 
two sets of receptor-receptor interactions. One interaction, Signal 1, is the binding of major 
histocompatibility complexes (MHC) or a surrogate, such as anti-CD3, to bind the T cell receptor 
(TCR). A second interaction, Signal 2, is the binding of co-stimulatory receptors on the APC, 
such as B7.1, to ligands on the T cell, such as CD28.  aAPC have been generated by coupling 
proteins that deliver Signal 1 and 2 to the surface of particles (Fig. 6.1A) made from a range of 
materials, including magnetic microparticles[8, 9], polystyrene particles[10], and PLGA 
microparticles[11-13]. Such systems have been broadly applied to tumor immunotherapy, 
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vaccination, and immunosuppression, and are amenable to in vivo or ex vivo T cell stimulation 
and offer possible novel translational approaches to immunotherapy[9, 14-19].   
While useful, the Signal 1 and 2 paradigms alone do not capture aspects of spatial 
organization or the geometry of interactions. Previous work developing aAPCs have not 
attempted to re-capitulate these aspects of APC behavior. As a result, all aAPCs tested thus far 
have used spherical particles for their aAPC platforms, which unlike DCs minimize surface area 
for a given volume (Fig. 6.1B).  
Further aAPC development may require incorporation of additional biomimetic cues 
beyond the presentation of signal 1 and signal 2 such as biomimicry of the surface density, 
dynamic protein spatial organization, and the geometry of the interface between the aAPC and 
the target.  These cues could potentially be incorporated into next-generation aAPCs by 
nanoengineering approaches including presentation of cues on fluid membranes or in a patterned 
manner and by utilizing non-spherical particle shapes[19, 20].  
Particle shape has only recently become a design parameter of interest in the field of 
material design for drug delivery. Shape can play a role in tuning the rate and mechanism of 
cellular uptake[21], can dramatically reduce internalization by phagocytic cells such as 
macrophages[22, 23], can change the biodistribution of the drug delivery vehicle[24, 25], and 
has been posited as potentially modulating the ability of a particle to bind a cell in part by 
increasing the surface area for interaction[24, 26]. In fact, a recent study by Barua et al. showed 
that antibody coated polystyrene nanorods had higher specific and reduced non-specific cellular 
uptake than spherical counterparts, demonstrating a significant relationship between particle 
shape and cell binding/unbinding [27].  
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A key consideration in cancer immunotherapy remains the efficient stimulation of 
antigen (Ag)-specific CTLs. In vivo, a criticial  interaction for generation of activated, effector  
CD8+ T cells  is the interaction between antigen presenting cells, such as dendritic cells or 
macrophages, with CD8+ T cells. In the development of acellular systems for T cellsstimulation, 
previous literature has focused predominantly on the proteins involved in the interaction between 
APCs and T cells[8, 9, 13, 28-30], and recent studies extended this to release of cytokines[12, 
31]. However, the biological interaction between T cells and their targets is distinctly not an 
interaction most appropriately represented by two interacting spheres. We hypothesized that non-
spherical aAPCs would offer improved activation of CD8+ T cells. To test this hypothesis, we 
adapted a film-stretching method for controlling the shape of microparticles made from poly 
(lactic-co-glycolic) acid (PLGA)[32] to generate ellipsoidal aAPCs with varying long axis 
lengths and aspect ratios (ARs)(Fig. 6.1C,D). To explore how particle shape might interact with 
particle dose and surface antigen density, we synthesized spherical and ellipsoidal aAPCs at 
different antigen densities, and then varied the particle dose, antigen density, and aAPC shape 
used to activate the T cells in vitro. To investigate the mechanism behind these effects, we 
performed confocal imaging to analyze  aAPC:T cell conjugate formation. Finally, we compared 
the ability of spherical and ellipsoidal aAPCs  in an in vivo melanoma tumor prevention model. 
6.2 Materials and Methods 
Film formation and particle stretching 
Lyophilized PLGA microparticles that were synthesized by single emulsion (see 
supplemental methods) were added to a solution containing 10% PVA and 2% glycerol by 
weight at 5 mg/ml (particles/ml solution). The solution was poured on a flat surface and allowed 
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to dry overnight. After drying, strips of the resulting film were cut out and placed on an 
aluminum-stretching device consisting of two aluminum blocks that can be separated by sliding 
on aluminum rods. The film and custom-made stretcher were placed in a 90°C oven for 10 
minutes and then the film was slowly stretched inside of the oven to the desired stretch ratio by 
separating the two blocks. After allowing the film to cool down to room temperature, the film 
was removed and dissolved in 10 ml of deionized water, then the particles were centrifuged 
(4000 rpm for 5 min) and washed 3x, and finally resuspended in deionized water, frozen, and 
lyophilized. Spherical particles in all experiments were also prepared similarly; they were heated 
along side of the ellipsoidal particles but simply not stretched. 
aAPC synthesis 
Soluble MHC-Ig dimers were prepared and loaded with peptide as described (see 
supplemental methods)[33]. Spherical and ellipsoidal microparticles were resuspended in 
coupling buffer (0.1M MES pH 6.0), and activated with EDC (1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide, Sigma-Aldrich) and sulfo-NHS (N-
hydroxysulfosuccinimide). As an example, 5 mg of microparticles were resuspended in 1 ml of 
coupling buffer and activated with 10 mg of EDC and 13 mg of sulfo-NHS for 15 min at 1000 
rpm on a multitube vortexer (VWR). Activated microparticles were then centrifuged, the 
supernatant was removed, and the activated particles were resuspended in 1 ml PBS (pH 7.4) and 
transferred to a 5 mL glass scintillation vial for coupling. As an example, 8 µg of MHC-dimer 
and 10 µg of anti-CD28 antibody (always in this ratio) were added to 2 µg of activated PLGA 
microparticles, and then the reaction was allowed to proceed in the cold room (4C) for 4 hours. 
After 4 hours, the aAPCs (here, 2 mg of aAPCs) were centrifuged and washed 2x with PBS, then 
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centrifuged, re-suspended in 200 µl of 0.2 mm-filtered sterilized 100 mg/ml endotoxin-free 
sucrose solution, frozen, and lyophilized overnight. 
In vitro CTL induction and CFSE dilution  
pMEL TCR/Thy1a Rag-/- transgenic mice were a gift from Nicholas Restifo (National 
Institutes of Health, Bethesda, MD) and maintained as homozygotes. C57BL/6j were purchased 
from Jackson Laboratories (Bar Harbor, ME).  All mice were maintained according to Johns 
Hopkins University’s Institutional Review Board. The pMEL T cells used were obtained from 
homogenized pMEL mouse spleens after depletion of RBC by hypotonic lysis. CD8+ T cells 
were isolated using a CD8-negative isolation kit and magnetic enrichment column from Miltenyi 
Biotec (Cologne, Germany) and labeled with carboxyfluorescein succinimidyl ester (CFSE) for 
15 minutes at 37C, then washed extensively. Cells and aAPCs at the indicated amounts and 
dosages were mixed and cultured for 4-7 days in complete RPMI media supplemented with T 
cell factor, a cytokine cocktail harvested from human plasma[34]. Cell proliferation was 
quantified by manual cell counting, and final T cell count was divided by the initial T cell count 
for fold-change data. 
aAPC-T cell conjugate formation evaluation 
For confocal imaging, PLGA microparticles with encapsulated 5(6)-carboxy-
tetramethylrhodamine dye (TAMRA, Nova Biochem, San Diego, CA) were synthesized (see 
supplemental methods). These labeled particles were then cast into a film, and the film stretching 
and subsequent sythesis of aAPC from spherical and ellipsoidal TAMRA-loaded particles were 
done as before. 1x106 CFSE-labeled CD8+ T cells were incubated with 1 mg spherical or 
ellipsoidal aAPC for 60 minutes at 37oC in a No. 1.5 glass bottom dish (MatTek, Ashland, MA). 
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Images were acquired on a Zeiss LSM 510 META (Zeiss, Oberkochen, Germany) laser scanning 
confocal at 40x magnification at the Johns Hopkins School of Medicine Microscopy Facility. 
aAPC/T cell areas of contact were quantitated by image analysis on ImageJ. 
In vivo activity of aAPCs  
We performed a subcutaneous B16 melanoma tumor prevention mouse model (Fig 6a). 
The animals were preinjected intravenously (i.v.) with naïve pMEL CD8+ T cells (day -1, 2x106 
cells/animal), subcutaneously (s.c.) in the flank with aAPCs (day 0, 2 mg aAPCs/animal), then 
injected with 2x105 tumor cells in the hindlimb (day 3). Responses were boosted with subsequent 
s.c. injection of a second aAPC batch (day 6, 2 mg aAPCs/animal), and tumor growth over the 
course of the experiment was followed by measurement with external calipers. Once the tumor 
size reached 200 cm2, the mice were sacrificed. Treatment groups consisted of ellipsoidal and 
spherical cognate aAPC (n=8), and control groups consisted of ellipsoidal non-cognate (n=8) and 
CD8+ T cell alone groups (n=5). 
Statistics 
All statistics were performed in GraphPad Prism. For analysis of surface protein 
quantification, we performed pairwise t-tests. For analysis of specific CD8+ T cell proliferation 
in response to specified aAPC dose, protein density, and shape of aAPC, we performed two-
tailed t-tests with a Bonferroni correction for multiple comparisons. For analysis of 
quantification of cognate formation and area of contact between aAPCs and CD8+ T cells, we 
performed pairwise t-tests. For analysis of tumor size, we performed a 1-way ANOVA with 
Tukey post-test. For in vivo survival analysis, we used the Log-rank (Mantel-Cox) test. Data in 
text are presented as mean ± SEM. 
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Microparticle fabrication 
The poly(lactide-glycolide) (PLGA) microparticles were made by dissolving 200 mg of 
acid-terminated PLGA (50:50 LA/GA, MW 38,000-54,000, Sigma-Aldrich) in 5 ml of 
dicholoromethane (ACS grade, Sigma-Aldrich). The dissolved PLGA was then added dropwise 
to 50 ml of an ice-cold 1% poly(vinyl alcohol) (PVA) solution, which was homogenized at 5,000 
rpm. After dropwise addition, the solution was allowed to homogenize for an additional minute, 
and then added to a 100 ml solution of 0.5% PVA which was stirring at 500 rpm in the cold 
room (at 4C). After stirring for 4 hours to allow for solvent evaporation, the particles were 
centrifuged (4000 rpm for 5 min) and washed 3x, resuspended in 5 mL of deionized water and 
lyophilized.  
For confocal imaging, tetramethyl rhodamine (TAMRA) loaded microparticles were 
synthesized via single emulsion as follows: The TAMRA was dissolved in dichloromethane at 1 
mg/ml. 200 mg of acid-terminated PLGA was dissolved in 4.9 ml of DCM and 100 µl of 
TAMRA solution was added to the PLGA DCM phase. Particle synthesis otherwise followed the 
same protocol as the single emulsion particles above. 
Preparation of MHC-Ig Dimers  
Briefly, Db-Ig molecules were stripped under mildly acidic conditions (pH 6.5) and 
refolded in the presence of 40 fold molar excess peptide and 2-fold molar excess of human β2-
microglobulin. Peptides GP100 (KVPRNQDWL; the “cognate” peptide) and ASN 
(ASNENMETH; a “non-cognate” peptide) were purchased from Genscript (Piscataway, NJ). 
Protein concentration was determined after labeling by size exclusion High Performance Liquid 
Chromatography. 
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Characterization of aAPCs: 
Measuring size and aspect ratio by SEM 
Lyophilized particle samples were spread on conductive carbon tape mounted on 
aluminum SEM mounts (Eletron Microscopy Sciences, Hatfield, PA). Samples were sputter 
coated with a chromium sputter coater and imaged on a Leo/Zeiss Field emission SEM in the 
Johns Hopkins Core Microscopy facility. Particle size and aspect was quantified using ImageJ 
software. For spherical particles, a single diameter was measured for each particle. For 
ellipsoidal particles, two diameters were measured (long-axis and short-axis) and the aspect ratio 
was calculated by dividing the two. 
Surface protein quantification and release 
Surface protein quantification was performed by conjugation of unlabeled anti-CD28 
mAb and fluorescently labeled MHC-IgG dimer and anti-CD28 antibody to the surface of 
EDC/sulfo-NHS pre-activated (or not pre-activated) 2-fold stretched (AR 2.8) ellipsoidal or 
spherical PLGA microparticles for 4 hours at 4°C. These aAPC were centrifuged washed 3x, and 
then their fluorescence was characterized on a Synergy 2 plate reader (Biotek, Winooski, VT) 
and by confocal microscopy. Colocalization analysis was done in ImageJ using "Just Another 
Colocalization Plugin (JaCoP)" with at least 10 particles/sample. 
 Release from surface was characterized by incubating 10 mg of aAPC (spherical, 
ellipsoidal) with labeled dimer in 500 µl PBS at 37°C for 1 week. At 3 days and 7 days, the 
particles were centrifuged and the supernatant was removed and stored for subsequent analysis. 
At 7 days, the supernatant was removed, and then the aAPC were resuspended the fluorescence 
was characterized. 
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Intracellular cytokine staining 
Six days after primary stimulation with aAPC, T cell functional activity was assessed by 
re-challenge with peptide-pulsed C57Bl/6j splenocytes. Splenocytes were pulsed with the 
indicated concentration of peptide for 2 hours at 37C then washed.  200,000 aAPC-activated T 
cells were incubated in complete RPMI with 200,000 splenocytes for 4 hours in a round bottom 
96 well plate in the presence of 0.2 μl GolgiPlug, 0.2 ul GolgiStop, and anti-CD107a-fitC (BD 
Biosciences, Mountain View, CA). Cells were washed and fixed using a BD Cytofix/Cytoperm 
kit (BD Biosciences) according to the manufacturer’s instructions, then stained with anti-IFNγ 
PE (BioLegend). Cytokine staining was assessed by flow cytometry and frequency of cytokine 
functional cells was assessed by comparison with an unstimulated control in FlowJo (TreeStar). 
6.3 Results and Discussion 
Ellipsoidal aAPC synthesis and characterization 
Ellipsoidal, biodegradable aAPCs were synthesized by first fabricating PLGA 
microparticles which were then stretched into ellipsoids using a film stretching method. This 
method offers the advantage of allowing a direct comparison of particle shape and surface area, 
while retaining equivalent volumes.  
The single emulsion PLGA (50:50 LA/GA, MW 38,000-54,000) microparticle synthesis 
resulted in spherical microparticles (Fig. 6.1D, spheres) with a number-weighted average 
diameter of 4.3 µm and a volume-weighted diameter of 6.7 µm (Fig. 6.1E). We were able to 
control the aspect ratio (AR) of ellipsoidal microparticles with a high degree of accuracy by 
imposing different degrees of stretch (STR) onto the film (Fig. 6.1D). This technique exhibits a 
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high correlation between predicted AR and empirically measured AR (by SEM) for a fixed 
volume ellipsoid that has been elongated in one direction (AR = STR1.5) (Fig. 6.1F). This 
indicates that particle stretching is a feasible, controllable process that allows for flexibility in 
specifying the shape of the resulting particles. Ellipsoidal and spherical microparticles were then 
made into aAPCs by EDC/sulfo-NHS mediated covalent coupling of a dimeric MHC-Ig fusion 
protein[35] and an antibody against CD28 to free carboxyl groups on the particle surface.  
Key parameters to evaluate these aAPCs include characterizing the total protein on the 
surface, the protein density, the dimer/anti-CD28 antibody ratio and the surface distribution on 
the spherical and ellipsoidal aAPCs. To characterize the conjugation efficiency with different 
amounts of protein added, we synthesized spherical and ellipsoidal (STR 2/AR 2.8) aAPC with 
fluorescently labeled MHC-Ig dimer and unlabeled anti-CD28 antibody, and characterized the 
particles by fluorimetry (Fig. 6.1G). By increasing the amount of MHC-Ig used during synthesis, 
-Ig/mg PLGA (Fig. 6.1G). Coupling 
efficiency was 15-20% over the entire range of protein analyzed, and there were no statistically 
significant differences between spherical and ellipsoidal aAPC in terms of their total protein 
content or protein density (p > 0.35 for all comparisons) (Fig. 6.1G). PLGA microparticles 
showed only minor auto-fluorescence and did not interfere with dye emission (Fig. 6.2). Of note, 
while total surface area increases modestly with stretching, with a modest increase of only 16% 
for AR 2.8 particles and maximum increase in net surface area of the aAPCs of 50% for AR 6.6 
aAPCs (Table 6.1C), stretching the aAPCs dramatically increases surface flatness along the long 
axis of the aAPCs, with the radius of curvature increasing 23-fold over the same range (Table 
6.1E).  
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To evaluate whether spherical or ellipsoidal aAPCs might show differences in dimer/anti-
CD28 antibody ratio or surface distribution of the two proteins, we synthesized spherical and 
ellipsoidal aAPCs with fluorescently labeled MHC-Ig dimer and labeled anti-CD28 antibody, 
and characterized the particles by fluorimetry and by confocal microscopy (Fig. 6.3). Spherical 
and ellipsoidal aAPC did not show significant differences in MHC-dimer amount or density, 
anti-CD28 amount or density, or MHC-dimer/anti-CD28 ratio (Fig. 6.3). Approximately 85-90% 
of the protein on the surface required the EDC/NHS pre-activation step and non-specific protein 
adsorption was low and equivalent between aAPC shapes (Fig. 6.3). The fluorescence signals 
from the two proteins were co-localized in both cases (quantified here by the Pearsons 
correlation), and the distribution pattern was equivalent between the two groups (Fig. 6.3). 
Taken together with the only modest increase in total surface area (16%) for 2-fold stretched 
particles (AR 2.8) as compared to spherical particles (Table 6.1), the protein surface 
characterization data indicate that the spherical and ellipsoidal particles are equivalent with 
respect to protein density, total protein amount, protein ratio, protein organization and co-
localization, and surface release.  
 While bulk polymer degradation from PLGA microparticles has been well investigated in 
the drug delivery field[36-38], the effect of degradation on release of surface-coupled proteins is 
less well studied. For aAPCs, presentation of immobilized proteins are critical for cytotoxic T 
cell (CTL) activation and thus it is important to study release of these proteins[10]. To 
characterize surface degradation, aAPCs bearing fluorescently labeled MHC-Ig were incubated 
for varying amounts of time in PBS at 37°C.  Supernatants were recovered through 
centrifugation of the aAPCs and released protein quantified by protein fluorescence.  For both 
spherical aAPCs and ellipsoidal aAPCs, 60-70% of the protein that was conjugated to the surface 
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was released over 7 days, with 30-40% of the protein released in the first 3 days. At 7 days, 30-
40% of the protein remained on the surface of the aAPCs, as quantified by total fluorimetry from 
the particles (Fig. 6.1H). There was no significant difference in this release profile between 
ellipsoidal and spherical aAPCs.  
We characterized the stability of the ellipsoidal aAPC shape by analyzing their relaxation 
rate to the more stable spherical shape.  Previous studies have indicated that relaxation rates are 
dependent on surface characteristics, molecular weight, polymer composition, and 
temperature[32]. We observed very little shape relaxation for high aspect ratio ellipsoidal aAPC 
over 1 week at 37°C in PBS, indicating that the shape transition is slow for ellipsoidal aAPCs 
with the chosen lactide to glycolide ratio (Fig. 6.4). This agrees with published relaxation 
timescales for high aspect ratio PLGA with hydrophilic surfaces, such as those used here[32].  
 
Effect of aAPC shape, dose, and antigen density on T cell activation 
In order to assess the impact of particle elongation, we measured the ability of aAPC to 
induce antigen specific CD8+ T cell expansion of pMEL TCR transgenic CD8+ T cells. 
Spherical and 2-fold stretched (AR = 2.8) ellipsoidal aAPCs were synthesized at 3 different 
cognate MHC-peptide densities by adding 4, 1, and 0.5 µg of Db-Ig GP100/mg PLGA with 
corresponding amounts of anti-CD28 antibody, resulting in spherical and ellipsoidal aAPC with 
0.75, 0.14, and 0.08 µg of MHC-dimer/mg PLGA (Fig. 6.1G). Spherical aAPCs bearing non-
cognate Db-Ig ASN at the highest protein density were used as a negative control. The aAPCs 
were added to pMEL TCR transgenic CD8+ T cells at 3 aAPC to cell ratios (1, 0.1 and 0.01 mg 
aAPC/105 cells). Proliferation was assessed at day 4 by CFSE dilution (see methods for details) 
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and on day 7 by cell counts. Day 4 CFSE dilution for a representative Db-Ig density (0.75 ug Db-
Ig/mg PLGA) is shown at each aAPC:cell ratio (Fig. 6.5A), while day 7 fold proliferation data 
are shown for all three parameters of aAPC shape, aAPC:cell ratio, and Db-Ig density (Fig. 
6.5B). 
At a subsaturating dose of aAPC, 0.01 mg/105 cells, ellipsoidal but not spherical aAPCs 
induced CD8+ T cell proliferation as measured by CFSE dilution (Fig. 6.5A 0.01mg). This was 
reflected in Day 7 cells counts, with only ellipsoidal aAPC bearing 0.75 or 0.14 µg Db-Ig/mg 
PLGA inducing CD8+ T cell expansion, of 22-fold and 11-fold expansion, respectively (Fig. 
6.5B 0.01mg; p<0.001 and p<0.01 for 0.75 and 0.14 µg Db-Ig/mg, respectively). At an 
intermediate aAPC:cell ratio (0.1 mg/105 cells), ellipsoidal aAPC also induced higher levels of 
CFSE dilution (Fig. 6.5A 0.1mg) than spherical aAPC. Cell counts indicated ellipsoidal aAPC 
conferred an approximately 3-fold increase in total CD8+ T cell expansion by day 7 compared to 
spherical aAPCs (Fig. 6.5B 0.1mg; p<0.001 and p<0.01 for 0.75 and 0.14 µg Db-Ig/mg, 
respectively). At saturating high aAPC:cell ratios (1 mg/105 cells) and the highest Db-Ig density, 
differences between ellipsoidal and spherical aAPCs were substantially smaller but still 
statistically significant (p<0.05) (Fig. 6.5A/2B, 1mg). However, when Db-Ig density on aAPC 
-Ig/mg PLGA, ellipsoidal aAPC regained their advantage, stimulating 
significantly more CD8+ T cell expansion than spherical aAPC (p<0.001). aAPC bearing non-
cognate MHC-peptide did not induce CFSE dilution or CD8+ T cell proliferation (Fig. 6.5A 
left).  
Two parameters that are important in T cell activation are total amount of antigen-MHC 
complex and antigen density[39-41]. We wanted to study the impact of shape independent of 
total antigen-MHC complex or antigen density. To separate the effect of shape from the effect of 
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total antigen-MHC dose or antigen density, we replotted the expansion data from Fig. 6.5B 
versus total antigen-MHC dose (Fig. 6.5C) and antigen density (Fig. 6.5D). Increasing total dose 
results in increased CTL expansion, but at all total doses, ellipsoidal aAPC (in red) outperform 
their spherical counterparts (in black) (Fig. 6.5C). For example, at a total dose of MHC near 0.1 
µg/105 cells, all 3 ellipsoidal formulations showed higher fold-expansion than the 3 spherical 
formulations. There is also a positive correlation between increased antigen density and CD8+ T 
cell proliferation at a given particle dose (Fig. 6.5D), but across the probed density ranges, 
ellipsoidal particles (in red) show higher fold-expansion than comparable spherical particles (in 
black).  For example, in Fig. 6.5D 0.1mgs, ellipsoidal particles with an MHC density of 400140 
and 24070 MHC-Ig dimer/µm2 displayed higher fold expansion (19.70.7 and 6.30.8 fold 
respectively) than spherical particles with a similar MHC density of 35060 MHC-Ig dimer/µm2 
(2.31 fold expansion). Thus, across a range of total antigen doses and protein densities, when 
controlling for dose and density, ellipsoidal aAPC were more efficient at inducing CD8+ T cell 
expansion than spherical aAPC. 
To further study the importance of AR on CD8+ T cell stimulation, PLGA microparticles 
were synthesized, stretched varying amounts, and made into aAPCs. There was a striking 
correlation between increased AR and increased CD8+ T cell proliferation (Fig. 6.6). 
Interestingly, the greatest gain in CD8+ T cell numbers was seen by increasing the aspect ratio of 
the ellipsoidal aAPC by increasing the applied stretch from 1.5-fold to 2-fold, which resulted in 
approximately 2 fold CD8+ T cell expansion up to approximately 20 fold CD8+ T cell expansion 
at a 0.01 mg aAPC/105 cells dose (Fig. 6.6C). Analysis of the number of divisions from the 
CFSE dilution data (Fig. 6.6A) revealed that increasing AR further resulted in a larger 
percentage of cells going through a significantly greater number of divisions (Fig. 6.6B). The 
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fraction of non-responders (generations 0-1) progressively decreases with increasing AR, 
eventually resulting in only 11% non-responders for the 3.5-fold stretched (AR 6.6) aAPCs.  The 
number of cells undergoing 4-5 or 6-7 divisions also increases with every additional .5-fold 
increase in applied film stretch. This effect was also saturable with very high doses of aAPCs 
(Fig. 6.7). Therefore, increasing aspect ratio of the aAPCs resulted in increased CD8+ T cell 
expansion consistently up to 3.5 fold stretched aAPCs (AR 6.6), with the greatest improvement 
in overall CD8+ T cell expansion seen when going from 1.5-fold to 2-fold applied stretch, which 
corresponds to a change in AR from 1.8 to 2.8.  
Thus, increasing aspect ratio of ellipsoidal aAPC results in improved CD8+ T cell 
activation, and this enhanced proliferation that is mediated by ellipsoidal aAPC is primarily 
dependent on aAPC geometry rather than any differences in the density or amount of conjugated 
surface protein. 
T cell quality, as reflected by the amount and diversity of cytokines and cytotoxic 
markers produced when T cells are re-challenged by antigen, is a critical parameter for assessing 
responses[42]. To determine the functional status of the expanded CD8+ T cell population, we 
re-challenged aAPC-activated CD8+ T cells with peptide-pulsed splenocytes and measured the 
production of a key cytokine, IFNγ, as well as measured the degranulation marker, CD107a in an 
intracellular cytokine staining (ICS) assay. Function tracked with proliferation; there was no 
significant difference in the quality of CD8+ T cells generated from spherical or ellipsoidal 
aAPCs as determined by IFNγ or CD107a expression (Fig. 6.8).  There was no significant 
difference when comparing CD8+ T cell quality after equal doses of aAPCs (which resulted in 
higher proliferation with the ellipsoidal aAPC) or when comparing equal proliferation (from 
lower doses of ellipsoidal aAPC). 
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aAPC aspect ratio and T cell conjugate formation 
Antigen recognition on APC is known to trigger coordinated cytoskeletal rearrangements 
in both T cells and APCs, leading to close apposition of their cellular membranes. The resulting 
interactions mediate T cell activation and, when visualized by imaging or flow cytometry, are 
termed cell-cell conjugates[43].  
To evaluate the formation of T cell-aAPC conjugates, naïve CD8+ T cells were incubated 
at 37°C with spherical or ellipsoidal aAPCs. Cell-aAPC interactions were visualized after a one-
hour incubation by confocal imaging. In the presence of ellipsoidal aAPCs bearing cognate 
MHC/peptide, T cell membranes could be observed in close apposition to the aAPC’s long but 
not short axis, creating a T cell “cap”, characteristic of conjugate formation (Fig. 6.7A).  
Conjugate formation was observed for CD8+ T cells incubated in the presence of either 
ellipsoidal (Fig. 6.7B) or spherical (Fig. 6.7C) aAPC. Importantly, conjugate formation was a 
process driven by recognition of cognate antigen, as neither spherical nor ellipsoidal aAPCs 
bearing non-cognate MHC/peptide induced cap formation (Fig. 6.7D, E). When quantitated, 
conjugate formation was approximately 2.5-fold more frequent with ellipsoidal aAPC, with 4.6 ± 
0.9% of the CD8+ T cells forming conjugates with the ellipsoidal aAPC compared to 1.8 ± 0.4% 
with spherical aAPC (p = 0.01, Fig. 6.8F). In addition to being 2.5-fold more frequent, we 
observed a significant increase (p = 0.01, Fig. 6.8G) in the contact length between the CD8+ T 
cells and the ellipsoidal aAPC (3.6 ± 0.6 μm/interface) as compared to spherical aAPC (1.9 ± 0.2 
μm/interface). 
Time-lapsed imaging revealed a striking reorientation and rearrangement of the CD8+ T 
cell surface against the aAPC long axis.  Initially, the CD8+ T cell appears to contact the aAPC 
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along the short axis but with time migrates along the long axis rearranging its membrane against 
the long axis of the ellipsoidal aAPCs (Fig. 6.7H). Membrane reorientation and alignment 
against the long axis of ellipsoidal aAPC strongly suggests a preference for the flat surface 
presented by the long axis of ellipsoidal aAPC.  We thus observe that ellipsoidal aAPCs generate 
increased biomimetic interactions with T cells compared to spherical aAPCs, and suggests that 
the improved T cell expansion seen in vitro is due to increased frequency and size of T cell-
aAPC contact along the long axis of the ellipsoidal aAPCs. 
Effect of aAPC shape in vivo 
To test the activity of high aspect ratio aAPCs in vivo, we utilized a subcutaneous B16 
melanoma tumor model. We injected a dose of aAPC subcutaneously 3 days before and a second 
dose 3 days after tumor injection into the hindlimb (see Fig. 6.9A).  Treatment with either 
ellipsoidal (p = 0.0009 vs. non-cognate) or spherical (p = 0.02 vs. non-cognate) cognate aAPCs 
led to significant reductions in tumor size as compared to controls that received control non-
cognate aAPCs or CD8+ T cells alone (Fig. 6.9B). By day 19, cognate ellipsoidal aAPC treated 
tumors had only reached a size of 42.5 ± 14.9 mm2, compared to 90.5 ± 33.8 mm2 for cognate 
spherical, 164.5 ± 28.6 mm2 for non-cognate ellipsoidal, and 154.4 ± 35.4 mm2 for CD8+ T cell 
alone treated mice. Area under the curve (AUC) of tumor growth over the course of the entire 
experiment showed a similar pattern, with tumors growing a total of 44.3 ± 15.6 mm2, compared 
to 105.3 ± 34.7 mm2 for cognate spherical, 251.0 ± 46.6 mm2 for non-cognate ellipsoidal, and 
238.0 ± 46.6 mm2 for CD8+ T cell alone treated mice. Cognate ellipsoidal aAPCs thus reduced 
tumor size more than spherical aAPCs, but this effect did not achieve statistical significance (p = 
0.13).  
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Survival studies revealed statistically significant differences in survival between mice 
injected with ellipsoidal cognate aAPC over spherical cognate aAPC (Fig. 5C)(p=0.05), as well 
as ellipsoidal non-cognate control aAPCs (p=0.004). 25% of the animals in the cognate 
ellipsoidal aAPC group completely cleared tumor by day 19 and survived the course of the 
experiment, which did not occur in any other treatment or control groups. Furthermore, 
ellipsoidal aAPC treatment led to a significant delay in tumor growth, with no mice reaching 
substantial tumor burden until 22 days after tumor injection, compared to 19 days for the other 
three groups. 
 Critically, this research demonstrates that increased aspect ratio acellular aAPCs, which 
only differ in their shape (and have equivalent volume, antigen dose, antigen co-localization, and 
antigen density) as compared to spherical controls, not only engender enhanced antigen specific 
activation in vitro but in vivo as well, and this enhanced activation has functional consequences 
which lead to reduced tumor burden and enhanced survival.  
6.4 Conclusions 
 Previous aAPC systems have utilized spherical particles, yet the biological interaction 
between T cells and APCs is dramatically dissimilar from two spheres interacting. In this study, 
we investigated how engineering the shape of an aAPC might enhance aAPC activity both in 
vitro and in vivo. When antigen dose, antigen density, protein ratio, protein co-localization, and 
particle volume were held equivalent between spherical and ellipsoidal aAPCs, high aspect ratio 
ellipsoidal aAPCs showed significantly enhanced activity over spherical aAPCs. Increasing the 
aspect ratio of ellipsoidal aAPCs led to enhanced activity up to AR 6.6. This enhanced activity 
was also observed in vivo, where ellipsoidal cognate aAPCs caused increased survival in mice 
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compared to ellipsoidal non-cognate aAPCs (p=0.004) as well as cognate spherical aAPCs 
(p=0.05). Additionally, confocal imaging suggests that the observed improvement in CD8+ T 
cell activation is due to increased interaction along this flatter, long axis of the biomimetic, 
ellipsoidal aAPCs. These findings indicate that shape matters and that aAPC geometry is a 
critical design criterion to consider in the synthesis of biomimetic acellular aAPC systems. 
aAPCs that more closely mimic endogenous cell-cell interactions may provide a more complete 
understanding of the underlying biological processes, such as the role of close membrane 
apposition and a large surface area of contact in the APC/T cell interaction. aAPCs thus may not 
only be an enabling tool for antigen-specific immunotherapy, but also for studying basic aspects 





Figure 6.1: Particle Shape and Size 
(A) Schematic of an aAPC. (B-D) Schematic of the interaction between a T cell, modeled as a 
sphere, interacting with (B) a sphere; (C) an ellipsoid (AR 2.83; stretch ratio 2). (D) 
Characterization by SEM (2000x magnification) of spherical and ellipsoidal aAPCs. Scale bar 
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corresponds to 10 µm. (E) Size distribution of aAPCs. (G) Comparison of degree of stretch 
imposed on the film (STR) with the aspect ratio (AR) of the generated ellipsoidal aAPCs. 
Predicted AR = STR3/2 (F) Coupling efficiency for protein during synthesis of aAPC from 
spherical and ellipsoidal microparticles (n=2). (G) Protein release from the surface of aAPC at 
37°C in PBS (pH 7.4) over the course of 1 week.
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Figure 6.2: Fluorescence Standard Curves 
Linear range of MHC-Ig fluorescence used as standard curves for quantifying labeled MHC 
dimer bound to PLGA microparticles. 2 mg microparticles per measurement. 
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Figure 6.3: Quantification of Protein Labeling 
Surface MHC-dimer (fluorescently labeled with alexa 488) and anti-CD28 (fluorescently labeled 
with APC) quantification by fluorescence. (A) Spherical and ellipsoidal aAPC synthesized with 
EDC/NHS chemistry did not have significant differences in MHC-dimer amount (p = 0.92) or 
density (p = 0.42), anti-CD28 amount (p = 0.70) or density (p = 0.39), or MHC-dimer/anti-CD28 
ratio (p = 0.72). Approximately 85-90% of the protein on the surface required the EDC/NHS pre-
activation step. (B) Representative confocal images of ellipsoidal and spherical aAPC showing 
anti-CD28 (red), MHC-dimer (green), and overlay of the two channels. (C) Pearson’s correlation 
between the red and green channels for spherical and ellipsoidal aAPC (mean 0.73 for spherical, 
0.71 for ellipsoidal; p = 0.74 for comparison). At least 10 particles were used per sample. 
Colocalization analysis was performed using Just Another Colocalization Plugin in ImageJ 
(Bethesda, MD, USA). 
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Figure 6.4: Particle Shape Characterized by TEM 
aAPCs do not change their shape in physiological conditions over one week. SEM of freshly 
prepared aAPCs (a) and aAPCs incubated in PBS at 37C for (b) 1 day, (c) 3 days, and (d) 7 




Figure 6.5: T Cell Expansion and Particle Shape 
Specific CD8+ T cell proliferation in response to specified aAPC dose, protein density, and 
shape of aAPC. (A) CFSE dilution data for ellipsoidal (red) and spherical aAPC (black) at the 
highest protein dose (0.75 µg dimer/mg PLGA) at 3 doses of aAPC (0.01 mg, 0.1mg, and 
1mg/105 CD8+ pmel CD8+ T cells) compared to non-cognate. (B) CD8+ T cell proliferation 
(fold expansion/105 cells) 7 days after aAPC addition to T cells with indicated doses, shapes 
(ellipsoidal in red, spherical in white), and protein densities. (For comparison of ellipsoid vs. 
spherical, * p<0.05, **p<0.01, ***p<0.001; n=3). (C) CD8+ T cell proliferation (fold 
expansion/105 cells) versus total MHC-dimer dose (in µg) for ellipsoidal (red) and spherical 
(black) aAPCs. (D) CD8+ T cell proliferation (fold expansion/105 cells) versus MHC-dimer 
density (in MHC-Ig/µm2) for ellipsoidal (red) and spherical (black) aAPC at 3 doses of aAPC 
(0.01 mg, 0.1mg, and 1mg/105 CD8+ pmel CD8+ T cells). 
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Figure 6.6: Response to differential stretching.  
Specific CD8+ T cell proliferation in response to 0.01 mg particles/100,000 cell dose for 
ellipsoidal aAPCs with different applied stretch compared to spherical aAPCs. (A) CFSE 
dilution after aAPC addition to CD8+ T cells. (B) Fraction of cells which underwent 0-1, 2-3, 4-
5, 6-7 rounds of proliferation after aAPC addition to CD8+ T cells. (C) CD8+ T cell proliferation 
(fold expansion/100,000 cells) 7 days after aAPC addition to CD8+ T cells. 
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Figure 6.7: Titration of Particle Stretching 
Fold expansion of PMEL T cells post incubation with (A) 0.01 mg / 100,000 cells, (B) 0.1 mg / 
100,000 cells, and (C) 1 mg / 100,000 cells of differentially stretched ellipsoidal aAPC as 

























































































Figure 6.8: Functional Assessment of T Cells After Expansion 
Intracellular cytokine staining after stimulation of aAPC-activated T cells. CD8+ isolated 
splenocytes were activated with 0.1 mg spherical aAPC (filled circle), 0.1 mg of ellipsoidal 
aAPC (filled square), or 0.01 mg of ellipsoidal aAPC (unfilled square). Seven days later, T cells 
were restimulated with splenocytes from C57BLACK6 mice pulsed with the indicated dose of 
cognate GP100 peptide. Unpulsed splenocytes (No Peptide) or no splenocytes (No Stim) were 





Figure 6.9. Confocal imaging of aAPC (green) conjugate formation to CD8+ T cells (red).  
(A) Conjugates appear as areas of close membrane apposition between aAPC and cells, with 
CD8+ T cell morphology rearrangement into a distinctive cap. (B) Spherical and (C) ellipsoidal 
aAPC form cell-bead conjugates, which are more frequently observed with ellipsoidal aAPC. (D-
E) Conjugate formation is not observed with aAPC bearing non-cognate MHC-peptide. (F) 4.6 ± 
0.9% of CD8+ T cells incubated with ellipsoidal aAPC (red) compared to 1.8 ± 0.4% with 
spherical aAPC (unfilled) were observed to have formed conjugates (p=0.01). (G) The area of 
contact between cells and aAPC was 1.9 ± 0.2 μm for spherical (unfilled) and 3.6 ± 0.6 μm for 
ellipsoidal (red) cognate aAPC (p = 0.01). (H) Time-lapse image of a single CD8+ T cell 
interacting with one ellipsoidal cognate aAPC; images acquired 2 s apart. 
 231 
 
Figure 6.10 In vivo tumor-prevention model.  
(A) Experimental protocol and timeline. (B) Tumor size measurements for mice injected with 
cancer and CD8+ T cells alone or also injected with non-cognate ellipsoidal (NonCognate), 
cognate spherical (Spherical), and cognate ellipsoidal aAPC (Ellipsoidal). AUC = area under the 
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curve. * p = 0.02 vs. non-cognate; ** p = 0.0009 vs. non-cognate. For comparison of ellipsoidal 
cognate and spherical cognate by AUC, p = 0.13. (C) Survival curve – mice were sacrificed and 
declared “dead” when tumor size reached 200 mm2. Subcutaneous injection of ellipsoidal aAPC 
resulted in increased survival vs. spherical non-cognate particles (p=0.05), ellipsoidal non-




Determining the lengths of a, b, c: For a spheroid that has been elongated in 1 dimension, since 
total volume is conserved from a sphere, the length of the short axes is related to the length of the 






Surface area of a prolate spheroid: Since the geometrical shape corresponds to a prolate 
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This surface area was then normalized by the surface area of a sphere with radius 1. 
 
Equivalent protein density: Equivalent protein density with total protein content held constant is 
the inverse of the normalized surface area (density = 1/SA). 
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Radius of curvature: The radius of curvature is the radius of a circle with the same curvature as 
the observed curve at that point. Thus, for flatter curves, the radius of curvature increases, as that 
flatness requires a larger circle to describe it. 
 
An ellipse can be described parametrically by 
 
x(t)  ac o s (t)
y(t) bc o s (t)
. 





the radius of curvature can be calculated[2] from: 
 
R
( ( x  )
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So for an ellipse: 

R 
(a2 sin2(t)b2 co s2(t))3/ 2
a bsin2(t) a bco s2(t)





To calculate the radius of curvature at the tip, since t = 0 corresponds to point 1 (Fig. S5), Ra can 
be calculated using a and b as the two axes of the ellipse. To calculate the radius of curvature at 
the tip, since t = π/2 corresponds to point 2 (Fig. S5), Rb can be calculated using a and b as the 
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7 Conclusions 
Artificial Antigen Presenting Cells are reductionist systems for inducing T cell activation and 
proliferation. There are two basic approaches to using aAPC: they can be injected in vivo as a 
direct vaccine, or used to expand T cells in vitro for adoptive transfer. I have addressed both 
approaches in this work. Nano-aAPC were initially envisioned as a platform to improve 
biocompatibility and trafficking after in vivo administration. Ellipsoid micro-aAPC were also 
administered in this manner. However, in both cases tumor inhibition was not particularly robust, 
and required the co-administration of tumor-specific transgenic cells and pre-treatment of 
tumors. This may be due to continuing difficulties with aAPC trafficking. While nano-aAPC had 
more drainage from subcutaneous injection sites than micro-aAPC, the majority of particles were 
not found in the lymph node after subcutaneous injection, and were quickly cleared after 
intravenous administration. Thus, better performance will require techniques to co-localize T 
cells and aAPC after administration. Even smaller aAPC may have better drainage to lymph 
nodes and tumors, or chemokines could be delivered from aAPC to attract T cells to the site of 
injection. 
In contrast, adoptive transfer of nano-aAPC activated cells combined with lymphodepletion 
mediated rejection of established tumors without use of transgenic cells. In vitro culture 
eliminates issues of trafficking and clearance of aAPC. Furthermore, lymphodepletion can 
remove tumor immune suppression networks. Thus, for the near-term, adoptive transfer appears 
to be a more effective method for tumor rejection than direct vaccination. However, adoptive 
transfer is still prohibitively complex and expensive, and further simplifying adoptive transfer 
and improving direct vaccination aAPC remain valuable goals. 
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In this work, I develop aAPC of differing size and shape from traditional spherical, cell-sized 
aAPC. Our efforts are guided by a desire to both re-capitulate and improve biology. Non-
spherical aAPC were designed to mimic endogenous T cell-APC interactions, which rely on a 
large surface area and contact surface that is minimized by spherical aAPC. In contrast, nano-
aAPC are decidedly not inspired by typical endogenous interactions, and it remains to be seen 
whether they can re-capitulate micro-scale interactions such as immune synapses or asymmetric 
cell division. However, the use of magnetic field induced-clustering led to a nano-aAPC/CD3 
aggregate that resembled a T cell “cap” or synapse-like structure, and which was associated with 
robust activation. Thus, both the paradigm of mimicking and replacing endogenous interactions 
were valuable in developing our work. 
Furthermore, the development of new aAPC platforms required a basic understanding of T cell 
activation. The T cell membrane is spatially heterogenous on a nano-scale, a characteristic which 
exerts greater influence on nano-aAPC binding and T cell activation than micro-aAPC. Guided 
by the concatenation of TCR/CD3 clusters during activation, we developed magnet-induced 
clustering to manipulate these clusters with an external magnetic field. Thus, the development of 
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$3000 first place prize. 
4. Immunology Retreat Best Presentation. 2012. Awarded by Johns Hopkins Immunology 
Training Program 
5. Johns Hopkins Institute for NanoBioTechnology Cancer Pilot Grant. 2011. $50,000 
research grant.  
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